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ABSTRACT 
This  scientific  report  provides  a  review  of  modern  methodologies  and  tools  to  depict  toxicokinetic  and 
toxicodynamic processes and their application for the human hazard assessment of chemicals. The application of 
these methods is illustrated with examples drawn from the literature and international efforts in the field. First, 
the  concepts  of  mode  of  action/adverse  outcome  pathway  are  discussed  together  with  their  associated 
terminology and recent international developments dealing with human hazard assessment of chemicals. Then 
modern  methodologies  and  tools  are  presented  including  in  vitro  systems,  physiologically-based  models,  in 
silico tools and OMICs technologies at the level of DNA/RNA (transcriptomics), proteins (proteomics) and the 
whole  metabolome  (metabolomics).  Future  perspectives  for  the  potential  applications  of  these  modern 
methodologies and tools in the context of prioritisation of chemicals, integrated test strategies and the future of 
risk  assessment  are  discussed.  The  report  concludes  with  recommendations  for  future  work  and  research 
formulated from consultations of EFSA staff, expert Panels and other international organisations.  
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SUMMARY 
Hazard  assessment  of  chemicals  for  humans  comprises  hazard  identification  and  hazard 
characterisation  through  understanding  of  toxicokinetic  (TK)  and  toxicodynamic  (TD)  processes. 
Traditionally,  a  pivotal  toxicological  study  in  test  species  is  identified  for  a  specific  chemical  to 
determine a reference point which is then used to derive either a health-based guidance value or a 
margin of exposure. Over the last decade, a number of modern in vivo, in vitro methodologies and in 
silico tools have been developed  to investigate TK and TD processes of chemicals, i.e. Mode of 
Action  (MoA)/Adverse  Outcome  Pathway  (AOP)  at  different  levels  of  biological  organisation 
(organism, organ, cellular and molecular level). These methodologies provide the opportunity to move 
towards a mechanistic understanding of toxicity and give options for Integrated Testing Strategies 
(ITS) to reduce animal use in toxicological research. These modern methodologies are reviewed in this 
scientific report to present their potential use in the future of human hazard assessment of chemicals 
with a view to anticipating their future use within EFSA‟s work.  
Currently, MoA/AOP information is not often available for specific chemicals, and risk assessors rely 
often on the dose response assessment to translate external dose to a quantitative reference point for 
hazard characterisation in test species. However, recent international developments have supported the 
move  towards  elucidating  such  MoA/AOPs  and  these  include  the  new  applications  of  the  WHO 
framework  on  MoA,  the  OECD  international  programme  on  AOPs.  In  addition,  two  research 
programmes,  TOX-21in  the  US  and  SEURAT-1  in Europe,  both  deal  with alternatives to  animal 
testing such as in vitro methods and other integrated testing strategies (ITS). Strengths of ITS such as 
high throughput screening (HTS) assays include the possibility to  screen and prioritise chemicals 
while  minimising  animal  testing.  Their  limitations  include  their  lack  of  prediction  for 
a) chemically-induced disease-associated pathways, b) metabolism, c) interactions between different 
cell types, d) tissue-level cellular interactions, and e) chronic exposure.  
A number of modern in vitro models based on human cells provide very useful tools to investigate TK 
processes  (absorption,  distribution,  metabolism,  excretion  of  chemicals  (ADME))  in  humans.  The 
current  updated  OECD  Test  Guideline  417,  mainly  related  to  absorption  and  metabolism,  has 
indicated that such in vitro models can provide supplemental TK information which may substantially 
reduce in vivo animal testing. Even though these in vitro models have still received little attention in 
hazard assessment of chemicals for the food safety area, they can provide key information on ADME 
such  as  bioavailability,  protein  binding  and  identify  human  transporters  and  metabolic  pathways. 
These parameters can be used to determine the in vivo hepatic clearance of a chemical and then can be 
scaled up to the whole liver and take into account human variability to build physiologically-based 
(PB) models. Another challenge that remains to be solved, so as to apply these in vitro methods 
routinely,  is  in  vitro  to  in  vivo  extrapolation  (IVIVE)  in  order  to  reflect  human  physiology  and 
metabolism (hepatic and extrahepatic such as intestinal metabolism) and incorporate human variability 
in quantitative IVIVE (QIVIVE).  
PB models are presented for the modelling of TK processes (PB-TK) and for TK and TD processes 
(PB-TK-TD). PB-TK models provide a quantitative means to address TK processes and are therefore 
very useful tools in hazard assessment. PB-TK-TD link both the TK and the TD dimensions and are 
therefore  more  complex  compared  with  PB-TK  models.  Their  use  has  been  recommended  by 
regulatory authorities worldwide and the World Health Organization (WHO) and the United States 
Environmental  Protection  Agency  (US-EPA)  have  highlighted  the  need  to  develop  a  guidance  to 
pursue common principles for their application in chemical hazard assessment and risk assessment as a 
whole. Reservations regarding their routine use include the need for detailed knowledge of TK for a 
particular  chemical,  high  level  expertise  and  resources,  and  the  need  to  validate  the  models. 
Consequently, PB-TK and PB-TK-TD models are mostly used in high-tier risk assessment (tier 3). 
PB-TK and PB-TK-TD models can also be developed using ITS, IVIVE and QIVIVE which remain 
challenges for the determination of both TK parameters and toxicity parameters. In the food safety 
area, these models have been mostly applied to pesticides, contaminants and food contact materials 
and are very useful to deal with key issues in hazard assessment such as interspecies differences, Modern methodologies for human hazard assessment of chemicals 
 
EFSA Journal 2014;12(4):3638  3 
human variability, biomonitoring programmes, combined exposure to multiple chemicals and in vitro 
to in vivo extrapolations. 
In  silico  tools  include  (quantitative)  structure  activity  relationships  ((Q)SARs)  and  read-across 
methods that have been developed to predict a number of toxicological properties of chemicals using 
models, databases and tools. Another tool that is increasingly used in hazard assessment and risk 
assessment as a whole is the threshold of toxicological concern (TTC). QSARs are typically used in 
combination with other non-testing methods (such as read-across) and testing methods (such as in 
vitro methods) in the context of ITS and Weight-of-Evidence (WoE) assessments. Both (Q)SARs and 
read-across methods are increasingly predictive for hazard assessment, particularly for acute toxicity, 
mutagenicity,  genotoxicity  and  bioacummulation.  However,  their  predictability  for  TK  properties 
(ADME) and sub-chronic and chronic toxicity is still limited and considerable research is undergoing 
to address these issues. It is foreseen that combining results from different Q(SAR) models, structural 
alerts, read-across estimates with in vitro and in vivo toxicological studies using a WoE approach will 
improve the use and validation of these tools and increase the overall reliability of in silico methods.  
OMICs technologies are valuable tools to measure biochemical changes associated with a MoA/AOP, 
at  the  level  of  DNA/RNA  (transcriptomics),  proteins  (proteomics)  and  the  whole  metabolome 
(metabolomics). They  provide  the  means  to  identify  biomarkers  in  humans  and  animals for  dose 
response modelling, investigate interspecies differences and their human relevance and incorporate 
human variability (age differences, inter-ethnic differences, polymorphisms). OMICs technologies can 
also investigate patterns of gene transcripts, proteins, and metabolites within an AOP using in vitro 
models and provide helpful means to validate ITS using mechanistic in vitro assays to reduce animal 
studies and move towards predictive modelling. Weaknesses of OMICs methods include the need for 
complex  molecular  and  analytical  techniques,  highly  specialised  training  and  sophisticated 
bioinformatic  tools  to  analyse  huge  datasets.  Another  key  issue  relates  to  the  sensitivity  of  the 
methodologies  which  may  lead  to  the  detection  of  changes  that  may  not  be  biologically  or 
toxicologically relevant. Finally, OMICs studies have a complex design and have been most often 
restricted to well known reference substances to allow researchers to correlate OMICs datasets with 
standardised  endpoints  (clinical  chemistry,  histopathological  endpoints).  It  is  foreseen  that  in  the 
future, publicly available databases combining in vitro and in vivo OMIC datasets for large databases 
of compounds with MoA/AOP knowledge will help considerably to a) identify biomarkers associated 
with specific AOPs, and b) to bring new tools for predictive toxicology. Applications to human hazard 
assessment of chemicals in the food safety area have already been explored and include benchmark 
dose modelling from transcriptomic profiling, investigation of epigenomic mechanisms, identification 
of biomarkers of toxicity (proteomics), and investigation of MoA for single and multiple compounds 
(metabolomics).  
A  number  of  approaches  have  been  developed  for  the  prioritisation  and  ranking  of  chemicals 
according  to  their  toxicological  properties.  At  the  US-EPA,  the  toxicological  prioritisation  index 
(ToxPi) decision support framework has been developed and enables the ranking of chemicals using 
multiple sources of evidence on toxicity and exposure surrogates. Future needs of ToxPi development 
include  further  studies  to  understand  the  relationship  between  simple  exposure  surrogates,  tiered 
screening-level exposure assessments, and population-level biomonitoring data. In addition the US-
EPA has also developed, during the NextGen project, a recent tiered approach as a prioritisation tool. 
In practice, Tier 1 aims to prioritise and screen chemicals using ITS (Toxcast HTS assays, in vitro 
genotoxicity tests, IVIVE TK models… ) for further testing in Tiers 2 and 3. Tier 2 uses limited in 
vivo toxicity testing (e.g. short-term in vivo transcriptomic studies, in vivo studies to identify a point of 
departure for chemicals with a selective MoA, and IVIVE TK studies to link exposure and internal 
dose). Tier 3 is equivalent to the traditional toxicological in vivo testing in experimental animals.  
For  the  identification  of  emerging  chemical  risks,  EFSA  has  recently  developed  a  systematic 
framework which uses a number of data sources as input, relating to the source of the chemical 
(industrial  chemical,  contaminant)  and  software  models  as  tools  to  predict  the  environmental 
behaviour and potential toxicity of chemicals from structural features and physico-chemical properties Modern methodologies for human hazard assessment of chemicals 
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(e.g. QSAR models and PB-TK models). The application of the framework consists of a multi-step 
selection process starting with a list of chemicals to which a sequence of selection criteria is applied to 
identify the substances of potential concern. The selection criteria take into account a number of 
parameters including volumes of production or import data related to the chemical, its environmental 
persistence,  bioaccumulation  potential,  dispersive  uses,  toxicity,  and  any  available  outcomes  of 
previous  risk  assessments.  Further  work  is  ongoing  to  test  the  framework  using  additional  data 
sources, selection criteria and through the development of databases and software, for the systematic 
identification of emerging chemical risks in the food chain. 
Overall,  this  report  has  highlighted  the  shift  towards  a  MoA/AOP  approach  in  chemical  risk 
assessment to depict TK and TD processes using ITS including in vitro methods based on human cells 
(e.g. HTS assays), OMICs, physiologically-based models and in silico tools. This paradigm shift will 
allow to a) move towards a systems toxicology view for human hazard assessment of chemicals, 
b) reduce animal use in toxicity testing, and c) provide support for the prioritisation of thousands of 
chemicals. Key issues remain to be solved and include the need to validate these methodologies, the 
inclusion of more case studies to test the methods and combine new knowledge and historical data for 
proof of concept, and the need for publicly accessible databases integrating data from such methods. It 
can be foreseen that, as knowledge of MoA/AOP advances, risk assessors and toxicologists will be 
able to refine models and tools for human risk assessment of chemicals (e.g. dynamic AOPs, complex 
cellular network models, integration of the impact of the human microbiome on TK and TD events). 
Finally, recommendations are presented as the result of a general consultation of EFSA Panels and 
staff  dealing  with  chemical  risk  assessment  and  other  experts  from  international  bodies  (ECHA, 
OECD, WHO…) performed between April and October 2013. In the context of these modern methods 
and tools the need for harmonisation of the terminology and definitions is highlighted particularly for 
human health, animal health and environment risk assessment. A review to highlight the use of these 
modern methodologies and tools in animal health and environment risk assessment is also emphasised 
as well as the need for a guidance document on the use of the MoA in risk assessment. Finally, 
exploration of the applications of these tools to risk assessment of combined exposure to multiple 
chemicals and multiple stressors (e.g. biological hazards, physical agents etc) is also highlighted. 
For TK processes, the lack of human TK data for chemicals represents a key data gap and such TK 
data are needed to allow the full characterisation of interspecies differences and human variability in 
these processes. This will provide a basis to link exposure, internal dose and toxicity using PB models. 
Finally, in the context of exposure to multiple chemicals, such human TK data will provide a scientific 
basis to set assessment groups based on TK criteria. 
Other recommendations include: 
a) Improvement of in vitro methods for generating TK data to measure human absorption, distribution, 
metabolism (gut and hepatic) and excretion patterns of chemicals.  
b) Development of a guidance on the use of PB models in chemical risk assessment together with the 
development  of  prototype  physiologically-based  models  using  specific  case  studies  to  integrate 
exposure, toxicokinetic information and toxicity data, for hazard assessment purposes.  
c)  Developing  databases  providing  critical  parameters  to  build  the  models  (physico-chemical, 
physiological, toxicological), and bioinformatic tools/algorithms in order to analyse and integrate such 
data. 
Further  work  is  needed  to  explore  the  application  of  in  silico  tools  in  chemical  risk  assessment, 
including the systematic and harmonised approach for the use of QSAR. Further development of the 
read-across methodologies are recommended, particularly using QSAR, physico-chemical properties 
and toxicological data together with refinements to the TTC approach. Modern methodologies for human hazard assessment of chemicals 
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For OMICs technologies, validation and standardisation of OMICs technologies for their use in human 
hazard assessment are needed, together with detailed guidance on criteria for acceptability. Further 
exploration of the use of OMICs in human hazard assessment using case studies relevant to the food 
and feed area is recommended and include benchmark dose modelling, consideration of in vitro data, 
use of biomarkers of exposure and effects. Application in other areas, such as animal health and 
ecological risk assessment, and nutrition are also foreseen. 
Future  work  on  ITS  is  recommended  using  specific  chemicals  as  case  studies.  Testing  should 
concentrate on differentiating chemicals with specific MoA and chemicals with non specific and or 
multiple  MoA,  giving  opportunities  to  rank  potencies  for  prioritisation.  Alternative  test  species 
bridging in vitro methods and mammalian tests should be further explored. Further exploration of 
these new methodologies for hazard assessment are needed for both regulators and industry, to screen 
large sets of chemicals, prioritise chemicals, and to assess chemicals for a specific purpose. In the case 
of exposure to multiple chemicals, a better understanding of MoA/interaction of multiple substances 
using  predictive  and  alternative  methodologies  will  again  allow  to  improve  the  basis  for  setting 
assessment groups.  
Regarding the future of chemical risk assessment, exploration of new risk assessment frameworks to 
bring a systems toxicology perspective to risk assessment using case studies is needed. Weight of 
evidence and uncertainty analysis methodologies are also essential for the integration of data from new 
methodologies in the mode of action framework and chemical risk assessment as a whole. Finally, 
reinforcing collaborations with international institutions is critical for EFSA and highly recommended 
in order to integrate these new methods and facilitate international harmonisation. 
   Modern methodologies for human hazard assessment of chemicals 
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BACKGROUND AS PROVIDED BY EFSA 
Methodologies to perform risk assessment are harmonised within EFSA, whether the hazard is of 
chemical  or  biological  origin,  and  follow  four  steps  namely  hazard  identification,  hazard 
characterisation, exposure assessment, and risk characterisation. Since its foundation, a number of 
activities have been ongoing at EFSA to keep up to date with key methodologies and tools available to 
the risk assessor.  
Modern  methodologies  and  tools  for  chemical  risk  assessment  are  numerous  for  both  exposure 
assessment and hazard assessment. For exposure assessment, advances in statistical methods have 
enabled  risk  assessors  to  develop  probabilistic  methods  quantifying  variability  and  uncertainty. 
Depending on the needs of the risk assessment, such methods can replace deterministic approaches. In 
relation  to  hazard  assessment,  a  number  of  tools  and  methods  are  available  such  as  OMICs 
technologies (e.g. genomics, proteomics, metabolomics, toxicogenomics, etc.) (Herrero et al., 2011; 
Kean, 2011) and other profiling techniques i.e. systems biology, biomarkers and biological pathway 
perturbations  (NRC,  2007),  in  vitro  and  in  silico  methods  such  as  quantitative  structure  activity 
relationships (QSAR), and biologically-based models such as physiologically-based toxicokinetic and 
toxicodynamic models. It is underlined that the possible applicability of tools such as in vitro and in 
silico methods would also contribute to the 3Rs (reduce, replace, refine) moving towards the reduction 
of animal use in toxicological research.  
Keeping up to date with such modern methodologies and tools for hazard assessment, understanding 
their strengths and weaknesses and the purpose they may serve in evidence-based approaches for the 
prioritisation and ranking of chemicals according to their toxicological properties is a priority subject 
for  the  science  strategy  of  EFSA.  Since  hazard  identification  and  characterisation  of  chemicals 
specifically investigate toxicokinetic and toxicodynamic processes, the scientific report should focus 
on new and emerging methods and tools to measure and quantify these two processes. Additionally, 
the report should also contribute to further discussions on the integration of these methods and tools in 
human risk assessment as a whole i.e. integrate hazard and exposure assessment using a harmonised 
and consistent approach. 
Needs for EFSA’s future activities 
In  the  discussions  supporting  the  development  of  an  EFSA  Science  Strategy,  modern  tools  and 
methods in risk assessment have been identified as one of the priority tasks for the coming years. 
Hence, it is proposed to establish an internal task force composed of staff members from the three 
science Directorates, with the aim to prepare a scientific report reviewing the state of the science of 
new  and  emerging  tools  available  for  the  hazard  identification  and  hazard  characterisation  of 
chemicals. Such a document would also prepare further discussion on the possible integration of such 
methodologies and tools, and their applicability, to the human risk assessment of chemicals using a 
harmonised and consistent approach. 
When preparing its scientific report, the task force will consider: 
  Relevant work previously done and on-going in EFSA, e.g. the applicability of QSAR analysis 
to the evaluation of the toxicological relevance of metabolites and degrades of pesticide active 
substances  for  dietary  risk  assessment  (EFSA,  2011),  the  use  of  physiologically-based 
toxicokinetic  models  and  biomarkers  for  the  hazard  identification  and  characterisation  of 
cadmium (Amzal et al., 2009; EFSA, 2009a, 2009b).  
  On-going  international  activities,  such  as  (i)  the  possible  integration  of  OMICs  in  risk 
assessment  frameworks,  involving  US-EPA,  WHO,  and  OECD  (US-EPA,  2004;  OECD, 
2009a),  (ii)  the  Tox-21  project,  involving  the  National  Toxicology  Program  (NTP),  the 
National Institutes of Health (NIH) and the Chemical Genomics Center (NCGC) in the US, 
and discussing new strategy for toxicity testing. (Schmidt, 2009), (iii) the investigation of 
tools  for  mode  of  action  elucidation  of  chemicals  and  risk  assessment  including  the Modern methodologies for human hazard assessment of chemicals 
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„effectopedia‟ by the working group of the International Program on Chemical Safety (IPCS) 
of  the  World  Health  Organisation  (WHO)  in  collaboration  with  EFSA,  the  European 
Chemicals Agency and the European Commission Joint Research Centre.  
TERMS OF REFERENCE AS PROVIDED BY EFSA  
The EMRISK unit is requested to establish an internal task force with staff members from the science 
Directorates. 
The specific aims of the task force are: 
  To review and produce an EFSA scientific report regarding the state of the science of modern 
methods  and  tools  available  and  their  applicability  to  the  hazard  identification  and 
characterisation  of  chemicals  with  specific  regard  to  toxicokinetics  and  toxicodynamic 
processes, i.e. biologically-based models such as physiologically-based toxicokinetic models 
and OMIC technologies, respectively. 
  Since  hazard  identification  and  characterisation  of  chemicals  specifically  investigate 
toxicokinetic and  toxicodynamic  processes,  the  scientific  report  should  focus  on  new  and 
emerging methods and tools to measure and quantify these two processes. The technical report 
should  not  review  methods  for  exposure  assessment  which  are  beyond  the  scope  of  this 
exercise. 
  To  consider  the  applicability  they  may  have  in  evidence-based  approaches  for  the 
prioritisation and ranking of chemicals according to their toxicological properties. 
   The  report  should  include  a  discussion  on  the  strengths  and  weaknesses  of  such 
methodologies and tools for hazard assessment and their possible integration in human risk 
assessment  as  a  whole  i.e.  in  relation  to  exposure  assessment,  using  a  harmonised  and 
consistent approach. 
  To discuss the outcomes of this work with the Scientific Committee for further consideration. 
  To  present  the  outcome  of  this  work  to  the  Scientific  network  on  harmonisation  of  risk 
assessment. 
CONTEXT OF THE SCIENTIFIC OUTPUT  
This  internal  mandate  is  in  direct  relation  with  EFSA‟s  Science  Strategy  (2012-2016)  and 
complements the work of the Scientific Committee and all units dealing with the scientific evaluation 
of chemical hazards (pesticides, contaminants, food contact materials, food and feed additives) and the 
work of the SCER unit on the chemical hazards database. Modern methodologies for human hazard assessment of chemicals 
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EVALUATION 
1.  Introduction  
Over the last 50 years, human risk assessments of chemicals have been performed for thousands of 
substances by international and national bodies dealing with food safety and consumer safety such as 
the Joint Expert Committee on Food Additives (JECFA) of the Food and Agriculture Organization 
(FAO)/World Health Organization (WHO), the US Environmental Protection Agency (US-EPA), the 
US Food and Drug Administration (FDA), the European Food Safety Authority (EFSA), the European 
Chemicals  Agency  (ECHA)  within  the  REACH  directive,  The  European  Commission‟s  Scientific 
Committee of Consumer Safety for Cosmetic Products (SCCS), the European Medicines Agency for 
pharmaceuticals - to cite but a few. The founding regulation of EFSA has defined risk assessment as „a 
scientifically based process consisting of four steps: hazard identification, hazard characterisation, 
exposure assessment and risk characterisation‟ (EC, 2002). The WHO has described; „principles and 
methods  for  the  risk  Assessment  of  chemicals  in  food;‟  in  the  Environmental  Health  Criteria 
monograph 240 (WHO, 2009).  
Hazard assessment involves hazard identification which is „the identification of the type and nature 
of adverse effects that an agent has an inherent capacity to cause in an organism, system or (sub)-
population‟  and  hazard  characterisation  which  is  „the  qualitative  and,  wherever  possible, 
quantitative description of the inherent properties of an agent or situation having the potential to cause 
adverse effects‟. The hazard characterization step should, where possible, include an assessment of 
dose-response  and  an  evaluation  of  uncertainties  (WHO,  2009).  In  traditional  practice,  an  apical 
endpoint is identified as: ‘an observable outcome in a whole organism, such as a clinical sign or 
pathologic  state,  that  is  indicative  of  a  disease  state  that  can  result  from  exposure to  a  toxicant‟ 
(Krewski et al., 2011). For a given chemical, the apical endpoint is identified on the dose-response 
relationship from the pivotal toxicity study in test species (rat, mouse, rabbit, dog). The apical point 
occurs at lower dose than other effects and is the basis to identify a Reference Point (RP) such as 
No-Observed-Adverse-Effect Level (NOAEL), Lowest-Observed-Adverse-Effect-Level (LOAEL) or 
the lower confidence limit of the Benchmark Dose (BMDL) (EFSA, 2009a, 2013).  
For threshold (non-genotoxic) chemicals, the RP is often divided by a 100-fold default uncertainty 
factor to allow for inter-species and inter-individual variability in toxicokinetics and toxicodynamics 
to establish a health-based guidance value (HBGV), also sometimes referred to as a Reference Value 
(RV) (EFSA SC, 2012). In the food safety area, these include the Acceptable Daily Intake (ADI) for 
food and feed additives and pesticides and the Tolerable Daily Intake (TDI) for contaminants and 
chemicals in food contact materials and, for acute effects, the Acute Reference Dose (ARfD). For 
genotoxic and carcinogenic compounds, the WHO has developed the Margin of Exposure (MOE) 
approach in which the RP is divided by the human exposure for risk characterisation (WHO, 2005). 
The MOE has also been applied by EFSA (EFSA, 2005). In this context, the Scientific Committee 
(SC) of EFSA has considered that MOE values of 10,000 or more, when based on a BMDL for a 10 % 
extra incidence of tumours in an animal study „of low concern from a public health point of view‟. The 
SC noted that the magnitude of a MOE only indicates a level of concern and does not quantify risk 
(EFSA, 2005; 2009a,b; EFSA SC, 2012).  
Over the last decade, a number of research programmes such as TOX-21 in the USA and SEURAT in 
Europe have investigated the use of new methodologies and tools using in vivo, in vitro and in silico 
approaches to investigate toxicokinetic and toxicodynamic processes of chemicals at the organism, 
organ, cellular and molecular level (NRC, 2007). Two key reasons have been driving such efforts, 
firstly  the  need  to  assess  thousands  of  chemicals  particularly  under  the  REACH  regulation,  and 
secondly the need to find alternatives to animal testing. These methodologies and tools provide the 
opportunity to move towards a mechanistic understanding of toxicity for hazard assessment (e.g. mode 
of action/adverse outcome pathways) due to the obligation under the 3Rs principles – reduce, replace, 
refine the use of animals use in toxicological investigations (3Rs: reduce, replace, refine) (SCHER, Modern methodologies for human hazard assessment of chemicals 
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SCENHIR, SCCS, 2012, or due to the ban on testing chemical ingredients in animals-as under the EU 
Cosmetics Regulation 1223/2009
4). Recent reviews have discussed such options and include the joint 
report of the three  non-food  committees of the European Commission  „New  challenges  in  Risk 
Assessment‟,  and  the  report  of  the  US-EPA  on  „Next  Generation  (NexGen)  Risk  Assessment: 
incorporation  of  recent  advances  in  molecular,  computational,  and  systems  Biology‟  (SCHER, 
SCENHIR, SCCS, 2012; US-EPA, 2013; Goodman et al., 2014).  
The purpose of this report is to provide a review of these modern and emerging methodologies and 
tools to depict and potentially predict toxicokinetic and toxicodynamic processes in the context of 
human hazard assessment of chemicals. First, the mode of action/adverse outcome pathway concept is 
discussed in the context of toxicokinetics and toxicodynamics of chemicals and illustrated with new 
developments and international research efforts (WHO, OECD, Tox-21 programme in the US and the 
SEURAT programme in Europe). Methodologies and tools to investigate toxicokinetic processes (in 
vitro  tools,  physiologically-based  toxicokinetic,  physiologically-based  toxicokinetic-toxicodynamic 
models), key in silico tools (QSAR, read-across) and the Threshold for Toxicological Concern (TTC)) 
for hazard assessment are then presented and illustrated with examples. The report also provides a 
brief  account  of  the  principles  behind  the  key  OMICs  technologies  at  the  level  of  DNA/RNA 
(transcriptomics),  proteins  (proteomics)  and  the  whole  metabolome  (metabolomics),  with  recent 
examples  of  applications  in  human  hazard  assessment  of  chemicals.  Future  perspectives  for  the 
potential applications of these methods and tools in the context of prioritisation/ranking of chemicals 
and the future of chemical risk assessment are also discussed. Finally, recommendations for future 
work  at  EFSA  are  formulated  based  on  consultations  of  EFSA  staff,  expert  Panels  and  other 
international organisations.  
2.  Mode of action: definitions, recent advances, TOX-21 and SEURAT 
2.1.  Definitions 
Mode  of  action  information  for  a  particular  chemical,  i.e.  the  events  leading  to  adverse  effects 
(toxicokinetics  and  toxicodynamics),  is  not  often  available  and  risk  assessors  rely  often  on  dose 
response assessment to translate external dose to a quantitative RP for hazard characterisation in test 
species.  Toxicokinetics  (TK)  describes  the  processes  leading  to  the  internal  concentrations  of  a 
chemical or its metabolites(s) through knowledge of absorption (A), distribution (D), metabolism (M) 
and excretion (E) (ADME). Toxicodynamics (TD) describes the processes that lead to the toxic effects 
of a chemical or its metabolites(s) once it has reached the organ(s) or tissue(s). Such information has 
the potential to improve hazard assessment, particularly to assess key uncertainties related to the RP. 
These uncertainties include the relevance of the test species to the human situation (qualitative and 
quantitative  interspecies  differences)  and  human  variability  in  TK  and  TD  processes.  Figure  1 
illustrates the level of knowledge for TK and TD processes, for a particular chemical, which can range 
from very basic (external dose and toxicity) to a full quantitative understanding (external dose to 
internal dose to target organ dose and metabolism (TK) to specific target organ toxicity (TD).  
The definition of Mode of action (MoA) has evolved over time and derives from earlier works by the 
US-EPA (US EPA, 1996, 2005) and the WHO. MoA analyses have been applied to a number of case 
studies for non-genotoxic and genotoxic chemicals (WHO, 2006a,b). The current WHO definition for 
MoA is „a biologically plausible sequence of key events leading to an observed effect supported by 
robust  experimental  observations  and  mechanistic  data‟.  MoA  describes  key  cytological  and 
biochemical events – that is, those that are both measurable and necessary to the observed effect – in a 
logical framework (Boobis et al., 2006; WHO, 2009; Meek et al., 2014). MoA does not imply full 
understanding of mechanism of Action, which refers to a detailed molecular description of individual 
biochemical and physiological key events leading to a toxic effect (Boobis et al., 2006; WHO, 2009; 
EFSA, 2008). In the US, MoA has been used as a term to reference a mechanistic understanding of the 
impact of a chemical on human health and to reference other terms from epidemiology including 
                                                       
4  Regulation (EC) No 1223/2009 of the EuropeanParliament and of the Council of 30 November 2009 on cosmetic products. 
OJ L342, 22.12.2009, p. 59-209. Modern methodologies for human hazard assessment of chemicals 
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„disease signature‟ and „network perturbations‟. In contrast, toxicologists would refer to the same 
concept using the terms „toxicity pathway, MoA, adverse outcome pathway or mechanism of action‟ 
as used by the National Research Council (NRC) report,  Science and Decisions: Advancing Risk 
Assessment (2009) (NRC, 2009) and the Nextgen report of the US-EPA (US-EPA, 2013).  
 
Figure 1:   Levels of knowledge of toxicokinetic and toxicodynamic processes 
 
The concept of Adverse Outcome Pathway (AOP) emerged from the field of ecotoxicology (Ankley 
et al., 2010). AOPs are regarded by the WHO as equivalent to MoA in the human health context and 
an AOP has been defined as „a sequence of events from the exposure of an individual or population to 
a chemical substance through a final adverse (toxic) effect at the individual level (from a human health 
perspective) or population level (from an environmental perspective)‟ (Ankley et al., 2010; Meek et 
al., 2014; OECD, 2013). AOPs are characterised by a number of Intermediate Key Events (IKE) and 
key events which individually correspond to „an empirically observable precursor step that is itself a 
necessary element of the MoA or is a biologically-based marker for such an element‟ which are then 
incorporated into the toxicity pathway and MoA for an adverse effect (Boobis, 2005; US-EPA, 2005; 
OECD,  2013).  Such  key  events  should  be  definable  and  make  sense  from  a  physiological  and 
biochemical  perspective  and  in  a  toxicity  pathway.  Early  key  events  including  the  Molecular 
Initiating Event (MIE) have been defined by the OECD as the „initial point of chemical-biological 
interaction within the organism that starts the  pathway‟ (OECD, 2013). The US-EPA has defined 
AOPs as „the mechanistic or predictive relationship between initial chemical-biological interactions 
(i.e. MIE) and subsequent perturbations to cellular functions sufficient to elicit disruptions at higher 
levels of organisation, culminating in an adverse phenotypic outcome in an individual and population 
relevant to risk assessment (e.g. disease progression or organ dysfunction in humans)‟ (Ankley et al., 
2010). The authors note that, although commonly used, the AOP term is a misnomer since pathways 
are not intrinsically adverse or non-adverse but rather pathways which, when perturbed in specific 
ways, can lead to adverse effects, and the same can be said for the term „toxicity‟ pathways (Ankley et 
al., 2010; US-EPA, 2013).  
In addition, a number of authors noted that although there is a rather naive view of the MoA/AOP 
which has been conceptualised as a series of linear key events; it is recognised that an AOP involves a Modern methodologies for human hazard assessment of chemicals 
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number of independent interacting cellular response networks „interconnected pathways composed 
of the complex biochemical interactions of genes, proteins, and small molecules that maintain normal 
cellular function, control communication between cells, and allow cells to adapt to changes in their 
environment‟.  Such  independent  networks  of  key  events  may  play  a  significant  role  in  their 
homeostatic regulation and will depend on interspecies differences and human variability, which will 
need to be considered to develop AOPs (Meek et al., 2014; Vinken et al., 2013). Figure 2 summarises 
the AOP concept in human and ecological risk assessment in relation to different levels of biological 
organisation and toxicity pathways from the molecular, cellular, organ, organism level (human risk 
assessment) through population level (ecological risk assessment) (modified from Ankley et al., 2010, 
Meek et al., 2014; OECD, 2013). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2:   Levels of biological organisation, toxicity pathway and Adverse Outcome pathway 
AOPs  can  have  a  number  of  applications  including  the  establishment  of  (quantitative)  structure-
activity relationships, the development of novel in vitro toxicity screening tests and the elaboration of 
prioritisation strategies and  new testing strategies (Andersen et al., 2012; OECD, 2013; US-EPA, 
2013).  Such  new  testing  strategies  have  been  designated Integrated  Testing Strategies (ITS) or 
equivalently Integrated Approach on Testing and Assessment (IATA) and are increasingly used to 
depict  MoA/AOPs  as  alternatives  to  animal  testing  (ECHA,  2013;  OECD,  2013).  Two  recent 
examples include the use of IATA and ITS strategies at OECD and ECHA, respectively. The OECD 
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proposed an eight steps IATA strategy for testing skin corrosion and irritation of chemicals which are 
sequentially  addressed:  1)  existing  human  and/or  animal  data,  2)  structure-activity  relationships, 
3) pH, 4) systemic toxicity via dermal route, 5) use of validated and accepted in vitro or ex vivo tests 
for skin corrosion, 6) the use of validated and accepted in vitro or ex vivo tests for skin irritation, and 
7-8) use of a confirmatory in vivo rabbit test in a stepwise manner if a negative result is obtained with 
the  in  vitro/ex  vivo  skin  irritation  assays  (OECD,  2013).  ECHA‟s  guidance  on  information 
requirements and Chemical Safety Assessment under the REACH Regulation includes a sequential 
ITS for skin irritation and/or corrosion. This ITS mostly follows the OECD approach with additional 
aspects on some elements such as the use of other toxicity data, or weight-of-evidence analysis of 
existing and relevant data. In addition, validated and accepted in vitro tests can be used to identify 
non-irritants and non-corrosives in order to avoid any in vivo tests (ECHA, 2013).  
2.2.  Recent advances 
A number of international efforts have been put together to investigate MoA/AOPs of chemicals for 
risk  assessment  purposes.  Four  key  international  activities  are  summarised  below:  the  new 
developments of the application of the MoA framework by WHO, the OECD guideline on developing 
and assessing AOPs, the TOX-21 and the SEURAT-1 research initiatives. 
2.2.1.   New developments in the application of the WHO/IPCs mode of action framework  
The WHO/International Programme on Chemical Safety (IPCS), within the context of the working 
group on MoA, has recently published a thorough account of „New developments in the evolution and 
application of the WHO/IPCS framework on mode of action/species concordance analysis‟ (Meek et 
al., 2014). The modified framework has been incorporated within a roadmap which contains a number 
of feedback loops that consider dose–response relationships, species concordance analysis using a 
weight of evidence approach and provide options for continuous refinement of fit-for-purpose testing 
strategies  and  risk  assessment.  The  authors  discussed  that  the  framework  can  also  be  used  to 
hypothesising effects resulting from chemical exposure, using information on putative key events in 
established MoA from appropriate in vitro or in silico systems and other lines of evidence. Finally, this 
is also expected to contribute to improving transparency in explicitly addressing weight of evidence 
considerations in MoA/species concordance analysis based on both conventional data sources and 
non-standard methods (including in vitro and in silico methods) (Meek et al., 2014).  
A number of cases studies have also  illustrated the use of the  MoA framework  in chemical risk 
assessment and ITS: 1. Investigation of the relevance of the test species to the human situation, using 
limonene as an example of qualitative differences in MoA between rat and humans that is not relevant 
to the human situation; 2. Use of TK and TD data in species concordance analysis; 3. Evaluation of 
epidemiological data; 4. Guiding more efficient testing strategies (ITS); 5. Prioritising substances for 
further testing; 6. Categorisation of chemicals; 7. Identifying critical data needs and testing strategies 
in read-across (Meek et al., 2014). 
2.2.2.  OECD guideline on developing and assessing adverse outcome pathways  
In 2012, the OECD launched a new programme on the development of AOP. In this context, the AOP 
concept  is  applied  to  both  human  and  ecological  risk  assessment  as  „an  analytical  construct  that 
describes a sequential chain of causally linked events at different levels of biological organisation that 
lead to an adverse health or ecotoxicological effect‟. In a risk assessment context, „AOPs are the 
central  element  of  a  toxicological  knowledge  framework  being  built  to  support  chemical  risk 
assessment based on mechanistic reasoning‟ (OECD, 2013). This AOP programme of the OECD is 
coordinated together with the WHO/IPCS work on MoA since both concepts are closely related and 
addresses three key OECD activities: 
  Test guidelines programme to identify new in vitro test methods as candidates to become 
OECD test guidelines, e.g. two recent methods identified in the AOP for protein binding 
leading  to  skin  sensitisation.  These  methods  investigate  gene  expression  in  human Modern methodologies for human hazard assessment of chemicals 
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keratinocytes  and  cell  surface  markers  (CD86)  in  monocytic  cells  respectively)  (OECD, 
2013); 
  QSAR Toolbox to identify new methods/profilers for grouping chemicals; 
  Hazard Assessment activities to develop ITS for defined hazard endpoints. 
The OECD published the „guidance document on developing and assessing AOP‟ in 2013, which 
provided a framework for collecting relevant chemical, biological and toxicological information on the 
effects of chemicals to develop AOPs. Since this is a new area of activity at OECD, it has been 
highlighted that the first version of this guidance will be revised in the future as expert groups and 
member  countries  get  more  experience  in  developing  and  assessing  AOPs.  Overall,  the  guidance 
provides insights into the type of information required for the identification and the documentation of 
an AOP, how to present such information and how to undertake the assessment of an AOP regarding 
its relevance, adequacy and its potential application for regulatory purposes. Further work is ongoing 
to  develop  the  detailed  guidance  on  the  use  of  AOPs  for  integrated  testing  strategies  and  risk 
assessment. In addition, an OECD template has been created to allow researchers and stakeholders to 
develop AOPs and improve the consistency in the AOP development process (OECD, 2013). The 
AOP development process is described into six phases: 1. Selection of AO and MIE, 2. Study of the 
relevant  physiology  underpinning  the  process,  3. Determination  of  the  IKE,  4.  Graphical 
representation of the AOP/MIE/IKE/AO, 5. Evaluation of evidence supporting the AOP hypothesis, 
and 6. Reporting of the AOP using the OECD template. 
A discussion is provided on the difference between a qualitative AOP „where the key events have 
been identified but methods for assessing these events have not been identified and/or assessed in 
sufficient detail to allow for identification of the applicability domains, threshold values and/or the 
response relationships to other key events‟ and quantitative AOP „where the methods for assessing 
the key events have been identified and sufficient data generated to identify the applicability domain, 
threshold values and/or the response relationships with other key events.‟ In relation to such AOP 
knowledge, a number of applications for risk assessment include priority settings for further testing 
exercise, when not all key events of an AOP are known; hazard identification and classification and 
labelling,  use  of  partial  knowledge  of  AOP  in  the  OECD  QSAR  Toolbox.  Physiologically-based 
toxicokinetic models and toxicokinetic information are currently out of the context of AOP and have 
been recognised as a key gap in the AOP development, therefore they will have to be addressed in the 
future. As knowledge of AOP increases, the levels of uncertainty and of evidence (e.g. detail, quality, 
and quantity of information and data) should be reported (OECD, 2013). Since the launching of this 
programme, a lot of efforts have been made to develop AOPs relevant to human and ecological risk 
assessment, drafts of which reports are already available (e.g. skin sensitisation) or will be available by 
the end of 2014. Table 1 illustrates the current AOP development work ongoing within the OECD 
programme and includes 18 AOP and 3 case studies. In addition, in vitro testing strategies are under 
development as a result of the AOP for skin sensitisation published on the OECD website. A number 
of AOP tools such as a web-based AOP Knowledge management and an AOP Wiki/Effectopedia 
Knowledge Base (AOP-KB) are also under development by the JRC and the US-EPA under the 
auspices of the OECD. AOP-KB is a knowledge-aggregation and collaboration tool, which facilitates 
the collection and dissemination of AOP information. Having delivered the „AOP–KB Wiki‟ module 
in early 2014, the project has now entered its next phase: AOP-KB Effectopedia. Whilst the AOP-KB 
Wiki  covers  the  qualitative  aspect  of  an  AOP,  the  upcoming  Effectopedia  module  will  add  the 
quantitative  aspect,  i.e.  the  possibility  to  capture  and  run  (mathematical)  models  describing  the 
mechanism leading from one Key Event in an AOP to the next. In addition, Effectopedia will add a 
graphical user interface to the Knowledge Base. More information can be found on the JRC website
5 
and on the US-EPA website
6.  
                                                       
5  See http://ihcp.jrc.ec.europa.eu/our_activities/alt-animal-testing-safety-assessment-
chemicals/improved_safety_assessment_chemicals/adverse-outcome-pathways-aop 
6  See: http://www.epa.gov/ord/priorities/docs/aop-wiki.pdf Modern methodologies for human hazard assessment of chemicals 
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Table 1:   Current Development of Adverse Outcome Pathways at the OECD 
Development of Adverse Outcome Pathways 
Skin Sensitisation Initiated by Covalent Binding to Proteins 
Nonpolar Narcosis 
Acetylcholinesterase Inhibition 
Five  Cell  Signalling  Pathways  Associated  with  Cell  Proliferation  and  Differentiation  Conserved  Across 
Species 
Mitochondrial Toxicity 
Embryonic Vascular Disruption and Developmental Defects 
Sustained Activation of the Avian Aryl Hydrocarbon Receptor 
Mutagenic Modes of Action for Cancer 
Upregulation of Thyroid Hormone Catabolism via Activation of Hepatic Nuclear Receptors, and Subsequent 
Adverse Neurodevelopmental Outcomes in Mammals 
Xenobiotic  Induced  Inhibition  of  Thyroperoxidase  and  Depressed  Thyroid  Hormone  Synthesis  and 
Subsequent Adverse Neurodevelopmental Outcomes in Mammals 
Heritable Germ Cell-Derived Disease (3 AOPs) 
1. Alkylation of DNA in male pre-meiotic germ cells causing inherited mutation; 
2. Chemical interaction with tubulin in oocytes leading to inherited aneuploidy 
3. Bulky DNA adducts in male pre-meiotic germ cells causing point mutation leading to inherited DNA 
sequence mutation 
Linking  Aromatase  Inhibition,  Androgen  Receptor  Agonism,  Oestrogen  Receptor  Antagonism,  or 
Steroidogenesis Inhibition, to Impaired Reproduction in Small Repeat-Spawning Fish Species 
Neurotoxicant-induced Neuroinflammation: a converging key event in an AOP 
From protein alkylation to liver fibrosis 
Neurotoxicity induced by GABAA receptor inhibition 
Haematotoxicity due to Nitroaromatics and N-hydroxyl anilines 
CAR and PPARα-mediated pathways to non-genotoxic rodent liver cancer 
CAR and PXR-mediated pathways to rodent liver hyperplasia 
Development of Case Studies 
Case Studies Using Aquatic Organisms 
Hepatotoxicity due to 2,4,6-trinitrotoluene 
Energy Metabolism by 2,6-Dinitroluene 
2.3.  Recent  research  programmes  and  initiative  in  the  US  and  Europe:TOX-21  and 
SEURAT  
2.3.1.  The National Toxicology Program and TOX-21 
In 2004, the National Toxicology Program (NTP) published „A National Toxicology Program for the 
21st Century: A Roadmap to Achieve the NTP Vision‟. The NTP intention was to transform toxicity 
testing  from  an  observational  science  based  on  whole  animal  testing,  to  a  target-specific  and 
mechanistic one, based on identifying mechanisms of cellular toxicity. In this report, the NTP argued 
that this was necessary given that: (i) traditional in vivo toxicity testing methods are resource-intensive 
and time-consuming; (ii) such methods are unable to assess the vast backlog of untested chemicals 
already present in the environment to which humans are exposed; (iii) emerging methods and new 
technologies were helping revolutionise other fields of biology  (Attene-Ramos et al., 2013; NTP, 
2004). In 2005, the US-EPA asked the National Research Council (NRC) to develop a long-term plan 
capable of revolutionising toxicity testing (Attene-Ramos et al., 2013). The NRC‟s answer was to 
produce the report 2007 „Toxicity Testing in the 21
st Century: A Vision and a Strategy‟. It provided a 
long-term strategy on how toxicity testing should be transformed by the consideration of new methods 
in molecular and systems biology, computational toxicology, and bioinformatics (NRC 2007; Tice 
2011; Attene-Ramos et al., 2013; Tice et al., 2013). Key recommendations from the NRC report 
(2007) included: Modern methodologies for human hazard assessment of chemicals 
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  Proposal  to  use  chemical  profiling  strategies  to  measure  biological  changes  induced  by 
chemicals using automated High-throughput screening (HTS) assays defined as „efficiently 
designed experiments that can be automated and rapidly performed to measure the effect of 
substances on a biologic process of interest‟. HTS assays can evaluate thousands of chemicals 
over wide concentration ranges to identify chemical mechanisms on gene, pathway, and cell 
function (US-EPA, 2013). 
  Assay parameters should be used as toxicological endpoints as the first steps in identifying 
MoA/AOP.  
  Findings from initial in vitro experiments can be used to prioritise chemicals for more in-depth 
evaluation and for the development of toxicological models.  
  Where possible, the assays should be based on human derived cells, cell lines or cellular 
components to avoid species dependent differences in response to the chemicals.  
Since  the  2007  report,  a  number  of  U.S.  Federal  Agencies  have  collectively  devised  an 
implementation  strategy  in  response  to  the  NRC  report.  The  collaborating  agencies  include  the 
National Institute of Environmental Health Sciences/National Toxicology Program (NTP), the US-
EPA‟s  National  Centre  for  Computational  Toxicology,  the  National  Human  Genome  Research 
Institute/National  Institutes  of  Health  Chemical  Genomics  Centre  and  the  Food  and  Drug 
Administration (FDA).  
This collaborative program is informally known as Tox-21 and is conducted by the NIH Chemical 
Genomics Center (NCGC) and the US-EPA via the ToxCast program (Attene-Ramos et al., 2013; 
Tice  et  al.,  2013).  ToxCast  has  been  divided  in  two  screening  phases.  Phase  I  of  ToxCast  was 
completed in 2009 and has screened around 320 compounds in 550 biochemical and cell-based assays. 
Compounds were mainly pesticides which had already been studied extensively in vivo so that toxicity 
endpoint(s) were already characterised (i.e. target organ, reproductive, developmental…) (Tice et al., 
2013). The assays evaluated known toxicity pathways e.g. cytotoxicity, apoptosis induction, DNA 
damage, perturbation of cell signalling pathways, inflammatory response induction, nuclear receptor 
modulation, oestrogen receptor, enzyme inhibition and membrane transport inhibition. Of particular 
current interest are HTS assays that have been evaluating biological signal transduction pathways such 
as  Wingless-related  integration  site  (Wnt),  Sonic  Hedgehog  (SHH),  Delta-notch,  Tumour  Growth 
Factor-beta  (TGFβ),  receptor  tyrosine  kinase  (RTK),  retinoid  and  endocrine  pathways:  oestrogen, 
thyroid, adrenal, and androgen. Such HTS, developed under phase I of Toxcast, have provided the 
possibility to classify chemicals according to their molecular interactions with cellular targets. Such 
classification  will  potentially  give  the  opportunity,  in  the  near  future,  to  separate  and  prioritise 
chemicals  that  affect  a  specific  MoA  affect  via  a  particular  signal  transduction  pathway  versus 
chemicals that have non-specific or multiple MoAs (Shukla et al., 2010; Tice, 2011; Tice et al., 2013; 
Wetmore et al., 2013). 
Phase  II  of  ToxCast  has  expanded  on  its  chemical  library  including  667  chemicals  selected  as 
chemicals for which there is potential human exposure or which represent potential ecological hazards, 
and  include  industrial  and  consumer  products,  food  additives,  „green‟  products,  cosmetic-related 
chemicals, and failed pharmaceutical drugs (Sipes et al., 2013). These chemicals lack the traditional 
toxicity data of phase I but human clinical data and other toxicological studies are available to assess 
and test the performance of predictive models developed in phase I (Truong et al., 2014). Phase II 
focused primarily on the detection of chemicals that induce one or more stress response pathway with 
the rationale that such stress responses would be markers of potential in vivo toxicity. These stress 
response pathways included: antioxidant response, cytotoxicity, DNA damage response, heat shock, 
and mitochondrial damage (Tice et al., 2013). 
Strengths and shortcomings of the Tox-21 have been discussed (Tice, 2011; Attene-Ramos et al., 
2013; Tice et al., 2013). The strengths comprise the coverage of thousands of compounds which can 
be  screened  in  a  single  experiment  as  a  cost-effective  way  to  prioritise  chemicals  based  on  their Modern methodologies for human hazard assessment of chemicals 
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molecular  interactions  with  their  target  in  the  cell.  In  other  words,  it  investigates  MoA  while 
minimising animal testing and the assays are based on human cells and cellular components and not 
test species. The shortcomings of the assays include, amongst others, the fact that they cannot yet: 
1. predict disease-associated pathways and diseases. 2. assess metabolism and interactions between 
different cell types. 3 replicate tissue-level cellular interactions. 4. Replicate chronic exposure as short 
term in in vitro assays. In addition, no proper methodology for the prioritisation of chemicals has been 
developed; there are limits as to what compounds can be screened (e.g. volatile compounds and gases). 
Finally,  authors  also recognised  that  Tox-21  program  is  still  in its  infancy,  it  is  fundamentally  a 
research and development program and may take decades to achieve the goals originally set by the 
NRC (Tice et al., 2013). Examples of results generated from Tox-21 are illustrated throughout this 
report. 
2.3.2.  The European Commission and the SEURAT initiative 
The Safety Evaluation Ultimately Replacing Animal Testing (SEURAT) initiative was initiated in 
2008 by the Health Directorate of the European Commission's Directorate General for Research and 
Innovation (DG RTD). The overall aim of SEURAT was to devise and implement a comprehensive 
EU research programme that will drive a major overhaul in the chemical safety assessment paradigm, 
ensuring the greatest protection of human health without animal testing. The first execution phase, 
SEURAT-1,  was  launched  in  January  2011.  The  overall  emphasis  of  SEURAT-1  was  on  the 
identification and elucidation of MoAs related to repeated dose systemic toxicity in humans, and to 
develop MoA-based systems of experimental and computational  methods to be applied in human 
safety assessment. SEURAT-1 comprises a cluster of five complementary research projects: 
- SCR&Tox: „Stem Cells for Relevant Efficient Extended and Normalized Toxicology‟ 
- HeMiBio: „Hepatic Microfluidic Bioreactor‟ 
- DETECTIVE: „Detection of endpoints and biomarkers of repeated dose toxicity using in 
vitro systems‟ 
- COSMOS: „Integrated In Silico Models for the Prediction of Human Repeated Dose Toxicity 
of COSMetics to Optimise Safety‟ 
-  NOTOX:  „Predicting  long-term  toxic  effects  using  computer  models  based  onsystems 
characterization of organotypic cultures‟ 
The research projects are supported by a central data and knowledge management project (ToxBank) 
and a coordination action (COACH). More than 70 research partners participated in the SEURAT-1 
projects.  
The SEURAT strategy has adopted a MoA approach to investigate how any substance may adversely 
affect  human  health  using  ITS.  Such  knowledge  provides  a  basis  to  develop  complimentary 
theoretical,  computational  and  experimental  (in  vitro)  models  and  assays  for  the  prediction  of 
quantitative points of departure (POD) for risk assessment. The SEURAT-1 framework builds on the 
idea that key molecular or biological events are common between different MoAs so that it is the 
particular  chain of  causally  linked  events  that  makes  a  MoA  unique.  It  is  also  recognised that  a 
substance may be „promiscuous‟ and may have multiple MoAs.  
Examples of the models that are being developed under SEURAT-1, include 3D tissue models that are 
produced either experimentally using bioreactor systems, or virtually, by using computational biology 
approaches to allow the qualitative association of a chemical with one or more MoAs and dose-
response assessment. In addition, differentiation and characterisation of human pluripotent stems cells 
are made for large scale production of cell models to be used in high throughput in vitro testing. 
Innovative biomarkers and OMICs readouts are further developed. Complementing the cell and tissue 
models,  computational  chemistry,  quantitative  structure-activity  relationships  (QSARs),  and 
chemoinformatics tools provide the means to understand and predict key biochemical events such as 
protein binding and metabolic transformation. Modern methodologies for human hazard assessment of chemicals 
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In terms of research strategy, SEURAT-1 investigators first decided on which MoA was of relevance 
to their particular study or test system, and then selected the associated reference chemicals. Thus 
MoA  was  brought  to  the  forefront,  with  the  design,  optimisation,  and  evaluation  of in  vitro  test 
systems being driven by the aim to capture one or more specific MoAs with high sensitivity and 
selectivity. As a consequence, the specifications of the biological model, the exposure protocol, the 
biomarkers to be measured, and the reference chemicals to be used as positive controls, all depend on 
the MoA chosen. The selection of MoAs was performed in the context of OECD AOP activities 
described above. The SEURAT-1 research initiative has resulted in the emergence of a generic AOP 
development process in six steps in line with the OECD guidance and template for AOP development. 
An important factor to consider is the impact of the TK on the TD of the chemical under investigation 
and it has been recognised both within the SEURAT-1 and the US ToxCast that this is a key factor to 
understand the potential use of in vitro tools in risk assessment. Indeed, TK can be very different in 
an in vitro system when compared to an in vivo  one because of a number of factors such as the 
chemical accumulation in a target organ due to its persistence, and the inhibition of a detoxification 
enzyme  or  the  induction  of  a  bioactivation  enzyme.  As  a  consequence,  a  central  issue  for  the 
SEURAT-1 research initiative was to further relate treatment concentrations used in the various in 
vitro test systems to in vivo serum and target organ concentrations, and vice versa. The SEURAT-1 
Research Initiative will deliver many important computational and experimental tools, and related 
know how that will be critical components in predictive toxicology approaches. To demonstrate the 
potential of these tools and how they can be assembled in an integrated manner, the cluster will 
undertake a proof-of-concept exercise to demonstrate how a MoA-based testing strategy can be used 
to predict aspects of repeated dose target organ toxicity. Two recent examples of AOP development 
within the context of SEURAT include drug-mediated cholestatic liver injury and skin sensitisation 
(OECD, 2013; Vinken et al., 2013). Detailed descriptions of the SEURAT-1 progress can be found in 
the annual reports (www.seurat-1.org). 
3.  Physiologically-based models and in silico tools 
The aim of this section is to describe basic tools to investigate TK processes,to then introduce the 
principles  underpinning  the  building  of  physiologically-based  models  to  address  both  TK 
(physiologically-based TK models (PB-TK)) and TD processes (PB-TK-TD). In silico tools such as 
quantitative structure activity relationships are then discussed together with read-across methods and 
the threshold of toxicological concern (TTC). Examples are also given to illustrate the applications in 
relation to human hazard assessment of chemicals.  
3.1.  Investigating toxicokinetics  
In  order  to  build  physiologically-based  models,  chemical  specific  TK  data  regarding  absorption, 
distribution in the body, metabolism and excretion (ADME) need to be integrated. Key players in 
ADME processes include phase I and phase II enzymes as well as efflux transporters (phase 0 and 
phase  III).  Phase  I  enzymes  catalyse  key  reactions  such  as  oxidation,  reduction,  dealkylation 
hydrolysis and include the cytochrome P-450 (CYP) superfamily of enzymes and other enzymes (e.g. 
alcohol  dehydrogenase,  epoxide  hydroxylase,  esterases).  Phase  II  enzymes  catalyse  conjugation 
reaction  and  include  key  enzymes  such  as  UDP-glucuronyltransferases,  sulphotransferases 
glutathione-s-transferases and methyl-transferases. Efflux transporters belong to two main clusters of 
families:  the  solute  carrier  (SLC) families and the  adenosine triphosphate  (ATP)  binding  cassette 
(ABC) carriers. SLC transporters include the human organic anion transporting polypeptides (OATPs) 
and  human  organic  cation  transporters  (OCTs)  and  are  often  denominated  as  phase  0  uptake 
transporters. ABC tranporters are often called efflux pumps or phase III and include examples of 
importance such as P-glycoproteins and multidrug resistance proteins (MRPs) (Hillgren et al., 2013; 
Doring and Peztinger, 2014).  
It is worth noting that TK information is only part of mandatory in vivo animal testing in some but not 
all  legislative  frameworks.  The  current  updated  OECD  Test  Guideline  417,  mainly  related  to 
absorption and biotransformation, indicates that in vitro testing using human cells, can be a valid Modern methodologies for human hazard assessment of chemicals 
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supplemental TK information and thus may substantially reduce in vivo animal testing. A number of in 
vitro  models  have  been  developed,  mostly  in  the  pharmaceutical  industry,  to  measure  ADME 
processes.  Additionally,  a  number  of  in  silico  models  have  been  developed  to  predict  ADME 
parameters with chemical structural features (e.g. Quantitative Structure-Activity Relationships) (see 
Section  3.3).  These  in  vitro  models  have  still  received  little  attention  in  hazard  assessment  of 
chemicals  for  the  food  safety  area  and  some  are  highlighted  below  for  the  investigating  of  TK 
processes (Blaauboer, 2010; Punt et al., 2011; Coecke et al., 2013).  
3.1.1.  Absorption 
Absorption has been defined by the WHO as: „the process by which a substance is transferred from 
the site of administration into the circulation. For chemicals in food, absorption usually refers to 
passage across the gut wall into the circulation, although for some chemicals, uptake may be only as 
far as the epithelium of the gastrointestinal tract‟ (WHO, 2009). In food safety, the oral route is the 
most relevant route of exposure and after oral ingestion, the chemical passes sequentially from the 
gastrointestinal lumen, through the gut wall, to the liver and becomes bioavailable after it has enters 
the systemic circulation. Oral bioavailability has been defined as „the product of three fractions: 1. 
Fraction of dose absorbed, 2. Fraction of absorbed dose passing through the gut into the hepatic portal 
blood unmetabolised, and 3. Fraction of dose not metabolised in the liver‟ (Thelen and Dressman, 
2009). In other words, oral bioavailability is a function of absorption and first-pass elimination of the 
chemical  in  the  gastrointestinal  tract  and  liver.  Low  oral  bioavailability  has  been  attributed  to 
compounds,  which  may  limit  solubility,  dissolution,  permeability,  affinity  for  efflux  transporters, 
metabolism in the gut lumen, in the intestine and/or in the liver (Bueters et al., 2013). Transporters 
have been shown to be of key importance in the absorption, bioavailability and excretion of chemicals. 
They are mostly expressed in liver, but are also present in extra-hepatic tissues (e.g. kidney, adrenal 
gland and lung). A number of in vitro tools are available to investigate absorption and bioavailability 
of chemicals as discussed in Coecke et al. (2013). Caco-2 cells are the most widely in vitro cell models 
to  estimate  intestinal  absorption.  This  cell  model  has  been  developed  from  a  human  colon 
adenocarcinoma in culture and it is grown to form a polarised monolayer, which displays similar 
morphological and functional characteristics as intestinal enterocytes. The cultured cells form tight 
junctions and express phase I and phase II enzymes and phase 0 and phase III transporters (Alqahtani 
et al., 2013). However, the predictability of Caco-2 cells has strong limitations particularly to predict 
absorption  for  highly  lipophilic  compounds,  substances  with  low-to-moderate  absorption  rates, 
substances that are substrates for transporters and/or substances which undergo first pass metabolism 
(Turco et al., 2011).  
In vitro and artificial membrane methods have also been developed to measure and predict absorption 
and  bioavailability  for  different  routes  of  exposure  (oral,  dermal,  inhalation…)  and  to  mimick 
physiologically-based absorption barrier (Faller et al., 2008; Lafond et al., 2011; Mitra et al., 2011). 
Affinity  of  chemicals  to  transporters  in  the  gut  and  liver  is  a  growing  issue  in  TK  and  hazard 
assessment, it is currently tested routinely in the pharmaceutical area to predict biovailability and 
potential  for  drug  interactions  but  it  is  not  a  routine  assay  for  food  regulated  substances  and 
contaminants in food. As a recent example, Meyer et al. (2013) tested the affinity to P-Gp for 47 drugs 
of abuse using Human P-gp (hP-gp) membranes prepared from baculovirus-infected insect cells and 
control  membranes. The  affinity  for  hP-gp  was  measured  and  modelled using  classical Michealis 
Menten  constants  (Vmax  and  Km)  and  provides  a  tool  for  measuring  intestinal  transport  of 
xenobiotics. 
A number of software and models are also available for the simulation and modelling of intestinal 
absorption  and  metabolism  (mostly  for  drugs)  including  compartmental  models  such  as  CAT 
(compartmental absorption transit) models, ACAT (Advanced compartmental absorption transit model 
model) (GastroPlus) and the ADAM (Advanced Dissolution model) (SimCYP) as well as dispersion 
models (Alqahtani et al., 2013). Recently, mechanistic physiologically based absorption models have 
been developed such as GastrointestinalSim (GI-Sim). The model is a compartmental gastrointestinal 
absorption and transit model combined with algorithms that describe permeability, dissolution rate, Modern methodologies for human hazard assessment of chemicals 
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effects of salts, partitioning into micelles, particle and micelle drifting in the aqueous boundary layer, 
particle growth and amorphous or crystalline precipitation (Sjogren et al., 2013). 
The integration of in vitro techniques and models as input parameters in PB-TK to predict absorption 
and bioavailability is still in its infancy and, in order to use such models routinely, further work is still 
needed.  For  example,  over  the  last  ten  years,  a  number  of  in  vitro  alternative  assays  have  been 
developed to assess dermal absorption and resulted in the OECD test guidelines 428. However, their 
uses are still limited because of the lack of the biotransformation capacity of such in vitro systems. 
Again,  a  critical  analysis  of  these  tools  in  relation  to  their  relative  capacity  to  predict  human 
absorption rates in vivo as input for PBTK models, is needed (Van der Merwe et al., 2006; Nossol et 
al., 2011). 
3.1.2.  Distribution 
Once a chemical enters the systemic circulation, it is distributed into interstitial and intracellular fluids. 
Distribution of the chemical in each organ will depend on key factors such as vascular permeability, 
regional blood flow, cardiac output and perfusion rate of the tissues and the chemical„s ability to bind 
tissue and plasma proteins, lipophilicity and pH partition. Major determinants include the volume of 
distribution, protein binding and clearance at steady state. A recent approach to determine the volume 
of distribution for lipophilic compounds uses in vitro, physicochemical data and a simplified tissue-
composition-based model to estimate tissue–plasma ratio (Poulin and Haddad, 2013).  
Protein  binding  of  chemicals  is  a  critical  part  of  TK  information  particularly  to  develop 
physiologically-based  models  since  affinity  for  plasma  proteins  varies  tremendously  between 
compounds and affects the free concentration of the compound and the whole TK (Bow et al., 2006). 
The blood to plasma ratio is a critical variable to convert tissue/plasma partitions to tissue/blood, or 
fraction unbound in the plasma to the fraction unbound in the blood (the free concentration) (Yoon et 
al., 2012). Using in vitro data to gather information on distribution, in vitro to in vivo extrapolation 
(IVIVE) methods have been developed. In this context, the in vivo plasma concentration of a chemical 
needs to be linked to a target-tissue response similar to the cellular response in the in vitro system and 
to do so, determination of the in vitro and in vivo free fractions is critical (Teeguarden and Barton, 
2004;  Yoon  et  al.,  2012).  Experimental  in  vitro  systems  to  measure  free  concentrations  include 
equilibrium dialysis, ultrafiltration, and ultracentrifugation Authors have recognised that a number of 
factors  affect  the  free  fraction/apparent  partitioning  of  a  compound  and  can  complicate  data 
interpretation. These factors include blood-plasma ratio, partitioning due to lipophilicity, plasma and 
tissue binding active transport (phase 0 and phase III), metabolism (e.g. clearance processes) (Yoon et 
al., 2012).  
3.1.3.  Metabolism 
In vitro characterisation of metabolism aims to identify key metabolic routes for a compound and to 
estimate clearance as a surrogate for in vivo metabolism. It also provides a basis to develop in vitro to 
in vivo extrapolations (IVIVE) and to predict potential interactions between compounds, which gives a 
basis  to  take  into  account  TK  interactions  for  hazard  characterisation  of  multiple  compounds 
(chemical mixtures) (Coecke et al., 2006; Chen et al., 2011; Jayaraman et al., 2011; Kumar et al., 
2011; Abass et al., 2013; EFSA, 2013). These comprise: 
Hepatic xenobiotic metabolism  
A  number  of  in  vitro  methods  to  investigate  hepatic  xenobiotic  metabolism  have  been  reviewed 
recently by Abass et al. (2013) and Yoon et al. (2012):  
Hepatic microsomes are the most frequently used subcellular fractions for drug metabolism studies of 
new drug candidates and consist of vesicles of the hepatocyte endoplasmic reticulum prepared by 
standard differential ultracentrifugation. Modern methodologies for human hazard assessment of chemicals 
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Hepatocytes including cryo-preserved hepatocytes are used to evaluate the metabolic stability of the 
compounds and to identify metabolising enzymes as well as enzyme inhibition. It is recognised that 
for interspecies comparison, hepatocytes in suspensions are more reliable than hepatocytes in culture. 
This is mainly due to the potential damage caused by cytotoxic substances produced by the cells in 
and the variations in the expression levels of phase I and phase II enzymes in cultures (Chen et al., 
2011; Vasdev et al., 2011; Abass et al., 2013).  
Cell line expressing CYP cDNA (single-enzyme systems) as recombinant xenobiotic metabolising 
enzymes, are well established and commercially available. The enzymes can be expressed in bacterial, 
yeast, and mammalian cell lines and human lymphoblast or baculovirus- infected insect cells (Abass et 
al., 2013).  
Immortalised cell lines have been isolated from primary tumours of the liver parenchyma, developed 
after  chronic  hepatitis  or  cirrhosis  such  as  HepaRG  derived  from  a  hepatocellular  carcinoma.  In 
contrast to the HepG2 cell line, HepaRG cells express a large panel of liver-specific genes including 
several human CYP isoforms (e.g. CYP1A2, CYP2B6, CYP2C9, CYP2E1 and CYP3A4), phase II 
enzymes (e.g. glutahione-s-transferases and UDP-glucuronyltransferases), transporters (e.g. P-gp) and 
nuclear transcription factors over six weeks in culture. An important limitation of HepaRG cells is that 
they have been derived from a single donor and do not provide measures of inter-individual variability 
for each of CYP isoforms (Abass et al., 2013). 
Liver slices constitute a powerful tool to study biotransformation in vitro, even though they begun to 
slowly fall out of use in the prediction of TK and drug metabolism for a number of reasons. These 
include issues associated with drug movement into and out of the slices, lower enzyme activities and 
the increased use of hepatocytes to study similar reactions.  
Using these in vitro assays, classical Michaelis Menten kinetic parameters are determined such as the 
maximum  rate  of  catalysis  (Vmax)  and  the  Michaelis  Menten  constant  (Km)  as  the  substrate 
concentration that gives half maximal velocity of an enzymatic reaction. The ratio between Vmax and 
Km is then calculated to give the intrinsic clearance (CLi). CLi can then be scaled up to the whole 
liver to determine the in vivo hepatic clearance of a particular compound using the milligrams of 
microsomal protein per gram of liver, liver blood flow, and the size of the liver (Abass et al., 2013; 
Yoon et al., 2012). Examples of IVIVE for hepatic clearance are numerous in the literature. Two 
recent examples recently illustrated the method for diuron (phenylurea herbicide), and carbosulfan 
(carbamate insecticide) (Abass et al., 2013). For enzyme inhibition, Rostkowski et al. (2013) proposed 
a tool for the prediction of which human CYP (amongst 1A2, 2C9, 2C19, 2D6 and 3A4), a given 
molecule  is  likely  to  inhibit.  Finally,  in  vitro  biotransformation  systems  and  modern  modelling 
techniques  can  also  nowadays  account  for  inter-individual  variability  in  metabolism 
(genetic/epigenetic) using cells from different individuals (Chaudhry et al., 2010). In a recent study, 
the impact of different CYP2C8 genotypes on rosiglitazone plasma levels and possible drug-drug 
interactions  was  investigated  using  in  vitro  metabolism  data  obtained  from  human  wild-type  and 
variant  enzymes  of  CYP2C8  which  were  then  converted  to  whole  organ  metabolic  CLi.  IVIVE 
extrapolation  of  the  in  vitro  data  to  in  vivo  and  incorporation  into  a  PB-PK  model  resulted  in 
reasonable predicted values which were within a 1.2-1.7-fold range of the observed values (Yeo et al., 
2013). 
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Intestinal xenobiotic metabolism  
As  highlighted  previously  (see  Section  3.1.1),  xenobiotic  metabolism  in  the  intestine  is  also  of 
considerable relevance in metabolism particularly in food safety since the main route of exposure is 
the oral route. However, intestinal metabolism has long been underestimated as a consequence of the 
technical difficulty to dissociate the role of the intestine from that of the liver in in vivo experiments 
and of the lack of in vitro models sufficiently viable and fully representative of the physiology and 
anatomy of the intestine. Recently the precision-cut slice model (PCIS), widely used for the liver and 
kidney, has been adapted for the small and large intestine and its applicability to investigate intestinal 
metabolism has been reviewed recently (Groothuis et al., 2013). PCIS can be prepared from animal 
and human tissues from all regions of the intestine and allow investigation of species differences and 
regional gradients of activities of metabolising enzymes. PCIS are viable for 8-24 h of incubation and 
show high activity of xenobiotic metabolising enzymes, and are good surrogates of in vivo activity. 
They have been successfully used to study drug-drug interactions such as induction, inhibition and 
regulation of xenobiotic metabolising enzymes, transporters and nuclear factors. Their uses as models 
for chemical-intestinal metabolism and chemical-induced intestinal toxicity are still limited but these 
methods appear to be promising to contribute to the reduction and replacement of animal experiments 
(Groothuis et al., 2013). 
3.1.4.  Excretion 
Excretion of chemicals is the last step in TK processes and may involve different organs (kidney, liver, 
lung, skin). The in vitro estimation of excretion has not been investigated much and no in vitro method 
is  currently  available  (Coecke  et  al.,  2013),  however,  some  progress  has  been  made  with 
pharmaceuticals (Kusuhara and Sugiyama, 2009). A main difficulty to develop models in organs, such 
as the kidney, relates to the relative spatial complexity of its tubular transport systems compared to the 
more homogenous architecture of the liver. In addition, a multitude of transporter proteins such as 
uptake pumps (phase 0) and efflux pumps (phase III) have been identified and are involved in both 
absorption and excretion which complicates the picture. However, Yang et al. (2010) argued that as 
knowledge on such transporters increases, it will be feasible to develop assays to identify whether a 
compound is a substrate for a particular transporter in the kidney (or intestine or liver) or not. In terms 
of PB-TK models, Tonnellier et al. (2012) noted that default assumptions are often made regarding 
excretion of chemicals and research efforts are needed to test the accuracy of such assumptions and 
how they affect the overall sensitivity of the models. For example, investigating the interplay between 
transporters and kidney excretion may provide indication of the likelihood that a compound‟s renal 
clearance might deviate from expectations based on glomerular filtration alone. 
3.2.  Physiologically-based toxicokinetic models and application in hazard assessment 
3.2.1.  Principles 
The WHO has defined TK models as ‘mathematical descriptions simulating the relationship between 
external exposure level and chemical concentration in biological matrices over time‟. TK models take 
into account ADME of the administered chemical and its metabolites (WHO, 2010). The integration of 
physiological parameters into TK models  results in a physiologically based -TK models which is 
defined as „a model that estimates the dose to target tissue by taking into account the rate of absorption 
into the body, distribution and storage in tissues, metabolism and excretion on the basis of interplay 
among critical physiological, physicochemical and biochemical determinants‟ (WHO, 2010).  
In a reverse way (reverse dosimetry), PB-TK models can be used to estimate the external dose or 
exposure concentration needed to achieve given target organ concentrations, measured for example 
using biomarkers in humans (Verner et al., 2009). 
PB-TK models are based on a compartmental approach that separates the organism‟s body into a 
series  of  biologically  relevant  anatomical  compartments  of  defined  volumes.  The  number  of 
compartments varies from model to model, i.e. one compartment model to multi-compartment models Modern methodologies for human hazard assessment of chemicals 
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depending  on  data  quality,  tissue  compartments  of  interest  (i.e.  site  of  pharmacological  or 
toxicological activity), purpose of the model, and the physico-chemical properties and behaviour of 
the chemical in the organism (lipophilic/hydrophilic). All compartments are in general connected in 
anatomical order based on the blood circulatory system to form an integrated model. The transfer of 
chemicals between compartments is thus governed by blood flow rates and tissue solubility (partition 
coefficients). Each compartment can also have several sub-compartments consisting of a vascular 
section, an interstitial space, and a cellular space (Gerlowski and Jain, 1983; EFSA, 2013). Recently, 
Rowland  et  al.  (2013)  described  the  PB-TK  major  components  as  system-specific  properties, 
chemical/drug properties, and the structural model. System-specific properties include organ mass or 
volume, blood flow, and tissue composition. Chemical/drug properties include tissue affinity, plasma-
protein binding affinity, membrane permeability, enzymatic stability, and transporter activities. The 
structural model comprises the anatomical arrangement of the tissues and organs of the body, linked 
by perfusing blood. Unlike empirical models, dictated by the observed chemical/drug data, a PB-TK 
structural model is independent of the chemical/drug and is the same for all mammalian species, 
although the degree of complexity often varies with the intended application.  
PB-TK models are increasingly developed from IVIVE or quantitative IVIVE (QIVIVE). The main 
difficulty is the measurement of the free and internal cell concentrations in these in vitro systems 
mainly determined by either abiotic processes (i.e. chemical stability of the compound over time, 
adsorption  to  the  plastic  devices,  binding  with  the  medium  components)  or  cellular  processes 
(mechanism of transport across the membranes, biotransformation, bioaccumulation). Consequently 
knowledge of the expression/activity of phase I and phase II enzymes and transporters in the in vitro 
model in use is critical. However, it has been acknowledged that many cell cultures have often totally 
or partially lost their metabolic and transport capacities resulting in an unbalanced situation compared 
to the in vivo situation (Yoon et al., 2012). This conclusion has been highlighted by Tice et al. (2013) 
for the Toxcast assays of the TOX21 program: a HTS assay to measure the free concentration of a 
compound in vitro is not yet available and xenobiotic metabolism is lacking in virtually all  HTS 
assays. Due to the above factors, the uncertainty about the actual level of exposure of cells in vitro is 
even greater after repeated treatments than after single dosing in vitro. Parallel to PB-TK models, 
integrated  mass  balance/fate,  cell  population  of  in  vitro  experiments  should  be  developed,  to 
understand the TK behaviour of a toxicant at the cellular level. Such peculiarities of in vitro TK may 
lead to large errors in the interpretation and use of the data generated, if ignored. Hence, if such IVIVE 
and QIVIVE are considered to replace animal testing in the future, concentration measurements of the 
parent compound and/or of the metabolites in in vitro systems have to be considered as critical parts of 
the experimental design (Yoon et al., 2012). 
In practice, two approaches for PB-TK modelling are used namely a bottom up and a top down, 
approach. The „bottom-up‟ approach includes each organ and tissue of the body as a distinct entity so 
that the interactions of a chemical/drug with all components of the body are integrated to allow for 
mechanistic insights into the global behaviour of the system to make valid extrapolations. The „top 
down  approach‟  uses  simplified  models  for  which  the  tissues  are  combined  together  („lumping 
tissues‟). This approach is used increasingly to estimate TK parameters for complex models coming 
from experimental data a. A key issue for such top down approach is the need to validate methods to 
reduce the complexity of models while preserving global body characteristics (e.g. cardiac output and 
body weight, criteria on the „lumping of tissues‟ based on their kinetic features, mass balance of the 
chemical/drug). 
Recently, a number of generic PB-TK models, applicable to a large number of substances, coupled to 
parameter databases and QSAR modules have been developed to model inter-individual variability in 
the ADME processes for pharmaceuticals, environmental contaminants and pesticides, in test species, 
humans as well as farm animals. Different methodologies are available to build these models ranging 
from one-compartment model to Markov chain Monte Carlo methods and multi-level (hierarchical) 
population  models  used  for  Bayesian  calibration  of  the  models  (Bois  et  al.,  2010).  Compared  to 
previous PB-TK models, current models usually contain more compartments and even more complex 
exposure equations. For example, recent models have included transporters from the gastrointestinal Modern methodologies for human hazard assessment of chemicals 
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tract  (e.g.  P-Gp,  OATP)  and  intestinal  metabolism  together  with  hepatic  metabolism,  to  predict 
bioavailability, first pass metabolism and to reflect human physiology and variability more accurately 
(Pang  et  al.,  2010).  It  has  been  recognised  that  building  such  complex  models  require  intensive 
resources  and  sophisticated  software  tools  as  well  as  detailed  knowledge  about  the  chemical 
deposition  in  the  body  and  physiological  input  parameters  for  animal  species  and  in  different 
subgroups of the human population.  
Over the last decade, a number of generic software platforms have been designed to support the TK 
modelling of pharmaceuticals with a focus on the oral and intravenous routes and metabolism by CYP 
isoforms and phase II conjugation enzymes. These platforms are available to support generic PB-PK 
modelling  mostly  for  pharmaceuticals  using  in  vitro  metabolism  data  and  IVIVE  (e.g.  Simcyp 
platform (Rostami-Hodjegan and Tucker, 2007; Jamei et al., 2009) and industrial compounds) using 
software such as  IndusChemFate (Jongeneelen and Berge, 2011) and MEGen (Loizou and Hogg, 
2011).  Software  packages  to  develop  these  models  range  from  user-friendly  excel  spread  sheet 
interfaces to software using complex algorithms such as MC-Sim, PK-Sim, Berkeley Madonna, acslX, 
MATLAB or PK-BUGS using full Bayesian inference (Loizou and Hoggs, 2011).  
Generally, PBTK model are very useful tools in hazard assessment but are often used in high-tier 
assessment (tier 3) since they require detailed knowledge and high level of expertise and they need to 
be validated (EFSA, 2013). When available and appropriate, the application and use of these models 
have been recommended by regulatory authorities around the world (ATSDR 2004; US-EPA, 2007; 
EFSA, 2008a; WHO, 2010; Meek et al., 2011; OECD, 2011). However, because of the specialised 
expertise required, these models have not yet been implemented routinely in human hazard assessment 
and WHO (2010) has highlighted that guidance needs to be developed to pursue common principles 
and harmonised approaches in relation to those models.  
Authors have discussed some key criteria that a generic PB-TK modelling would need to have to be a 
useful  practical  tool:  (i)  user  friendly,  open  access;  (ii)  database  for  physiological  parameters; 
(iii) inhalation,  dermal,  and  oral  exposure  routes  and  (iv)  capability  to  model  multiple  parallel 
metabolic pathways (Yoon et al., 2012). The US-EPA has discussed a number of criteria for the 
acceptance of PB-TK models in risk assessment: (1) the model represents the species and life stage of 
relevance for the specific risk assessment, (2) the model has been evaluated and peer-reviewed for 
transparency,  adequacy  of  its  structure  and  parameters,  and  (3)  the  model  provides  adequate 
simulations of the concentration of the toxic moiety (parent compound or metabolite(s)) in the target 
organ (or a surrogate compartment of the body), relevant exposure route(s) and relevant time-course 
for which the chemical would be present in that target organ/surrogate compartment (US-EPA, 2006). 
In  terms  of  validation,  4  key  aspects to  be  reviewed  have  been  identified  1.  model  purpose  and 
structure, 2. mathematical representation, 3. calibration of the parameter estimations, and 4. computer 
implementation of the model. In the future, PB-TK models may be increasingly used, on a case by 
case basis depending on the purpose of the risk assessment and data availability, as more generic 
predictive tools become available (Conolly et al., 2005; US-EPA, 2007; EFSA, 2008; Dorne et al., 
2012).  
3.2.2.   Application in hazard assessment 
Generic applications of PB-TK in human hazard assessment are numerous and include interspecies 
differences, route-to-route extrapolation, analysis of human variability in TK to integrate differences 
between  subgroups  from  varying  exposure  condition,  chemical  mixtures,  high-to-low  dose 
extrapolation (WHO, 2010). Historically, they have been mostly applied to pharmaceuticals (PB-PK) 
and for hazard assessment of industrial chemicals (solvents). In food safety, PB-TK are increasingly 
developed for substances with well known TK. These include regulated substances (mostly pesticides 
(organophosphates, fungicides…)), food contact materials (bisphenol A) and contaminants (persistent 
organic  pollutants),  acrylamide,  heavy  metals  (cadmium,  lead,  mercury…),  metalloids  (arsenic). 
Applications  of  PB-TK  models  in  key  areas  of  hazard  assessment  are  highlighted  including Modern methodologies for human hazard assessment of chemicals 
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interspecies differences, human variability,  biomonitoring programmes, and combined  exposure to 
multiple chemicals and in vitro to in vivo extrapolations.  
Interspecies differences 
PB-TK models have been used to investigate interspecies differences/similarities in TK processes, in 
order  to  facilitate  extrapolations  between  test  species  and  humans.  In  the  pesticide  area,  PB-TK 
models  have  been  developed  for  the  conazole  fungicide  triadimefon  and  its  primary  metabolite 
triadimenol from rat experimental data and were then extrapolated to humans using in vitro metabolic 
constants from human hepatic microsomes. Human equivalent doses (HEDs) were then calculated 
from a rat NOAEL dose using the area under the concentration curve in  the brain and blood for 
triadimefon and triadimenol. Such reverse dosimetry PB-TK models are expected to be applied in the 
future to better estimate the human exposure profile (external dose) based on internal dose of other 
conazole fungicides and other compounds (Crowell et al., 2011). Interspecies differences in bisphenol 
A (BPA)-TK were investigated using a 7-compartment oral PB-PK model (brain, liver, fat, slowly 
perfused, richly perfused, plasma, and gonads) in the infant and adult monkey and a one compartment 
sub-model for BPA phase II metabolites (e.g. BPA-glucuronide and sulphate). The model showed 
metabolism of BPA at all ages (post-natal day PND 5 to adult) by the gut wall and liver (Doerge et al., 
2010). From the monkey model, Fisher et al. (2011) extrapolated the model to humans, incorporating 
knowledge of gut wall and liver metabolism (e.g. glucuronidation). The authors could demonstrate that 
previous  human  models  that  did  not  take  into  account  gut  metabolism  over-estimated  the 
concentrations of BPA as parent compound in the serum.  
A PB-TK model was developed in monkeys for the contaminants perfluorooctanoic acid (PFOA) and 
perfluorosulphonate (PFOS) and extrapolated to humans taking into account differences in half life 
between monkeys (several months) and humans (several years). In addition, the model successfully 
simulated  human  plasma  concentrations  using  data  collected  from  residents  of  two  communities 
exposed to PFOA in drinking water. Sensitivity analysis was performed to test whether the model was 
able  to  describe  the  available  PFOA  and  PFOS  plasma  concentrations  adequately.  Overall,  even 
though  the  data  were  highly  variable  due  to  the  long  half  life  of  PFOS  and  PFOA  in  humans, 
predictions of the model were in good agreements with the experimental data (Loccisano et al., 2011). 
Human variability 
PB-TK models are particularly suited to explore, understand and predict the determinants of inter-
individual variability in TK when the required information is adequately incorporated. Bois et al. 
(2010) reviewed the prediction and sources of inter-individual variability in ADME parameters. They 
distinguished  three  main  contributing  sources  to  the  total  variability:  (1)  the  variation  across  a 
population of „normal‟ individuals at the same age, e.g. young adults; (2) the variation across the 
population resulting from their different ages, e.g. infants or the elderly; and (3) the variation resulting 
from the existence of subpopulations that differ in some way from the „normal‟ population, e.g. due to 
genetic polymorphisms. The authors pointed out that a fourth source of variability, namely the health 
status, which is frequently disregarded, should also be considered. Human variability in PB-TK has 
been applied to methylmercury and combined with a Monte Carlo analysis to provide information on 
the distribution of acceptable ingestion rates across the population (Clewell et al., 2000). Clewell et al. 
(2004)  developed  an  age-dependent  PB-TK  model  for  isopropanol  and  its  metabolite  acetone 
incorporating time dependent  changes in physiological and biochemical parameters based on data 
from the literature. A PB-TK model was combined with Monte Carlo techniques in order to take into 
account human variability in paraoxonase polymorphism in relation to parathion TK and the inhibition 
of acetylcholinesterase (Gentry et al., 2002). Finally, chemical specific adjustment factors (CSAFs) 
have been derived for a number of chemicals in specific subgroups of the population using PB-TK 
models taking into account variability in physiological parameters and TK processes (Valcke and 
Krishnan, 2014).  Modern methodologies for human hazard assessment of chemicals 
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Finally, it has been argued that Bayesian methods for PB-TK modelling have emerged as the best 
suited  approaches,  given  the  large  amount  of  prior information they  require  (Bernillon  and  Bois, 
2000). A number of applications of posterior Bayesian PB-TK modelling have been published on 
chloroform (Lyons et al., 2008), dichloromethane (David et al., 2006), methylmercury (Allen et al., 
2007), nanoparticles (Péry et al., 2009), tetrachloroethylene (Chiu and Bois, 2006; Covington et al., 
2007) and cadmium (Amzal et al., 2009; EFSA, 2009c). 
Human Biomonitoring 
A number of biomonitoring programmes are currently ongoing to assess environmental exposure of 
humans to xenobiotics (e.g. EU ESBIO, COPHES; US CDC NHANES; Canadian Health Measures 
Survey). The goal of these projects is to determine relative trends in exposure to chemicals, across 
time and subpopulations. Due to the lack of data, there is often little information correlating biomarker 
concentrations with exposure levels and durations. As a result, it can be difficult to use biomonitoring 
data to derive Derived No-Effect Level (DNEL) values under the EU REACH program, or Reference 
Dose/Concentration (RfD, RfC) values of the US EPA based on internal dose (Bartels et al., 2012). 
PB-PK  models  have  been  shown  to  be  of  great  help  for  a  quantitative  interpretation  of  human 
biomonitoring  data  to  relate  exposure  to  blood  concentrations  as  exemplified  with  the  NHANES 
biomonitoring data for cadmium (Clewell et al., 2008; Ruiz et al., 2010). 
Verner et al. (2009) developed a mother–infant PB-PK model for Persistent Organic Pollutants (POPs) 
and using maternal blood levels at the time of delivery, exposure of mothers to several metabolites of 
1,1,1-trichloro-2,2-bis(p-chlorophenyl)ethane  (DDT),  polychlorinated  biphenyls  (PCB)  and  other 
POPs  was  estimated  to  subsequently  simulate  infant  blood,  breast  milk,  and  cord  blood  POP 
concentrations. Simulations were then compared with corresponding measured levels and predictions 
were  strongly  correlated  with  measured  concentrations  of  residues  that  were  above  the  limits  of 
detection. This study shows how PB-PK model can be validated with individual data and how they can 
help reduce sampling efforts. In addition, these models enable the use of individual TK profiles of 
POPs  and  incorporate  them  in  epidemiological  studies  to  investigate  adverse  effects  on  child 
development. Another example by Verner et al. (2012) illustrates the relevance of PB-TK model to 
integrate  the  characterisation  of  exposure  accounting  for  uptake  through  multiple  pathways  and 
physiological parameters influencing the TK. Using styrene as an example, the authors determined the 
best times to sample venous blood and end-exhaled air for biomonitoring purposes, characterised 
inter-individual  variability  in  biological  levels  following  occupational  exposure  to  styrene,  and 
proposed biological limit values using a population-based PB-TK model.  
Combined exposure to multiple chemicals („Chemical mixtures‟) 
 In the context of combined exposure to multiple chemicals, a number of PB-TK models have enabled 
to investigate potential TK interactions to calculate potency factors such as interaction-based hazard 
index (HI) using information on the chemicals‟ tissue concentrations (EFSA, 2013). Haddad et al. 
(2001) proposed a methodology to model occupational inhalation exposure to airborne mixtures of 
dichloromethane,  benzene,  toluene,  ethylbenzene,  and  m-xylene.  The  basis  of  the  proposed 
methodology related to the characterisation of the change in tissue dose metrics in humans, during 
mixed exposures using an interaction-based PB-TK model. More recently, PB-TK models for four 
solvents (styrene, benzene, ethylbenzene and toluene) were developed taking into account metabolic 
interactions at the level of their oxidation pathway mediated via CYP2E1. The models were calibrated 
using three joint models of benzene, toluene, ethylbenzene, m-xylene toxicokinetics using Markov 
chain Monte Carlo simulations and single-substance exposure data (Cheng and Bois, 2011). Sasso et 
al. (2010) developed a generalised PB-TK model for mixtures using a chemical independent approach 
based  on  modules  approach  that  can  be  directly  „mapped‟  to  individual  TK  models  for  specific 
chemicals, while maintaining physiological consistency across different  chemicals, the model was 
applied to a mixture methylmercury, cadmium, lead, arsenic (and metabolites), toluene, and benzene. 
In vitro-In vivo extrapolation Modern methodologies for human hazard assessment of chemicals 
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A number of QIVIVE models have been developed to extrapolate from an in vitro concentration used 
in an experimental setting to an in vivo dose, which could be significant for human exposure. Two 
examples  of  QIVIVE  that  included  biotransformation  measured  in  vitro  into  PB-TK  models  are 
provided  by  studies  on  deltamethrin  (Mirfazaelian  et  al.,  2006;  Tornero-Velez  et  al.,  2010)  and 
chlorpyrifos/diazinon  (Timchalk  and  Poet,  2008).  The  deltamethrin  example  also  showed  another 
value of using in vitro derived metabolism data in the PB-TK model. Using the age-specific enzyme 
kinetic parameters determined in vitro, it was possible to extend the adult PB-TK model to different 
life stages. This capability of PB-TK modelling is advantageous for considering potentially sensitive 
subpopulationssuch as infants and children in risk assessment (Mirfazaelian et al., 2006, Tornero-
Velez et al., 2010). 
Another recent QIVIVE approach evaluated the complex metabolism of estragole in rats and humans 
from in vitro data. Punt et al. (2008) characterised the multiple steps of estragole bioactivation and 
detoxification  mediated  by  a  number  of  enzymes  (CYPs,  UGTs,  dehydrogenases,  and 
sulfotransferases) using in vitro systems (microsomes or subcellular fractions (S9). The Michaelis-
Menten kinetic parameters (Vmax and Km) parameters were then scaled to in vivo, based on the 
microsomal/S9 protein content, and the interplay of these multiple reactions were integrated into a PB-
PK model. Simulated concentrations of a metabolite (1-hydroxyestragole glucuronide) from the PB-
TK model for rat and human were consistent with the observed in vivo data from rat and human urine.  
Recently,  a  3D  dynamic  flow  model  with  primary  human  hepatocytes  was  used  to  predict  the 
metabolic clearance of ethoxycoumarin. The model was optimised for cell seeding density, medium 
composition and extracellular matrix proteins and the hepatocytes were cultured for up to 7 weeks. In 
addition, the model provided in vivo liver-like structure as well as important liver-specific functions 
which included albumin and total protein production, glucose utilisation, lactate production, and CYP 
3A4 activity across multiple tissue donors. The in vitro intrinsic clearance of 7-ethoxycoumarin was 
determined and compared to that in hepatocyte suspension and gave reproducible and stable estimates 
of clearance that were similar to previously published values. The authors discussed that such tools 
could be valuable to make accurate QIVIVE to predict metabolic clearances and provide ways to 
assess chronic effects of chemicals and their metabolites in a complex 3D-environment under dynamic 
flow more accurate (Choi et al., 2013). Such a model is not strictly speaking a PB-TK but provides a 
sound approach for QIVIVE to determine TK parameters. 
Other recent in vitro tools for QIVIVE include models to investigate phase II metabolism such as 
glucuronidation, as the major phase II metabolic pathway in humans. Wu et al. (2013) reviewed the 
use of hepatic microsomes incubated with bovine serum albumin in addition to hepatocytes which 
provide accurate predictions of in vivo glucuronidation including both hepatic clearance and intestinal 
availability (Wu et al., 2013). Such models have the potential to predict in vivo metabolism and dose 
metrics from in vitro data and can improve IVIVE for the design of PB-TK models.  
3.3.  Physiologically-based  toxicokinetic-toxicodynamic  models  and  application  in  hazard 
assessment 
3.3.1.  Principles  
Toxicodynamic  (TD)  models  have  been  defined  as  „mathematical  descriptions  simulating  the 
relationship between a biologically effective dose and the occurrence of a tissue response over time‟ 
(WHO, 2009). When the TD for a specific compound is known at the target organ or site (e.g. a cell or 
enzyme) it can be linked to the predicted TK from a PB-PK model. Therefore, a PB-TK model is 
combined with dose response data to get to a PB-TK-TD model. Historically, biologically-based dose-
response  (BBDR)  models  were  introduced  to  bring  mechanistic  information  into  dose-response 
assessment  and  today  PB-TK-TD  are  considered  to  be  the  most  comprehensive  and 
phenomenologically-based models and thereby the most comprehensive BBDR (Shuey et al., 1994; 
Setzer, 2001).  Modern methodologies for human hazard assessment of chemicals 
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PB-TK-TD models are very useful since they provide a highly refined tool, in which it should be 
possible  to  reduce  uncertainty  for  higher  tier  risk  assessments  of  single  and  multiple  chemicals. 
Generally speaking, PB-TK-TD models can provide a tool to estimate the internal concentration of a 
chemical and its metabolites, together with its toxicity, by integrating population variability into TK 
and  TD.  They  also  allow  better  understanding  of  the  mechanistic  basis  for  extrapolation  from 
experimental data (using either IVIVE/QIVIVE or animal studies) to the in vivo human situation such 
as  high  doses  to  low  dose  extrapolation  between  animals  and  humans,  dose  and  interspecies 
differences  in  bio-activation  and  detoxification,  non-linearity  in  dose  response,  qualitative  and 
quantitative  response  to  the  same  cumulative  dose  administered  by  different  routes  and  exposure 
scenarios (Krishnan and Andersen, 2001). As described for PB-TK models, PB-TK-TD are built using 
the body as a set of interconnected compartments of differential mathematical equations describing the 
ADME of a specific chemical and/or its metabolite, and then they connect the internal dose to the dose 
response of the adverse  dynamic  effect  (from  in  vivo  and  more recently  in vitro  studies) for the 
compound and/or its metabolites (s).  
IVIVE and QIVIVE approaches can incorporate in vitro data into in vivo PB-TK-TD based on cellular 
toxicity  assays.  As  discussed  for  PB-TK,  the  first  step  of  QIVIVE  is  the  identification  of  the 
consequence of metabolism (detoxification or bioactivation) to identify  the toxic entity (parent or 
metabolite). Again, the collection of in vitro data to support the prediction of in vivo clearance is a 
complex process particularly to relate the concentration that would be equivalent to a toxic effect in 
vitro (such as using HTS assays as in Toxcast). Ideally, key variables need to be predicted for a full 
QIVIVE model that would reflect metabolism and physiology in a holistic manner. Such key variables 
include  intestinal  absorption  and  pre-hepatic  clearance,  extrahepatic  metabolic  clearance,  renal 
clearance, and volume of distribution (particularly for acute in vivo exposures). Current examples of 
QIVIVE often use historical in vivo data and it has been anticipated by a numbers of authors that such 
information will be generated in the near future using in silico tools and targeted in vitro studies, 
particularly novel in vitro systems that better mimic in vivo conditions (Yoon et al., 2012).  High-
throughput in vitro toxicity screening can provide an efficient way to identify potential biological 
targets for chemicals, but relying on nominal assay concentrations may misrepresent potential in vivo 
effects of these chemicals due to differences in bioavailability, clearance, and exposure (Wetmore et 
al., 2012). However, it has been estimated that at the moment, QIVIVE calculations can be associated 
with uncertainties of more than an order of magnitude (Rotroff et al., 2010; Yoon et al., 2014). 
The use of the nominal concentration in the in vitro toxicity assay to characterise the toxicity of a 
compound is an easy, fast and cost effective process compared with QIVIVE which involves much 
more  complex  measurements  and  understanding.  However,  in  vitro  toxicity  test  results  are 
quantitatively meaningless for risk assessment without QIVIVE. Relative potency estimates from in 
vitro toxicity assays are obtained under conditions that do not reflect differences in the bioavailability 
and clearance of the chemicals, which are the key determinants of the doses in vivo that would be 
associated with tissue exposures equivalent to the  in vitro assay, Therefore, except for qualitative 
hazard identification, in vitro toxicity assay results can only be interpreted on the basis of QIVIVE 
(Yoon  et  al.,  2012).  In  order  to  understand  the  inter-individual  differences  in  hepatic  clearance, 
knowledge is required on population distributions of protein binding, hepatic uptake, biliary transport, 
blood flow in healthy adults and subgroups of the populations. Key issues include better in vitro tools 
to measure multiple determinants of clearance through the manipulation of proteins levels, flow rates 
and  transport  inhibitors.  New  developments  include  liver  bioreactors  that  are  promising  tools  to 
investigate the effect of biological conditions on hepatic clearance, protein binding and transport rate 
constants which can be used in a high troughput context. It is foreseen that, in the future, databases 
will be generated and can be combined with physicochemical properties to  create QSAR models, 
which may facilitate IVIVE/QIVIVE using clearance data generated from hepatocytes or microsomes 
(Yoon et al., 2014). Modern methodologies for human hazard assessment of chemicals 
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3.3.2.  Application in hazard assessment 
Currently, applications of PB-TK-TD in human hazard assessment are possible for compounds with 
well  known  TK  and  TD.  It  is  foreseen  that,  in  the  future,  as  databases  describing  TK  and  TD 
parameters for numerous compounds, these models may be applied in a more predictive manner. 
Examples  of  PB-TK-TD  applied  to  interspecies  differences,  human  variability,  epidemiological 
studies, combined exposure to multiple chemicals and in vitro to in vivo extrapolations are presented 
below. 
Interspecies differences  
Young et al. (2007) developed a physiologically based pharmacokinetic model for acrylamide (AA) 
and three of its metabolites: glycidamide (GA) and the glutathione conjugates of acrylamide (AA-GS) 
and glycidamide (GA-GS) in mice and rats. Then human urinary excretion data and  haemoglobin 
adducts data were used to extrapolate to a human model. GA-DNA adducts and haemoglobin (Hb) 
adducts with AA and GA were included as pharmacodynamic components of the model. Doerge et al. 
(2008),  estimated  probable  AA  intake  in  the  U.S.  population,  and  used  PB-TK-TD  modelling  to 
integrate the findings of rodent neurotoxicity and cancer into estimates of risks for humans. These 
modelling techniques have reduced the uncertainty inherent in extrapolating toxicological findings 
across species and dose by comparing common exposure biomarkers. 
PB-TK-TD  models  can  simulate  bioactivation  and  detoxification  of  alkenylbenzenes  (estragole, 
methyleugenol and safrole), which are a class of naturally occurring compounds found in herbs and 
spices, known to be carcinogenic (Punt et al., 2008; Al-Subeihi et al., 2011; Martati et al., 2011). 
These models can be used to extrapolate from benchmark dose causing 10 % extra tumour incidence 
(BMD10) down to the so-called virtual safe dose (VSD) (the dose resulting in one in a million extra 
tumour incidence upon life time exposure). The PB-TK models were built using available literature 
information and in vitro TK parameters (Vmax and Km) from human and rat microsomes for each 
metabolite (Punt et al., 2007, 2011). Additionally, a PB-TD  model was developed, by  measuring 
formation of estragole DNA adducts in rat primary hepatocytes and was further validated in vivo with 
male SD rats (Paini et al., 2012). Recently, Van der Berg et al. (2013) applied the estragole PB-TK/TD 
model to the hazard assessment of plant food supplements containing estragole to predict in vivo 
effects in humans.  
Human variability  
Human variability is a key parameter influencing cadmium levels in urine, which are widely accepted 
as a measure of the body burden and its cumulative amount in the kidneys. The Scientific Panel on 
Contaminants in the Food Chain (CONTAM Panel) of EFSA carried out a meta-analysis on a selected 
set of studies to evaluate the dose-response relationship between urinary cadmium and urinary beta-2 
microglobulin  (B2M).  B2M,  a  low  molecular  weight  protein,  was  recognised  as  the  most  useful 
biomarker in relation to tubular effects and .a Hill model was fitted to the dose-response relationship 
between urinary cadmium and B2M for subjects over 50 years of age and the whole population. From 
the model, a BMDL5 of 4 μg Cd/g creatinine was derived for a 5 percent increase of the prevalence of 
elevated B2M. A chemical-specific adjustment factor of 3.9, to account for inter-individual variation 
of urinary cadmium within the study populations, was applied, leading to a value of 1.0 μg Cd/g 
creatinine. Such a value was also supported by data from occupationally exposed workers and by the 
results of several individual studies using a variety of biomarkers. A one-compartment model was 
fitted to a large data set based on non-smoking Swedish women (age range from 58 to 70 years), to 
allow  an  estimation  of  the  relationship  between  dietary  cadmium  exposure  and  urinary  cadmium 
concentration. The dietary cadmium exposure that corresponds to the critical urinary cadmium in food 
cadmium concentration of 1 μg/g creatinine after 50 years of exposure was then estimated using the 
model corresponding to. A safe average daily dietary cadmium intake 0.36 μg Cd/kg body weight 
(b.w.) or weekly dietary intake of 2.52 μg Cd/kg b.w. Based on these figures, EFSA established a 
tolerable weekly intake (TWI) for cadmium of 2.5 μg/kg b.w. (Amzal et al., 2009; EFSA, 2009a,b,c). Modern methodologies for human hazard assessment of chemicals 
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Epidemiological Studies  
Cord serum levels of PCB-153, a highly persistent polychlorinated biphenyl (PCB) congener, were 
recently  reported  to  be  associated  with  lower  birth  weight  in  a  meta-analysis  of  data  from 
> 7,000 pregnancies (Govarts et al., 2012). Verner et al. (2013) suggested that gestational weight gain, 
which is associated negatively with PCB levels in maternal and cord blood and positively with birth 
weight, could substantially confound this association. They thus estimated the influence of gestational 
weight gain on the association between PCB-153 exposure and birth weight using a pharmacokinetic 
model and Monte Carlo simulations accounting for variability in physiologic parameters and their 
correlations. The PB-PK model was evaluated by comparing simulated plasma PCB-153 levels during 
pregnancy  to  serial  measurements  in  10  pregnant  women  from  another  study  population.  The 
association between simulated plasma PCB-153 levels and birth weight were estimated using linear 
regression  models.  The  plasma  PCB-153  level  profiles  generated  with  the  PB-PK  model  were 
comparable to measured levels in 10 pregnant women. A 118-g decrease in birth weight (95 % CI: -
129, -106 g) was estimated for each 1μg/L increase in simulated cord plasma PCB‑153. This decrease 
in birth weight, was in the same range as the value estimated (-150 g) from a previous meta-analysis. 
The estimated decrease in birth weight was reduced to -6 g (95 % CI: -18, -6 g) when adjusted for 
simulated gestational weight gain. This study, based on a pharmacokinetic approach, suggests that the 
association between prenatal levels of PCBs and birth weight may be strongly confounded by the 
effect of gestational weight gain on both blood PCB levels and birth weight. Overall, the PB-TK-TD 
model illustrates that epidemiological associations between pollutants and health outcomes may be 
attributable partly to TK and can be applied to other pollutants in the future (Verner et al., 2013).  
Combined exposure to multiple chemicals  
In a study by Hinderliter et al. (2011) inter-individual variability in physiology,  metabolism, and 
physical  activity  was  estimated.  This  allowed  the  evaluation  of  individuals‟  susceptibility  to  the 
potential effects of chlorpyrifos (CPF) using a sensitivity analysis in a PB-TK-TD model. The results 
indicated that the metabolic capacities of liver CYP and paraoxonase-1 (PON-1) in liver and blood 
were  sufficient  to  prevent  significant  toxic  responses  due  to  brain  and  red  blood  cell 
acetylcholinesterase (AchE) inhibition (unsaturated) at low dietary CPF exposure in both children and 
adults.  
Several PB-TK-TD models have been developed to address combined exposure to multiple pesticides 
such as organophosphates (Timchalk et al., 2002; Knaak et al., 2004; Poet et al., 2004; Lee et al., 
2011a),  carbamates  (Zhang  et  al.,  2007;  Knaak  et  al.,  2008;  Pelekis  and  Emond,  2009),  and 
pyrethroids  (Mirfazaelian  et  al.,  2006;  Tornero-Valez  et  al.,  2010;  Aylward  et  al.,  2011).  For 
organophosphorus  insecticides,  a  PB-TK  model  was  developed  to  model  potential  interactions 
between CPF and nicotine at a) the TK level to predict CPF‟s metabolite concentrations (CPF-oxon) in 
blood and brain, and at b) the TD level to compare prediction of (AchE) inhibition in the brain with 
experimental data. Results showed that CPF-oxon levels were lower following the expected Vmax 
increase  in  rats  co-exposed  to  nicotine  and  CPF.  Authors  concluded  that  that  repeated  nicotine 
exposure can alter CPF metabolism in vivo, resulting in altered AchE inhibition (Lee et al., 2011b).  
Other PB-TK-TD models have been developed for CPF and diazinon (DZ) and the models included a 
number of important metabolic steps such as CYP450 mediated activation/detoxification, B-esterases, 
butyrylcholinesterase (B-E) and AchE or PON-1 oxon detoxification. Since both insecticides were 
shown to inhibit the CYP-mediated metabolism in vitro in a concentration-dependent manner, the 
PBPK model was modified to reflect the TK of the CYP inhibition (competitive vs. non-competitive). 
In addition, B-esterase metabolism was described as dose-additive, and no PON-1 interactions were 
assumed. The PBTK model was then compared with previously published rodent oral TK data and TD 
data (AchE inhibition) for co-exposure to CPF and DZ. No differences between predicted TK and 
published TK data were shown for either CPF or DZ or their respective metabolites, while TD AchE 
inhibition was shown to be described using dose-addition. The authors concluded from the model that, Modern methodologies for human hazard assessment of chemicals 
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at low environmentally relevant binary doses of CPF and DZ, the TK and TD of the mixture were 
expected to be linear and dose-additive (Timchalk et al., 2008). 
In vitro to in vivo extrapolations 
The JRC of the European Commission has recently developed a number of Virtual Cell-based (VCB 
assays). An example took into account the fate of a compound in the experimental in vitro system 
as 1) the partitioning between the plastic wall, headspace, serum proteins, lipids, and 2) the compound 
dynamics within the cell. The model was then coupled with a cell growth model and a toxic effect 
model (Zaldívar et al., 2010; Zaldivar Comenges et al., 2011). In addition, the VCB assay model could 
been coupled to PB-TK models to give a PB-TK-TD establishing the relationship between TK and TD 
taking into account the real concentration affecting the cells. The model was applied to acetaminophen 
to predict the internal concentration using the VCB assay and compare it with cell viability data (Péry 
et al., 2013). 
An example of a simple QIVIVE modelling using HTS from the Toxcast assays programme of the 
US-EPA has been recently published (Wetmore et al., 2013). Rat hepatic metabolic clearance and 
plasma protein binding were measured for 59 ToxCast phase I chemicals. IVIVE provided estimates 
of the daily internal dose in rats as an oral equivalent dose (OED). This OED would then result in 
steady-state in vivo blood concentrations equivalent to an AC 50 (concentration at 50 % of maximum 
activity)  or  lowest  effective  concentration  (LEC)  across  more  than  600  ToxCast  in  vitro  assays. 
Statistical classification analysis was performed using either the OED or unadjusted AC50/LEC values 
for the in vitro assays to predict the in vivo effects of the 59 chemicals. The authors concluded that 
adjusting the in vitro assays with a PB-TK did not improve the ability to predict in vivo toxicity as 
either a discrete response or as a low effect level on a continuous dose scale. However, a comparison 
of such in vitro assays with the lowest oral equivalent dose with in vivo endpoints (LOEL) effect level 
suggested that: 1) the lowest oral equivalent dose may provide a conservative estimate of the POD for 
a chemical in a dose-response assessment, and 2) the approach may also be used to identify potential 
MIE leading to adversity HTS assays s can provide an efficient way to identify potential biological 
activity of chemicals (Wetmore et al., 2013). 
3.4.  In silico tools and threshold of toxicological concern 
3.4.1.  In silico tools  
Broadly interpreted, ‟in silico‟ tools available to toxicologists and risk assessors aim to predict toxicity 
of chemicals and cover a wide range of methodologies that would also comprise molecular modelling 
approaches and general computational toxicology tools, including theoretical models based on the 
intrinsic structural and physicochemical properties of chemicals and rule-based expert systems. These 
computational tools often require chemical structure and/or a few physico-chemical properties, as 
input to provide a fast method for screening of untested substances. They are also helpful tools for 
identifying emerging risks in the food chain from those chemicals that have not yet been tested for 
safety to human health or the environment (EFSA, 2014). This section highlights briefly key in silico 
tools  that  widely  used  in  chemical  hazard  assessment  namely  (Quantitative)  Structure  Activity 
Relationship models and read-across methods as well as decision making tools such as the threshold of 
toxicological concern.  
Structure-Activity  Relationships  (SARs)  and  Quantitative  Structure  Activity  Relationships 
(QSARs) are sometimes collectively referred to as (Q)SARs and are mathematical models that relate 
the structure of chemicals to their biological activities. A SAR  provides a qualitative relationship 
between a particular substructure and the presence or absence of a biological activity, regarding the 
capacity  to  modulate  a  biological  activity  imparted  by  another  sub-structure  (e.g.  suspected 
carcinogens mutagens, and reprotoxicants). A QSAR provides a mathematical relationship between a 
biological activity and one or more molecular descriptors that are used to predict the activity. The term 
„quantitative‟ refers to the fact that the molecular descriptors are quantifiable on a continuous scale Modern methodologies for human hazard assessment of chemicals 
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and  thus  provide  a  quantitative  relationship  with  toxicity  (which  may  itself  be  expressed  in 
quantitative  or  categorical  terms).  The  molecular  descriptors  of  the  chemical  are  generally  their 
inherent  physicochemical  properties  such  as  atomic  composition,  structure,  sub-structures, 
hydrophobicity, surface area charge, and molecular volume. QSARs may be classified based on their 
dimensionality with 1D-QSAR referring to a system where the effect can be correlated with a single 
(e.g.  physicochemical)  property,  2D-QSAR  with  atomic  connectivity  or  two-dimensional  (e.g. 
pharmacophoric)  patterns,  and  3D-QSAR  with  the  three-dimensional  structure  of  a  compound. 
Dimensionalities  with  n > 3  (n = 4,  5,  6)  are  referred  to  as  „multi-dimensional  QSAR‟  or  short 
„mQSAR‟ and typically include a multiple representation of the ligand such as 4D-QSAR (Vedani et 
al., 2000; Tseng et al., 2012) and the protein 5D/6D (Vedani et al., 2006). 
QSARs are typically used in combination with other non-testing (e.g. read-across) and testing (e.g. in 
vitro) methods in the context of ITS and Weight-of-Evidence assessments.  
Read-across has been defined by ECHA as „a technique for predicting endpoint information for one 
substance  (target  substance),  by  using  data  from  the  same  endpoint  from  (an)other  substance(s), 
(source substance(s))‟. ECHA pointed out that the read-across approach has to be considered on „an 
endpoint-by-endpoint basis due to the different complexities (e.g. key parameters, biological targets) 
of  each  endpoint‟.  In  addition,  ECHA  used  the  term  analogue  approach  „when  the  read-across 
approach is employed‟ within a group of a very limited number of substances for which trends are not 
apparent: i.e. „the simplest case is read-across from a single source substance to a target substance‟ 
(ECHA, 2008). In the case of a high number of substances in a group the term category approach is 
used (ECHA, 2008). A wide range of in silico tools are available for grouping chemicals and applying 
read-across.  Being  a  non-formalised  approach,  it  requires  considerable  expert  knowledge  and 
judgment. The comprehensive guidance on grouping and read-across has been published by the OECD 
(OECD, 2007) and ECHA (ECHA, 2008). 
The concepts of grouping chemicals and read-across has been reviewed and illustrated elsewhere by 
Enoch  et  al.  (2010).  A  comprehensive  guidance  for  applying  the  grouping  approach  has  been 
published by OECD (2007) and more recently, other systematic expert-driven processes have been 
proposed for read-across (Wu et al., 2010; Blackburn et al., 2011). Grouping and read-across have 
been  used  within  the  OECD  High  Production  Volume  Chemicals  Program  as  an  alternative  for 
experimental testing  and  are  currently  being  applied  under  REACH.  Examples  of  applications  of 
grouping read-across have been reported (Wu et al., 2010; Blackburn et al., 2011). The reliability of 
read-across depends on the selection of suitable analogues associated with reliable experimental data. 
In some cases, it is only possible to identify one or a limited number of suitable analogs, whereas in 
other cases it is possible to build up groups of chemicals. Schilter et al. (2014) discussed options to 
group chemicals according to their similarities:  
  Physico-chemical properties (e.g. molecular weight, solubility, vapour pressure lipophilicity), 
play a key role in the bioavailability of chemicals. 
  Functional/mechanistic/structural  alert  groups  (e.g.  aldehyde,  epoxide,  ketone,  Michael 
acceptor, nitrosamines, aromatic amines).  
  Chemical similarity, e.g. based on the Tanimoto coefficient. If a new substance is very similar 
to an existing one, it is assumed that minor modifications to its structure are unlikely to affect 
its properties and, for hazard assessment purposes, the same hazards and potencies can be 
used.  
  Similarity  in  breakdown  or  metabolic  products.  Physical  or  biochemical  processes  may 
generate compounds of similar structure (e.g. ester hydrolysis; oxidation of primary alcohols 
and aldehydes to carboxylic acids).  Modern methodologies for human hazard assessment of chemicals 
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When QSAR and read-across approaches are applied to toxicity prediction, they are typically based on 
data  or  knowledge  relating  to  both  TK  and  TD  processes.  In  the  case  of  QSARs,  some  of  the 
underlying parameters (predictor variables) may be associated with TK (e.g. partitioning coefficients) 
whereas others may be associated with TD (e.g. electronic properties). Often however, the predictor 
variables included in QSARs already account for both TK and TD contributions to toxicity. QSARs 
can also be used to predict physicochemical properties that may serve as input parameters in PB-TK 
models  (e.g.  protein  binding  coefficients  and  partitioning  coefficients  across  biological  barriers). 
Recently, the use of OMIC technologies such as metabolomics has been suggested to optimise the 
chemical grouping process by providing biologically-based criteria for toxicological equivalence; the 
authors  have  named  this  approach  Quantitative  biological  activity  relationship  (QBAR)  (Van 
Ravenzwaay et al., 2012).  
EFSA  (2014a)  has  discussed  a  typical  workflow,  which  would  first  examine  existing  data  and 
information for possible read-across and grouping using the OECD QSAR Toolbox and the databases 
discussed above. A second step would be to predict metabolism in the relevant species (human, rat..) 
using metabolism prediction tools such as the expert systems METEOR (LHASA), OASIS-TIMES or 
the  US  EPA MetaPath pesticide  database.  Another option is to  use  molecular  modelling  tools  to 
conduct 3-D docking studies in potential target receptors and enzymes and these studies can also be 
used to build QSAR models (EFSA, 2014a).  
Key  databases  for  QSAR  and  read-across  include  the  OECD  QSAR  Toolbox 
(http://www.qsartoolbox.org/),  a  hazard  identification  tool,  which  contains  QSAR  relationship 
methodologies  that  can  be  used  to  group  chemicals  into  categories  sharing  the  same  structural 
characteristics  and/or  MoA.  The  systematic  grouping  of  chemicals  according  to  the  presence  or 
modulation of a particular effect for all members of the category is based on the presumption of a 
common chemical structure or MoA/AOP. The Toolbox can be used to provide: 
- estimates for all substances in a category;  
- extrapolation of the empirical data from tested chemicals to derive estimates for an untested 
chemical within a category;  
-  trend  analysis  estimates  (increasing,  decreasing  or  constant)  among  relevant  regulatory 
endpoint data; 
- estimates using category-based statistical models (QSARs).  
The QSAR Toolbox is entering the phase 3 of its development over a six to ten year period, and a 
common terminology/ontology has been developed for the Toolbox by ECHA. The aim is to improve 
the user-friendly features of the toolbox in terms of architecture, workflows as well as to address new 
and less experienced user guidance needs. In addition, the quality assurance and range of the databases 
will be addressed together with ontology harmonisation, improvements of information technology and 
additional functions, such as: report documentation and options to save searches and relevant scientific 
approaches; three dimensional molecular docking function possibilities, up to the eventual population 
of the toolbox with the AOP data (EFSA, 2014a).  
Other databases providing toxicity data for chemicals include the eChemPortal hosted by the OECD, 
which allows simultaneous searching of reports and datasets by chemical name and number and by 
chemical property. Direct links to collections of chemical hazard and risk information prepared for 
government chemical review programmes at national, regional and international levels are available. 
In addition, the eChemPortal provides exposure and use information on chemicals. Other databases 
include Chembase (www.chembase.com/), ChemIDplus (http://chem.sis.nlm.nih.gov/chemidplus/), 
ChemSpider: (www.chemspider.com/), Pubchem (http://pubchem.ncbi.nlm.nih.gov/), Carcinogenic 
Potency  Database  (http://toxnet.nlm.nih.gov/cpdb/cpdb.html),  DSSTox 
(www.epa.gov/comptox/dsstox/),  European  chemical  Substances  Information  System Modern methodologies for human hazard assessment of chemicals 
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(esis.jrc.ec.europa.eu/),  NTP  Database:  (http://ntp.niehs.nih.gov/),  IPCS  (www.inchem.org/), 
ToxNet (http://toxnet.nlm.nih.gov/) (EFSA, 2014a).  
QSAR software and models are being used by international and national organisations such as the 
Toxicity Estimation Software Tool (TEST), the OECD QSAR toolbox models and High-throughput 
Virtual Molecular Docking (HTVMD) (OECD, 2004, 2012; Rabinowitz et al., 2008; Benfenati et al., 
2009; Zhu et al., 2009), MetaCore (Teschendorff and Widschwendter, 2012), and the TOPKAT model 
(Rakyan et al., 2011). HTVMD models use a ligand-based chemoinformatics strategy that allows for 
the prediction of relationships between various attributes of ligands and their binding to a number of 
known targets as a direct agonist, such as the oestrogen receptor (US-EPA, 2013). HTVMD models 
are increasingly being used in risk assessment and can screen thousands of chemicals for the potential 
affinity of their 3D structures to the binding sites of active proteins (US-EPA, 2013). Other public and 
commercial (Q)SAR models and expert systems are available for assessment of chemical toxicity. 
These include DEMETRA, CAESAR, VEGA, TEST, DEREK, METEOR, Multicase, PASS, OASIS 
Times.  The latter also allows prediction of metabolites as well as assessment of their toxicity. 
Overall, (Q)SARs methods are increasingly predictive for hazard identification in relation to acute 
toxicity, mutagenicity, genotoxicity and bioacummulation. However,  applications of Q(SARs) and 
read-across  to  the  prediction  of  TK  properties  (ADME  and  sub-chronic  and  chronic  toxicity)  for 
chemicals relevant to the food safety area are still limited and considerable research is undergoing in 
this area (Roncaglioni et al., 2013; Scholtz et al., 2013; Gissi et al., 2014). In addition, a increasing 
number of Q(SAR) models, and databases are available and their precision, specificity and sensitivity 
may vary and would need to be evaluated (Roncaglioni et al., 2013; Scholtz et al., 2013). In terms of 
hazard assessment, combining Q(SARs) from more than one model with additional information from 
structural alerts, read-across estimates but also from in vitro and in vivo toxicological studies using a 
Weight of Evidence (WoE) approach can improve the utility and the validation of these tools and 
increase overall reliability of in silico methods (Scholtz et al., 2013; Roncaglioni et al., 2013; US-
EPA, 2013; EFSA, 2014a). 
3.4.2.  Threshold of Toxicological Concern 
The Threshold of Toxicological Concern approach (TTC) is a well known decision making tool that 
has been used for a number of years for hazard assessment purposes. The reader is referred to the 
opinion  of  the  Scientific  Committee  of  EFSA  on  „exploring  options  for  providing  advice  about 
possible human health risks based on the concept of Threshold of Toxicological Concern‟ (EFSA SC, 
2012). The approach is based on a historical toxicological database built on the empirical evidence that 
for non-cancer effects there are thresholds below which toxicity does not occur, whereas for cancer 
effects the likelihood of tumour incidence is zero to very small at very low exposure levels. The TTC 
values are based on the analysis of the distribution of NOAELs for compounds sorted to different 
categories of toxicity (Cramer classes). These values are based on the 5
th percentile NOAELs along 
with the application of default uncertainty factors of 100-fold allowing for interspecies differences and 
human variability (Kroes et al., 2005). The Scientific Committee of EFSA concluded on the following 
human exposure threshold values to be sufficiently conservative to be used in EFSA‟s work: 0.15 
μg/person per day for substances with a structural alert for genotoxicity, 18 μg/person per day for 
organophosphate and carbamate substances with anti-cholinesterase activity, 90 μg/person per day for 
Cramer  classes  II  and  III,  and  1800  μg/person  per  day  for  Cramer  class  I  substances.  Thus,  for 
chemicals of unknown toxicity, human exposure thresholds (TTC values) can be established below 
which there is a low probability of adverse effects on health. The combined and stepwise use of TTC 
values, i.e. the TTC approach, can be used to assess substances of unknown toxicity present at low 
levels in the diet. Application of the TTC approach requires only knowledge of the chemical structure 
of the substance concerned and reliable information on human exposure. The extent to which the TTC 
is  accepted  depends  on  the  regulatory  application  and  context.  In  general,  the  approach  is  better 
accepted for the assessment of non-intentionally added substances, such as contaminants, reaction by-
products,  and  metabolites,  for  which  experimental  toxicity  data  are  not  available  and  consumer 
exposure  is  low  compared  to  the  TTC  threshold.  The  TTC  approach  is  also  used  in  the  safety Modern methodologies for human hazard assessment of chemicals 
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assessment of flavourings, in which read-across of toxicological properties within structurally defined 
groups is also permitted (EFSA SC, 2012). 
3.4.3.  Application of in silico tools and TTC to human hazard assessment 
 A wide range of (Q)SAR models are available to predict a number of toxicological properties in silico 
including mutagenicity, genotoxicity, acute toxicity and bioaccumulation as reviewed elsewhere (JRC, 
2011; Worth et al., 2011; EFSA, 2014a).  
Several surveys have been conducted to establish the extent to which in silico tools are accepted and 
used by regulatory bodies and industry (Lo Piparo et al., 2011; Mays et al., 2012; IEH, 2013). These 
surveys provide consistent findings, and reveal that grouping and read-across approaches are the most 
often used approaches across different regulatory sectors. (Q)SAR tools are used much less commonly 
in  hazard  assessments,  and  rarely  as  stand-alone  methods.  As  an  example,  the  new  Commission 
Regulation (EU) 283/2013 setting out data requirements for pesticide approval does not discuss the 
potential use of QSARs for ecological and human health hazard assessment (EU, 2013). However, 
examples for which (Q)SARs can be/are used to generate toxicity data include: a) compounds for 
which a risk assessment is not explicitly required by legislation (e.g. contaminants, impurities, co-
formulants, pesticide residues in food of animal or plant origin, pesticide groundwater metabolites); 
and b) compounds for which there is an urgent need to inform risk management decisions, such as in 
the case of incidents of food contamination. 
The  possible  applications  of  (Q)SARs  in  the  assessment  of  pesticide  residues  for  dietary  risk 
assessment have been explored in several projects at EFSA, focussing in particular on the use of 
(Q)SARs  for  predicting  genotoxicity  and  carcinogenicity  (JRC,  2010),  as  well  as  developmental 
toxicity and neurotoxicity (JRC, 2011). While recognising that further efforts are needed to improve 
and evaluate (Q)SAR models for these endpoints, the Scientific Panel on Plant Protection Products 
and their Residues (PPR Panel) of EFSA proposed the application of in silico tools (QSAR and read-
across)  for  the  prediction  of  genotoxicity  and  developmental  toxicity,  to  complement  the  TTC 
approach  in  the  assessment  scheme  for  pesticide  metabolite  exposure  (EFSA  PPR  Panel,  2012). 
Possible  use  of  QSARs  has  also  been  foreseen  in  the  QPS  (qualified  presumption  of  safety)  of 
botanical food supplements (EFSA, 2014a). 
Recently,  a  database  on  ADMET  (Absorption,  Distribution,  Metabolism,  Excretion  and  Toxicity) 
structure activity relationship, abbreviated admetSAR, has been published (Cheng et al., 2013). The 
database is an open source, text and structure searchable, and is continually updated. AdmetSAR 
manages available ADMET-associated properties data from the published literature with over 210 000 
ADMET annotated data points for over 96 000 compounds with 45 kinds of ADMET-associated 
properties, proteins, species, or organisms. A specific chemical profile can be queried in admetSAR 
using  either  the  CAS  registry  number,  the  common  name,  or  structure  similarity.  Finally, 
22 qualitative classification and 5 quantitative regression models are included allowing to estimate 
ecological/mammalian ADMET properties for novel chemicals (Cheng et al., 2013). 
In a recent a recent statement, the Scientific Panel on Food Additives and Nutrient Sources added to 
Food (ANS Panel) of EFSA has assessed the new scientific information on the food colouring Allura 
Red AC (EFSA ANS Panel, 2013) that became available since their previous opinion (EFSA, 2009d) 
using read-across methods. The assessment dealt particularly with the positive findings from an in vivo 
Comet assay in mice. These findings were interpreted together with all the available relevant data from 
genotoxicity  testing,  metabolism  and  carcinogenicity,  and  in  consideration  of  possible  species 
differences between mouse and rat. The Panel considered  the overall relevant data available in a 
read-across exercise, not only for Allura Red AC but also for a number of other structurally related 
sulphonated mono azo dyes authorised as food additives, namely: Amaranth, Ponceau 4R, Sunset 
Yellow FCF, Tartrazine and Azorubine/Carmoisine (EFSA ANS Panel, 2013). The Panel concluded 
that the new data were insufficient to change the conclusions of the 2009 opinion and that the read-
across exercise highlighted a shared pattern of effects for this class of substances that would need Modern methodologies for human hazard assessment of chemicals 
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further investigation. The Panel recommended that in vivo Comet assay in mice should be performed 
for  all  the  sulphonated  mono  azo  dyes,  in  compliance  with  the  most  recent  and  internationally 
validated experimental protocol, using whole cells and examining a wide range of tissues (EFSA ANS 
Panel, 2013). 
A generic application of the TTC includes to the categorisation of chemicals based on their level of 
concern for oral systemic toxicity (Cramer classification scheme), and to the prediction of the potential 
for genotoxicity using  in silico tools. These in silico tools include the widely used software tool 
Toxtree  (Patlewicz  et  al.,  2008;  Lapenna  and  Worth,  2011),  which  is  freely  available  (at 
th://ihcp.jrc.ec.europa.eu/our_labs/predictive_toxicology/qsar_tools/toxtree  and 
Sourcetoxtree.sourceforge.net/). A recent specific example includes the use of the TTC approach for 
the risk assessment of Alternaria toxins by the CONTAM Panel of EFSA since no toxicological data 
were available (EFSA CONTAM Panel, 2011).  
4.  OMICs:  principles  and  application  to  human  hazard  assessment,  strengths  and 
limitations 
The term „OMICs’ refers to a broad field of studies in biology, ending in the suffix „-omics‟, such as 
transcriptomics, proteomics and metabolomics, and associated „bioinformatics‟ (US-EPA, 2002). The 
OMIC technologies are rapidly developing in life sciences and their application to toxicology and 
ecotoxicology is one of the promising methodologies for evaluation and estimation of chemical risks 
(OECD, 2009a). Potential applications of OMICs in risk assessment applied to the food and feed area 
has been reviewed elsewhere (Pielaat et al., 2013).  
The  US-EPA  defines  genomics  as  ‘the  study  of  all  the  genes  of  a  cell  or  tissue,  at  the  DNA 
(genotype),  mRNA  (transcriptome),  or  protein  (proteome)  level‟.  The  main  difference  between 
genomics and genetics is that genetics scrutinises the functioning and composition of the single gene 
whereas genomics addresses all genes and their interplays in order to identify their combined influence 
on the growth and development of the organism. In the 1990s, it has been recognised that molecular 
biology  methods  (e.g.  Northern  blotting,  RNAse  protection  assays,  S1  nuclease  analysis,  plaque 
hybridisation, slot blots) did not provide sufficient throughput to effectively tackle genomic issues. 
The development of new methods in the late 1990s such as differential display, high-density filter 
hybridisation, serial analysis of gene expression, and cDNA- and oligonucleotide-based microarray 
„chip‟ hybridisation (microarrays) has provided new solutions to allow the monitoring of expression 
levels  of  thousands  of  genes  simultaneously  (Pietu  et  al.,  1999).  In  toxicology,  the  term 
„toxicogenomics‟ has been originally coined by Nuwaysir et al. (1999) and refers to the integration of 
the genomic technologies with bioinformatics as an alternative means to study underlying MoA/AOP 
of  chemicals  and  a  way  to  potentially  address  challenges  that  are  difficult  to  overcome  by 
conventional  toxicology  methods.  This  section  provides  a  short  overview  of  the  principles  of 
transcriptomics,  proteomics  and  metabolomics  with  a  number  of  examples  of  existing  potential 
applications in human hazard assessment of chemicals and their potential for future developments.  
4.1.  Transcriptomics 
4.1.1.  Principles of transcriptomics 
Transcriptomics deal with the expression level of mRNAs in a given tissue, organ or other cell 
population,  using  DNA  microarray  and  other  high-throughput  technologies  that  can  estimate  the 
quantities of mRNAs (NRC, 2007).  
The transcriptome is the set of all RNA molecules, including mRNA, rRNA, tRNA, and other non-
coding RNA (e.g. microRNA-transcriptional and post-transcriptional regulation of gene expression), 
produced in one or a population of cells (Pietu et al., 1999). The term can be applied to the total set of 
transcripts in a given organism or to the specific subset of transcripts present in a particular cell 
type. The key aims of transcriptomics are to catalogue all species of transcripts, including mRNAs, 
non-coding  RNAs  and  small  RNAs,  to  determine  the  transcriptional  structure  of  genes,  splicing Modern methodologies for human hazard assessment of chemicals 
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patterns and other post-transcriptional modifications and to quantify the changing expression levels of 
each transcript during development and under different conditions (Wang et al., 2009).  
Two main technologies are used for transcriptomics, namely oligonucleotide microarrays and next- 
generation sequencing.  
Oligonucleotide microarrays (OM) technology is hybridisation-based which is most common approach 
used for gene expression profiling, it makes use of the information created by genome sequencing 
(www.genomesonline.org), and from the myriad of expressed Sequences Tags (ESTs) using the first 
generation  Sanger  sequencers.  Hybridisation-based  approaches  are  high  throughput  and  relatively 
inexpensive, except for high-resolution arrays that interrogate large genomes. Today, it is possible to 
design an array of oligomer probes that covers the whole transcriptome of any organism for which the 
genome  sequence  is  known  and  the  possible  open  reading  frames  and  gene  models  have  been 
identified  using  well-established  bioinformatics  analysis  pipelines.  However,  these  methods  have 
several  limitations,  including  their  dependency  on  prior  knowledge  of  genome  sequence,  high 
background levels caused by cross-hybridization and a limited dynamic range of detection. Moreover, 
inter-experimental  expression  level  comparison  is  often  difficult  and  requires  complicated 
normalisation methods (Metzker, 2010). 
Next Generation Sequencing (NGS) technologies can deliver fast, high-throughput, inexpensive and 
accurate genome information, including genomic and epigenomic sequencing. NGS include methods 
for determining the sequence content and abundance of mRNAs, non-coding RNAs and small RNAs 
(collectively  called  RNA–seq)  and  methods  for  measuring  genome-wide  profiles  of 
immunoprecipitated DNA–protein complexes (ChIP–seq), methylation sites (methyl–seq) and DNase I 
hypersensitivity sites (DNase–seq). A key feature is the ability to sequence the whole genome of many 
organisms  and  it  has  allowed  large-scale  comparative  and  evolutionary  studies  to  be  performed 
(Metzker, 2010). In addition, the entire transcriptome can be queried, down to an individual base, 
whether or not a reference genome is available (McGettigan, 2013). This is illustrated with the recent 
publication  of  the  genome  of  1 092  individuals  from  14  human  populations  constructed  using  a 
combination of low-coverage whole-genome and exome sequencing as part of the 1000 Genomes 
Project.  In  addition,  NGS  also  allow  the  genome-scale  mapping  of  epigenomic  modifications 
important  for  transcriptional  control,  including  DNA  methylation  and  covalent  modifications  of 
histone proteins. Several large-scale analysis techniques are available that enable the survey of DNA 
methylation status at nucleotide resolution throughout the genome. NGS platforms for genome and 
epigenetic techniques are discussed elsewhere (Metzker, 2010). Overall, NGS is likely to replace OM 
because of their greater accuracy that closely matches quantitative polymerase chain reaction (PCR) 
and enable gene-expression studies in organisms for which OM are not available. Finally, they are 
likely to offer a higher throughput compared with microarrays as new developments will likely allow 
for the analysis of thousands of transcriptome samples in a single sequencing run (Sturla et al., 2014). 
However, the technology is limited by artefacts and biases that still need to be fully identified and 
controlled for (McGettigan, 2013). 
Analysis of transcriptomic data requires a combination of statistical techniques, bioinformatic tools 
and databases. The huge amount of data produced by NGS platforms requires powerful information 
technology  tools  for  data  storage,  tracking  and  quality  control  and  data  processing.  Datasets  are 
transformed  using  standardisation,  normalisation  or  scaling  in  order  to  be  able  to  compare 
measurements within and between studies. The challenge is to turn the large data sets with relatively 
high amounts of noise and without obvious biological/toxicological meaning into relevant findings. 
Advances in bioinformatics and algorithms have recently been reviewed, with focus on state-of-the-art 
techniques to support experimental scientists in analysing transcriptomic data (Berger et al., 2013). A 
number  of  methods  for  transcriptomics  data  analysis  and  interpretation  exist  and  include: 
mathematical  clustering  algorithms  (e.g.  hierarchical  clustering),  K-means  clustering  and  self-
organising maps, and calculation of a measure of similarity between gene profiles. Clustering creates 
subsets of similar sequences and enables to select, amongst thousands, the sequences with biologically 
relevant characteristics. Multivariate statistical methods include Principal Component Analysis (PCA) Modern methodologies for human hazard assessment of chemicals 
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and Partial Least Squares (PLS). PCA is an unsupervised method which determines intrinsic structure 
within data sets, without prior knowledge, and that is used to calculate similarity between large data 
sets,  such  as  microarray  measurements.  PLS  as  principal  component  discriminant  analysis  are 
supervised methods that use additional information (biochemical, histopathological or clinical data) to 
optimise the discrimination between samples (Draghici et al., 2003). In addition, software tools are 
under development to enable in-depth analysis of any list of inter-related biological data (pathway 
analysis tools) and many databases are available (Davies et al., 2010). These databases include the 
early Protein Data Bank, US National Center for Biotechnology Information (NCBI) sequence data 
sets  and  the  University  of  California,  Santa  Cruz  Genome  Browser164,  ENCODE165  and 
modENCODE166 projects. Data sets are usually generated by different laboratories and can have 
different dimensionalities and organisation. In order to support formatting, storing and calibrating of 
datasets, there have been substantial efforts to analyse such databases and online analysis tools have 
allowed performing a number of integrative data analyses on genomic data (e.g. Galaxy, DAVID119, 
STRING, Cytoscape, mouseNET).  
4.1.2.  Application of transcriptomics in human hazard assessment  
The uses of transcriptomics for human hazard assessment have been reviewed elsewhere and the 
general  view  is  that  accurate  prediction  of  chemical  toxicity  with  such  technologies  remains  a 
challenge (OECD, 2013; Thomas et al., 2013a; US-EPA, 2013). Key historical issues include that OM 
technology  and  PCR  data  have  generally  been  limited  to  single  time  points,  thus  providing  only 
snapshot information. However, NGS has allowed broader applications which include information on 
MoA of chemicals, dose-response assessment, inter- and intra-species differences in TK and TD, in 
vitro to in vivo extrapolations, epigenetic mechanisms and toxicity of multiple chemicals. To illustrate 
this,  four  examples  are  presented  below  in  relation  to  interspecies  differences,  benchmark  dose 
modelling,  epigenetic  mechanisms,  and  combined  toxicity  of  exposure  to  multiple  chemicals 
(chemical mixtures).  
Interspecies differences  
The contribution of toxicogenomics in defining the MoA of selective acting compounds has been 
illustrated  by  studies  carried  out  on  the  aryl  hydrocarbon  receptor  (AhR)  ligand  2,3,7,8-
tetrachlorodibenzo-p-dioxin (TCDD). Nault et al. (2013a) have demonstrated, by comparing TCDD 
with other AhR ligands such as β-naphthoflavone and using DNA microarrays, that divergent gene 
expression occurred between different AhR ligands and between in vitro liver cells (mouse hepatoma 
Hepa1c1c7 cells) and the liver in vivo (C57BL/6 mice). The acute hepatotoxicity of TCDD in mice 
following a single dose was found to correlate with changes in gene expression, which in turn were 
correlated with hepatic TCDD levels (Kopec et al., 2013). A comparison between human, mouse, and 
rat  primary  hepatocytes  showed  that  with  TCDD,  495,  2305,  and  711  orthologous  genes  were 
differentially expressed in human, mouse, and rat hepatocytes, respectively (Forgacs et al., 2013). 
However, in that study, only 16 orthologues were differentially expressed across all three species, 
demonstrating species-specific gene expression profiles of TCDD despite the conservation of the AhR 
and its signalling mechanism. Similar conclusions were made in a further study (Nault et al., 2013b) 
when the genome-wide hepatic gene expressions elicited by TCDD were compared in vivo between 
Sprague-Dawley rats and C57BL/6 mice. The functional analysis of the genes that were differentially 
expressed  has  identified  different  orthologues  in  the  rat  (nucleotide  binding  and  acetyltransferase 
activity)  in  comparison  with  the  mouse  (steroid,  phospholipid,  fatty  acid  and  carbohydrate 
metabolism). Transcriptomics can provide valuable data regarding not only on the MoA of selective 
acting compounds but also inform on interspecies differences in MoA. 
Benchmark dose modelling  
The possibility of deriving BMD and BMDL from transcriptomic data has recently been explored 
(Thomas et al., 2007, 2011, 2012, 2013a,b). In a first study, dose-response microarray data were 
analysed  using  BMD/BMDL  calculations  and  gene  ontology  (GO)  classification  in  the  rat  nasal Modern methodologies for human hazard assessment of chemicals 
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epithelium following acute formaldehyde exposure (Thomas et al., 2007). The authors matched gene 
expression patterns to associated GO categories and, from these, computed average BMD and BMDL 
values for each category. Using these results and comparing them to doses of formaldehyde exposure 
causing alterations of individual cellular processes, the authors showed that the BMD estimates for the 
GO  categories  related  to  cell  proliferation  and  DNA  damage  were  similar  to  those  measured  in 
previous  studies  using  cell  labelling  indices  and  DNA-protein  cross-links.  Moreover,  the  BMD 
estimates were consistent with the BMD estimated for rat nasal tumours (Thomas et al., 2007). This 
approach  was  subsequently  extended  to  two  case  studies,  one  comprising  five  chemicals  (1,4-
dichlorobenzene,  1,2,3-trichloropropane,  propylene  glycol  mono-t-butyl  ether,  naphthalene  and 
methylene  chloride)  that  were  positive  in  a  2-year  cancer  bioassay  and  that  were  tested  in  mice 
(Thomas et al., 2011, 2012), and a second case study in which six chemicals (1,2,4-tribromobenzene, 
2,3,4,6-tetrachlorophenol,  bromobenzene,  4,4‟-methylenebis(N,N-dimethyl)  benzenamine, 
hydrazobenzene and N-nitrosodiphenylamine) were tested in rats (Thomas et al., 2013a). Three of the 
latter six compounds were found positive in rodent carcinogenicity tests. Multiple dose levels were 
used for each chemical and four time points (5 days, 2 weeks, 4 weeks and 13 weeks), and the 13-
week time point, were used in the rat and mouse studies respectively. The authors analysed target 
tissues  for  traditional  apical  cancer  and  non-cancer  endpoints  (e.g.  histological  and  organ  weight 
changes)  and  transcriptional  changes  using  microarrays.  The  dose-response  changes  in  gene 
expression were analysed using a BMD approach and the responses grouped based on either biological 
processes (Thomas et al., 2011) or signalling pathways (Thomas et al., 2012, 2013a). For chemicals 
with human exposure data, the transcriptional BMD values were also used to calculate MOEs. The 
transcriptional BMD values, when compared with those for the traditional non-cancer and cancer 
apical endpoints, showed a high degree of correlation for specific pathways (> 0.85). Many of the 
correlated pathways have been implicated in non-cancer and cancer diseases pathogenesis. The results 
demonstrated that transcriptomic changes in pathways can be used to estimate non-cancer and cancer 
points  of  departure  for  use  in  quantitative  risk  assessments  and  have  identified  potential  toxicity 
pathways involved in chemically induced responses in rodents (Thomas et al., 2011, 2012, 2013a). 
Moreover, the authors showed that the correlation between the transcriptional BMD values for the 
most sensitive pathway and the apical BMD values (> 0.85) was relatively stable over time for both 
non cancer- and cancer-related endpoints.  
Investigation of epigenetic effects of chemicals  
Recent work in the area of genomics has highlighted the importance of the epigenetic control of gene 
expression. A key feature of epigenetics is that they define heritable changes that are superimposed on 
the genome in the absence of genome sequence variability (Supic et al., 2013). This regulation occurs 
at the level of DNA methylation or hydroxymethylation, post-translational histone modification and 
circulating miRNAs that inhibit mRNA translation or accelerate their degradation. Some attempts 
have been made to evaluate miRNA as a tool in the risk assessment of drug-induced organ injury 
(Antoine et al., 2013; Shi et al., 2013; Yokoi and Nakajima, 2013). However, at present the lack of a 
standard quantification method for miRNAs and the small number of confirmatory studies limit the 
use of miRNA biomarkers in risk assessment. An attempt to incorporate epigenetic transgenerational 
effects in chemical risk assessment was recently performed by Alyea et al. (2014) who compared 
several transgenerational studies on the fungicide vinclozolin from a comprehensive suite of dose-
response data (NOAEL, reference dose, and human exposure estimates) for both conventional and 
epigenetic endpoints. Overall, the analysis revealed that vinclozolin transgenerational effects were 
demonstrated at a 100 mg/kg/day in rats which would be 40-fold and 80-fold higher than the overall 
LOAEL  and  NOAEL  from  rat  guideline  studies  respectively  around  80,000-fold  higher  than  the 
reference dose and 1.2-million fold above human exposure estimates.  
The  authors  concluded  that  additional  research  is  needed  to  investigate  the  interplay  between 
epigenetics  and  apical  endpoints  before  epigenetics  can  be  considered  in  human  health  risk 
assessment.  Finally,  the  authors  recommended  focusing  research  to  examine  the  potential  causal 
relationships  between  epigenetic  alterations  and  adverse  apical  endpoints  and  if  such  a  causal Modern methodologies for human hazard assessment of chemicals 
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relationship can be demonstrated the dose response relationship should also be investigated (Alyea et 
al., 2014). 
Recently, the use of zebrafish (Danio rerio) to investigate adaptive and adverse responses to chemicals 
in  relation  to  global  transcriptomic  responses  has  been  reviewed.  The  review  highlights  specific 
applications in the area of epigenetic effects (e.g. DNA methylation, histone modifications and micro-
RNA  expression)  through  the  integration  of  high-throughput  screening,  OMICs  techniques  and 
bioinformatics leading to the discovery of AOPs (Williams et al., 2014). 
Combined exposure to multiple chemicals  
Transcriptomics  may  support  the  hazard  characterisation  of  the  combined  toxicity  of  multiple 
chemicals  through  the  analysis  of  individual  gene  expression  changes  and  multivariate  statistical 
analysis of such gene profile changes (Stierum et al., 2005). In a study, Padhi et al. (2008) exposed 
rats perinatally to the so called „Northern contaminant mixture‟ (NCM), (methylmercury (MeHg), 
polychlorinated biphenyls (PCBs) and organochlorine pesticides (OCs)) separately or together with 
the goitrogen propylthiouracyl. The study was designed to reflect the blood contaminant profile of 
human populations in arctic Canada. Post-natal day 14 cerebellum global gene expression resulting 
from such exposures was investigated using high-density cDNA microarrays validated by quantitative 
PCR (qPCR) on a subset of 10 genes. A number of differentially expressed genes involved in a 
number  of  neural  functions  were  identified  between  controls  and  treated  animals  (e.g.  nerve  cell 
differentiation, migration, myelination and synaptic transmission). The comparison of cerebellum gene 
expression profiles resulting from exposure to the NCM and its individual components in male and 
female  pups  revealed  inter-gender  differences  in  transcriptomic  responses  and  that  co-exposure 
significantly masked the effects of individual components on cerebellum gene expression. 
Toxicity of the phytoestrogen genistein with the anti-androgenic food contaminant vinclozolin on the 
male reproductive tract and fertility was assessed in rats combining a number of standard reproductive 
toxicology end points together with testicular mRNA expression profiles using long OM. Overall, the 
endpoints for reproductive function (decreased sperm counts, reduced sperm motion parameters) were 
correlated with testicular mRNA expression profiles (Eustache et al., 2009).  
4.2.  Proteomics  
4.2.1.  Principles of proteomics  
Proteomics  „deal  with  cell  and  tissue-wide  expression  of  proteins  encoded  by  a  genome.  After 
transcriptomics, proteomics is the next step in OMICs studies. It is more complicated than genomics 
because, while a particular genome is more or less constant, the proteins that are produced differ from 
one cell type to another and from time to time in the same cell type (OECD, 2009a)‟. Merrick and 
Bruno have termed a distinct set of expressed proteins that distinguish between health, toxicity or 
disease as „toxicity signature‟ (Merrick and Bruno, 2004).  
The identification and quantification of the proteome remains one of the greatest challenges in the 
post-genomic era. The three key challenges faced in proteomics are caused by (i) the ca. 1,000,000 
estimated proteins transcribed from only 20,000 human genes, (ii) the dynamic range from 6 orders of 
magnitude for the proteins present in a mammalian cell up to 10 orders of magnitude in body fluids 
and  (iii)  the  constant  dynamic  flux  of  the  proteome.  This  section  will  highlight  principles  of 
proteomics  including  technological  tools  used  to  study  the  proteome  and  illustrate  application  of 
proteomics in human hazard assessment of chemicals. 
The main technologies currently applied for separating proteins from complex biological samples 
(cells,  organs…)  are  gel-based  (e.g.  two-dimensional  gel  electrophoresis  (2-DE)  and  gel-free 
techniques (e.g. liquid chromatography tandem mass spectrometry (LC–MS/MS)) (Cecconi and Zamo, 
2011; Yu, 2011; Sabido et al., 2012; Rodriguez-Suarez and Whetton, 2013). These techniques can be 
used  in  combination  because  they  focus  on  different  subsets  of  proteins  that  are  only  partially Modern methodologies for human hazard assessment of chemicals 
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overlapping and, therefore, are complementary. The subsequent identification of proteins occurs by 
combining the separation methods with tandem mass spectrometry. 
In 2-DE, the proteins in a sample are separated first by iso-electric focusing on an immobilized pH 
gradient gel under the influence of an electric field, then separated according to their molecular mass 
by SDS–polyacrylamide gel electrophoresis and visualised after staining. The main drawback of 2-DE 
is the high inherent variability of the technique, rendering comparison between protein samples very 
difficult. This problem has been reduced by the introduction of differential gel electrophoresis, which 
allows two proteins samples labelled with different fluorescent dyes prior to be run together on the 
same gel along with an internal standard labelled with a third dye. The gel is then scanned and the 
protein  spots  analysed  by  dedicated  software.  Identification  of  the  individual  proteins is  done  by 
protein spot picking from the gel, followed by protease digestion and identification by soft ionisation 
mass  spectrometer  (using  electrospray  ionisation  or  matrix  assisted  laser  desorption  ionisation 
(MALDI) from a target plate. Overall, 2-DE is an accurate and relatively easy technique to perform 
quantification  of  individual  proteins,  and  remains  currently  the  most  used  method  of  protein 
separation. However, despite the major improvement obtained with Difference Gel Electrophoresis 
(DIGE) technology, co-migration of different proteins on the gel and the inability to run hydrophobic 
(membrane) proteins and proteins with an extreme pI remain major difficulties. Moreover, 2DE and 
the individual spot analysis by mass spectrometry are time consuming. 
As an alternative to gel-based protein separation, the analysis of complex protein samples by liquid 
chromatography-tandem  mass  spectrometry  (LC-MS/MS)  has  gained  popularity  over  the  past  ten 
years, as the so-called „shotgun proteomics approach‟. In this approach, the protein sample is first 
digested into a complex mixture of peptides that are separated by reversed-phase high-performance 
LC and analysed using soft ionisation techniques such as electrospray ionisation mass spectrometry 
(ESI-MS) or MALDI-MS. In contrast to 2-DE, shotgun proteomics can be used to study hydrophobic 
proteins as a high throughput platform, since thousands of peptides can be analysed simultaneously. 
However, the quantification of the individual proteins remains challenging. To this effect, a number of 
quantitation techniques involving metabolic and chemical labelling of the protein sample with stable 
isotopes and label-free approaches has been developed for LC–MS/MS-mediated proteome analyses 
(Rodriguez-Suarez and Whetton, 2013). In contrast to 2-DE and shotgun proteomics that have been 
used to analyse all the proteins present in a sample, targeted proteomics based on multiple reaction 
monitoring (MRM) or selective reaction monitoring (SRM) was developed to verify the identity of 
specific  proteins  of  interest  and  to  follow  them  with  high  throughput.  MRM  requires  a  triple 
quadrupole mass spectrometer, with the first quadrupole (Q1) selecting the known precursor ion, Q2 
fragmenting the ion and Q3 monitoring the fragment ions (Meng and Veenstra, 2011). The immense 
data information provided by a single proteomic analysis necessitates specific tools for data processing 
to enable the extraction of key information on the identity and quantity of the detected proteins. 
As  discussed  previously  for  transcriptromic  data,  analysis  of  proteomics  data  requires  complex 
statistical  methods,  databases  and  bioinformatic  tools.  Three  main  families  of  regression-based 
methods currently being applied in the analyses of OMICS data: univariate approaches and associated 
multiple  testing  correction  procedures,  dimension  reduction  techniques,  and  variable  selection 
approaches. These are reviewed elsewhere (Chadeau-Hyam et al., 2013). Recently, Knudsen et al. 
(2014)  have  published  online  a  comprehensive  open-source  tool  for  merging  multidimensional 
quantitative proteomics data into a common format ready for subsequent bioinformatic analysis. 
Recent technological advances allow now > 2500 proteins to be detected in a single LC-MS/MS run 
with a dynamic range of 4-5 orders (Rodriguez-Suarez and Whetton, 2013). However, the robustness, 
reproducibility and mass accuracy of the technology will need to be further increased to face the 
technological challenge that 75 % of the proteome is present at < 5000 protein molecules per cell 
(Washburn et al., 2003). As a result, many low-abundance proteins, among which are often found the 
biomarkers of interest, remain un-analysed. A further problem is that the technologies in proteomics 
are not yet standardised between laboratories despite the formation of several consortia. This lack of Modern methodologies for human hazard assessment of chemicals 
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standardisation  will  present  a  major  challenge  to  regulatory  agencies  whose  task  will  be  to  help 
establishing standardised transparent methods to interpret „omics‟ data.  
Efforts to compare proteomic with transcriptomic data have met mixed success. It has become clear 
over the past decade that the biological dogma „DNA → RNA → protein‟ is not only affected by 
complex  relationship  between  the  20,000  genes  from  which  an  estimated  1,000,000  proteins  are 
produced,  but  also  the  differences  in  dynamic  processes  between  the  events  of  transcription, 
translation and  post-translational  modification  and, finally,  protein turnover. While only  a  limited 
correlation  between  changes  in  individual  mRNAs  and  the  corresponding  proteome  is  generally 
observed, several studies have found good correlations at the pathway level (Boitier et al., 2011; 
Collins  et  al.,  2012).  However,  these  correlations  tend  to  be  limited  to  chemical  agents  where 
biological or toxicological activity is receptor-mediated.  
4.2.2.  Application of proteomics to human hazard assessment  
The past decade has seen a rapid increase in the application of proteomics in toxicology and hazard 
assessment,  where  it  is  often  referred  to  as  toxicoproteomics  (Van  Summeren  et  al.,  2012). 
Applications  of  proteomics  to  human  hazard  assessment  of  chemicals  are  illustrated  for  the 
identification and quantitation of protein targets for in vivo (with tissues and biological fluids) and in 
vitro  (cell  cultures)  studies,  as  well  as  for  the  identification  of  biomarkers  of  toxicity  with  the 
overarching aim to depict MoA/AOP. 
Identification of protein targets for toxicants in vivo 
A promising application of proteomics has been the identification of protein targets for toxicants in 
vivo to investigate MoA. For instance, Fountoulakis et al. (2000) found in a proteomic study in mice, 
that  the  levels  of  approximately  35  proteins  out  of  256  hepatic  proteins  (identified  by  DE)  were 
modified after paracetamol treatment (Fountoulakis et al., 2000). In a related study by Koen et al. 
(2007), 33 new protein targets forming bromobenzene metabolite adducts in mouse liver, including 
glutathione  S-transferases,  protein  disulfide  isomerases  and  liver  fatty  acid-binding  protein,  were 
identified by 2-DE combined with MALDI-MS (Koen et al., 2007). In another study, protein samples 
from livers of rats treated 14 days with troglitazone were separated by DIGE and analysed by MALDI 
MS (Boitier et al., 2011). This study identified 55 proteins belonging mostly to the pathways of fatty 
acid metabolism, PPARα/RXR activation, oxidative stress and cholesterol biosynthesis, whose levels 
were up-regulated, and some to carbohydrate metabolism, whose levels were down-regulated. The 
same pathways were also identified to be affected at the transcriptomics level (Boitier et al., 2011).  
In an integrated study evaluating gentamycin nephrotoxicity in rats  (Com et al., 2012), proteomic 
analysis of the kidney after 14 days of treatment revealed that of the 2000 polypeptide spots detected 
by  2D-DIGE,  56  different  down-regulated  proteins  and  49  different  up-regulated  proteins  were 
identified by MALDI-TOF MS. The modulation in protein levels was suggestive of a mitochondrial 
dysfunction with impairment of cellular energy production, induction of oxidative stress, an effect on 
protein biosynthesis and on cellular assembly and organisation. In an attempt to access the proteome 
using non-invasive techniques, proteomics have also been applied to serum and urine. For instance, 
proteomics  were  used  to  identify  proteins  up-  and  down-regulated  in  rat  plasma,  in  response  to 
treatment with doses of cationic nanobubles that caused liver fibrosis and inflammation (Pan et al., 
2012) and to identify multi-organ responses induced by paracetamol treatment of mice (Sun et al., 
2013). Several studies have assessed the proteome in urine after treatment with toxic chemicals.  
Identification of protein targets for toxicants in vitro 
Attempts have also been made to use proteomics to study complex toxicological responses such as 
teratogenicity. Meganathan et al. (2012) applied proteomics to the study the in vitro effects of the 
teratogenic agent thalidomide on differentiation of human embryonic stem cells (Meganathan et al., 
2012).  The  authors  showed,  with  the  help  of  genomic  and  proteomic  expression  patterns,  the 
differential expression of limb, heart and embryonic development related transcription factors and Modern methodologies for human hazard assessment of chemicals 
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biological processes and the effect of thalidomide treatment on the levels of select proteins such as 
RANBP1 (a RAN GTPase binding protein mediating the translocation of RNA and proteins through 
the nuclear pore complex). 
Discovery and validation of biomarkers of toxicity  
The other key application of proteomics in toxicology is in the research and validation of biomarkers. 
Biomarkers provide important information on exposure, susceptibility and response to a chemical in 
biofluids, tissues or cell cultures. Therefore, a signature of specific molecular changes at the level of 
proteins is expected to accompany the development of toxicity. Proteomics present several major 
advantages over traditional biochemical or immunological approaches when applied to biomarkers 
(Amacher,  2010;  Van  Summeren  et  al.,  2012).  For  instance,  biomarker  identification  is  greatly 
facilitated by MS-based techniques and the use of targeted proteomics based on multiple reaction 
monitoring (MRM) enables 30-100 candidate protein biomarkers to be simultaneously targeted and 
measured.  A  further  advantage  of  MS-based  proteomics  is  that  it  allows  to  distinguish  multiple 
posttranslational variants of a protein and to quantitate them. It is therefore not surprising that major 
efforts have gone into initiatives such as the European InnoMed PredTox project, the Predictive Safety 
Testing  Consortium,  the  Human  Urine  and  Kidney  Proteome  Initiative  and  FDA‟s  Critical  Path 
Initiative  for  safety  science  with  the  aim  to  identify,  develop  and  validate  new  biomarkers  for 
preclinical safety evaluation. An example of the successful application of proteomics in biomarker 
discovery  is  the  identification  of  glycine  amidinotransferase  and  plasma  retinol-binding  protein 
precursor as novel potential biomarkers for nephrotoxicity  (Com et al., 2012). Similarly, a recent 
evaluation  of  liver  protein  samples  from  rats  treated  with  the  hepatotoxic  agent  EMD  335823 
separated by label-free LC-MS identified, using SRM, 48 putative liver toxicity biomarkers (Collins et 
al., 2012).  
4.3.  Metabolomics  
4.3.1.  Principles of metabolomics  
The US-EPA has defined metabolomics: the evaluation of tissues and biological fluids for changes in 
metabolite levels that result from toxicant-induced exposure (US-EPA, 2004). The OECD refers to 
metabolomics as a discipline, which “deals with endogenous metabolite profiles of tissues or organs 
derived from mass spectrometry or nuclear magnetic resonance spectrometry analyses of plasma or 
homogenates. Metabolic profiling can give an immediate picture of the physiological state of  the 
tissue (OECD,  2009a).  More  recently,  Sturla  et  al. (2014)  gave  a  more  quantitative  definition  of 
metabolomics: „metabolomics analyses in a comprehensive and quantitative manner all metabolites or 
low  molecular  weight  organic  or  inorganic  chemicals  that  are  products  or  substrates  of  enzyme-
mediated processes‟.  
The metabolome is composed of all the low molecular weight compounds (typically < 1500 Da) of 
endogenous nature, which are important modulators, substrates, by-products, and building blocks of 
many  different  biological  processes  such  as  endogenous  metabolites  (amino  acids,  carbohydrates, 
lipids, etc…). It also includes the exogenous metabolites such as drug metabolites, xenobiotics and 
contaminants  living  organisms  may  be  exposed  to,  and  in  this  case  has  been  referred  to  as  the 
„exposome‟  (Wild,  2005,  2012).  Metabolomics  thus  offer  a  powerful  tool  for  discovering  the 
functional status  of an  organism  and  elucidating  the  consequences of internal  (genetic  mutations, 
diseases) and external (environment, food composition, xenobiotics) perturbations. For example, the 
accumulation of a specific metabolite may either signal an AOP (activation of a toxicity pathway) or 
the optimisation of a biosynthetic pathway (anabolism).  
Currently, two complementary approaches are used in metabolomics: the targeted approach and the 
non-targeted approach.  
The  targeted  approach,  also  called  metabolic  profiling  in  some  instances,  enables  to  perform 
quantitative analysis (relative abundances and concentrations) of specific sets of metabolites such as Modern methodologies for human hazard assessment of chemicals 
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biomarkers of toxicity, or substrates, and products of known enzymatic reactions (Illig et al., 2010; 
Menni  et  al.,  2012).  A  key  disadvantage  is  that  the  method  is  not  applicable  to  identify  new 
metabolites because the exact structure of the metabolite(s) needs to be known so that they can be used 
as standards for quantitation (Wishart et al., 2007; Bouhifd et al., 2013). On the other hand, this allows 
a  systematic  collection  of  data  with  good  quality  control  for  toxicological  studies  and  hazard 
assessment. 
The  untargeted  approach  is  often  referred  to  as  „global  metabolome  analysis‟  or  „metabolic 
fingerprinting‟  and  provides  a  comprehensive  view  of  all  metabolites  in  a  biological  sample. 
Metabolites  different  in  their  relative  quantitation  and  annotation  (i.e.  MS/chromatographic/ 
spectroscopic peaks), are generated and the initial raw data may produce thousands of signals. The 
main applications of this approach are investigation of MoA, hypothesis generation and identification 
of biomarkers. However, a key weakness is that untargeted metabolomics provides only a relative 
quantification and some significant metabolites are not always identifiable (Bouhifd et al., 2013). 
Analytical techniques to identify endogenous and exogenous metabolites in metabolomics include 
Nuclear Magnetic Resonance (NMR) and MS, coupled to separation techniques, or using direct flow 
injection.  NMR  has  a  number  of  advantages:  non-discriminating  and  non-destructive  technique, 
minimal  requirements  for sample  preparation  and  versatile technique  which  can  be  used  in  high-
throughput fingerprinting context and for the analysis of biological fluids (serum, urine etc.) and intact 
tissues  (for  example,  tumours)  The  major  weakness  of  NMR  spectroscopy  is  that  it  is  orders  of 
magnitude less sensitive than MS. Modern MS now enables to measure compounds in the femto-molar 
to atto-molar range. Coupling MS with LC or GC allows the measurement of hundreds of individual 
species within a single sample. The combination of mass accuracy and real-time tandem MS, along 
with increasingly comprehensive databases, can automate the identification of metabolites in a routine 
manner.  
The identification of metabolites chemical structure and their quantitative analysis provide information 
that can be interpreted in the light of biochemical pathways and metabolites causing group segregation 
in the fingerprinting approach need to be identified using quantitative methods. This will allow both 
metabolic fingerprinting and profiling. In order to do that, annotation of the metabolome is important 
and over the past years, the metabolomics community has made efforts and progress towards more 
robust approaches for such annotation. Thus, the development and enrichment of databases of known 
metabolites and the accessibility to a few on-line data processing and annotation workflow may now 
facilitate  the  tedious  work  of  pre-processing,  statistical  analysis,  and  annotation  of  metabolomics 
studies (Patti et al., 2012; Wishart et al., 2013). Although these approaches can be very powerful to 
reveal metabolites of interest, the validation of these biomarkers, particularly for small molecules 
reflecting metabolic processes, remains essential (Koulman et al., 2009). 
Data analysis in metabolomics requires a pre-processing step, a normalisation step and a statistical 
analysis step. The pre-processing step consists of alignment of spectral data in order to obtain a matrix 
of the characteristic features of the samples within a batch of analyses. This can be complex and time 
demanding especially in the case of high-resolution LC-MS (Boccard et al., 2010). Normalisation of 
the data aims at making the data comparable as much as possible to allow the quantification of signals 
detected in  multiple samples.  Recent  methods  for  data  normalisation include  optimal selection of 
multiple internal standards (Sysi-Aho et al., 2007). Data analysis is the final step in the schematic 
work-flow  of  metabolomics  and  a  number  of  multivariate  statistical  tools  are  available  and  the 
selection will depend on the experimental objectives or the type of question investigated including 
PCA, partial least square discriminant analysis (PLS-DA) and orthogonal PLS-Discriminant Analysis 
(OPLS-DA). PLS-DA is a method applied to both discriminating or classifying a set of samples in a 
metabolomic context, and OPLS-DA has been increasingly used to identify metabolites of potential 
biochemical significance with a graphical output to allow visualisation/discrimination of metabolites 
(Wiklund  et  al.,  2008).  A  full  review  of  statistical  methods  to  analyse  OMIC  data  including 
metbsolomics is included in Chadeau-Hyam et al. (2013). Modern methodologies for human hazard assessment of chemicals 
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Guidelines for reporting data, experimental conditions as well as harmonisation regarding ontology 
and common semantics for metabolomics are needed to facilitate the exchange of information and the 
re-use and interpretation of results across several scientific disciplines. Through the Metabolomics 
Standards  Initiative  (MSI  -  http://msi-workgroups.sourceforge.net/),  the  Metabolomics  Society  has 
encouraged the scientists to apply standards for reporting on their metabolomics experiments and 
studies (Fiehn et al., 2007; Sumner et al., 2007). This Core Information for Metabolomics Reporting 
(CIMR)  specifies  minimal  guidelines  and  seeks  in  the  long  term  to  cover  all  application  areas, 
analytical technologies, biological context metadata, chemical analysis and data processing, as well as 
formats for exchange of data and the ontology. 
Recent metabolomic databases include the human metabolome database (HMDB) which contains ca. 
2500 metabolites, 1200 drugs and 3500 food components encountered in the human body (Wishart et 
al., 2007), the MetaMap®-Tox developed at metabonomics and containing rat plasma metabolome for 
more than 500 references compounds (Kamp et al., 2012; Mattes et al., 2013). Finally, the EU research 
project COordination of Standards in MetabOlomicS (COSMOS) (http://cosmos-fp7.eu) developed the 
MetaboLights  dataset://www.ebi.ac.uk/metabolights/)  as  a  central  repository  of  metabolomics 
experiments (Haug et al., 2013). MetaboLights is a cross-species, cross-technique database, which also 
covers metabolite structures, their reference spectra as well as information on the biological roles of 
the  metabolites, their locations  and  concentrations,  and  the experimental  data  from  the  metabolic 
studies  uploaded  in  this  repository  (Steinbeck  et  al.,  2012).  Such  efforts  provide  existing  e-
infrastructures to report metabolomic studies, make them available to a broader community so that the 
data can also be used as standards for the interpretation of future metabolomic studies. 
4.3.2.  Applications of metabolomics in hazard assessment 
Overviews and application of metabolomics in a regulatory context have been published (Bouhifd et 
al., 2013; Ramirez et al., 2013). Examples of the applications of metabolomics are provided below 
regarding MoA/AOP and toxicokinetic aspects using in vivo studies, predictive models using in vitro 
methods and in vivo studies of combined exposure to multiple chemicals (chemical mixtures).  
In vivo studies and MoA 
An increasing number of studies investigating MoA/AOP using metabolomic biomarkers of toxicity in 
vivo are being published. Montoya et al. (2014) have developed a database (MetaMap
®Tox) based on a 
rat plasma metabolome consisting of approximately 300 endogenous metabolites. Male and female 
Wistar rats were treated with > 500 reference compounds over a period of 28 days and more than 120 
specific  toxicity  patterns  of  common  metabolite  changes  associated  with  unique  MoAs  were 
established. The authors applied the results to predictive direct/indirect adverse effects on the thyroid. 
Animals  were  treated  using  compounds  acting  either  directly  on  the  thyroid  function  (e.g. 
methimazole, ethylenethiourea) or indirectly on the thyroid (e.g. induction of liver enzyme inducers by 
agents such as aroclor 1254 and boscalid leading to an increased excretion of thyroid hormones). The 
authors identified metabolites in plasma, which were commonly regulated irrespective of whether the 
effect on the thyroid was indirect or direct. For example, direct thyroid hormone synthesis inhibitors 
affected enzymes in the urea cycle, increased the ω-oxidation of fatty acids and decreased glutamate 
and oxoproline levels whereas indirect thyroid hormone inhibiting compounds interacted with the lipid 
mediated and liver metabolism (Montoya et al., 2014). 
Toxicological and metabolomics studies of 3-chloropropane-1,2-dipalmitate (3-MCPD dipalmitate) 
were carried out based on an acute oral toxicity test, a 90-day feeding test, and on ultra-performance 
LC-MS analysis. The results of the 90-day feeding test in male Wistar rats showed that 3-MCPD 
dipalmitate caused a significant increase in blood urea nitrogen and creatinine differences analysed 
by PLS-DA of the chromatographic data. Renal tubular epithelium cell degeneration and renal 
tubular hyaline cast accumulation were the major histopathological changes in rats administered 3-
MCPD  dipalmitate.  The  combination  of  histopathological  examination,  clinical  chemistry  and 
metabolomics analyses in rats resulted in a systematic and comprehensive assessment of the  sub-Modern methodologies for human hazard assessment of chemicals 
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chronic toxicity of 3-MCPD dipalmitate and provided specific metabolomic markers of toxicity (Li et 
al.,  2013a).  Another  study  investigating  the  metabolomics  of  dimethoate  toxicity  in  rats  showed 
alterations  in  the  excretion  of  a  number  of  endogenous  metabolites  (e.g.  L-tyrosine, 
dimethylthiophosphate,  dimethyldithiophosphate,  citric  acid,  uric  acid,  suberic  acid,  glycylproline, 
allantoin, isovalerylglutamic acid) reflecting perturbation in liver function, antioxidant and nervous 
systems, as well as the metabolisms of lipids, glucose, fatty acids, amino acids, and collagen in rats 
(Feng et al., 2012). 
In vivo metabolomics and toxicokinetics 
Recent applications of metabolomics have included the investigation of toxicokinetic processes. In 
mice, the use of stable isotope- and mass spectrometry-based metabolomics to underpin the metabolic 
routes and effects of the drug tempol has been recently published. PCA of the urinary metabolomics 
data separated tempol  metabolites  versus  endogenous  metabolites,  which  had been  altered  by  the 
tempol treatment (Li et al., 2013b). In humans, endogenous metabolic markers of hepatic CYP3A, 
activity, the major human CYP isoform in the liver and the  gastrointestinal (GI) tract have been 
investigated  in  24 healthy  subjects:  CYP3A  substrate  (midazolam),  inhibitor  (ketoconazole)  and 
inducer  (rifampicin).  Metabolomic  analyses  supported  the  development  of  a  predictive  model  for 
CYP3A activity using midazolam as a probe substrate and a combination of concentrations and ratios 
of several endogenous metabolites (Shin et al., 2013). 
Predictive in vitro methods  
Many in vitro metabolomic studies have also been published with the aim of developing predictive 
models.  For  example, the use of  human embryonic stem cells combined with the  use of LC-MS 
analysis, as alternative models to identify potential developmental toxicants, has been highlighted 
recently. In this study the authors demonstrated correlation between teratogenicity and changes in the 
ratio of arginine to asymmetric dimethylarginine (greater than 10 %) (West et al., 2010; Kleinstreuer 
et al., 2011). The authors built a predictive model and validated the predictability of the model for 
eight teratogenic drugs (West et al., 2010). 
Combined toxicity of multiple chemicals 
Recently, a number of in-vivo metabolomics studies have been used to study the toxicological effects 
of combined exposure to multiple chemicals. For example, the acute renal toxicity of melamine and 
cyanuric acid in rats has been investigated combining several analytical techniques and endpoints 
based on metabolomic markers of kidney damage and compared with histopathology results. In the 
future,  these  metabolomic  markers  could  be  used  to  model  BMDLs  to  derive  a  HBGV  for  the 
melamine-cyanuric acid mixture and compared to traditional histopathological endpoints(Xie et al., 
2010; Kim et al., 2012; Schnackenberg et al., 2012; Sun et al., 2012). In the pesticide area, recent in 
vivo  toxicity  studies  investigating  the  long-term  effects  of  combined  exposure  to  multiple 
organophosphate pesticides (dichlorvos, dimethoate, acephate, and phorate) showed global disturbance 
in  lipid  metabolism,  tricarboxylic  acid  cycle  and  oxidative  stress  (Du  et  al.,  2013).  The  use  of 
metabolomics  coupled  with  multivariate  statistical  tools  to  address  polyTK  in  the  context  of 
multicomponent pharmaceuticals or nutraceuticals has been discussed. A research framework has been 
proposed  to  integrate  the  dynamic  concentration  profile  of  bioavailable  xenobiotics  (e.g.  in  vivo 
absorption, hepatic and gut microbial metabolism.) as well as the human metabolic response profile 
(Lan et al., 2013). 
4.4.  Strength and limitations of OMICs technologies 
The era of OMICS technologies opened great opportunity to characterise MoA/AOP of chemicals for 
a number of endpoints addressing different levels of biological organisation (DNA, mRNA, proteome 
and metabolome level). In the future, it is foreseen that the integration of such OMIC technologies will 
provide endpoints to quantify key events associated with AOPs for chemically-induced adverse effects Modern methodologies for human hazard assessment of chemicals 
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in humans. However, during the development and refinement of the different OMICs technologies, 
scientists have soon realised that the „holy grail of prediction‟ was not yet available.  
A  self-evident  strength  of  the  application  of  the  OMICs  technologies  to  toxicology  and  hazard 
assessment is the possibility to measure experimentally comprehensive biochemical profiles of the 
modifications  occurring  during  an  AOP.  Pattern  recognition  in  biochemical  signals  from 
transcriptomic, proteomic, and metabolomic experiments will lead to the identification and validation 
of the biomarkers relevant to monitor defined toxicity in humans and animals (Ellinger-Ziegelbauer et 
al., 2011; Peng et al., 2013). It is foreseeen that these biomarkers can then be used for dose response 
modelling such as BMD/BMDL modelling to then derive POD for hazard assessment purposes (see 
transcriptomic examples and Thomas et al., 2007, 2011, 2012). As illustrated above, the combined 
results from OMIC technologies can potentially produce a comprehensive profile of the molecular 
events  leading  to  an  AOP  and  allow  testing  interspecies  differences  in  toxicity  and  their  human 
relevance (Burgess-Herbert and Euling, 2013). In addition, OMICs allow addressing the relevance of 
human variability and particularly genetic polymorphism in response to chemical exposures. This is 
already an important research field in the pharmaceutical area with many clinical applications. The 
investigation  of  human  variability  provides  a  great  opportunity  in  the  food  safety  area  to  better 
integrate inter-individual differences in: a) TK processes for age differences, inter-ethnic differences 
and  polymorphisms  in  phase  I  enzymes  (CYP,  alcohol  dehydrogenase,  epoxide  hydroxylase, 
esterases),  phase  II  enzymes  (UDP-glucuronyltransferases,  sulphotransferases  glutathione-s-
transferases and methyl-transferases) and transporters (OATPs, OCTs, P-glycoproteins, MRPs), b) TD 
processes  for  age  differences  and  inter-ethnic  differences  in  toxicity  targets  (e.g.  receptors,  ion 
channels, enzymes…) (Ozdemir et al., 2009; Squassina et al., 2010; Dorne, 2010; US-EPA, 2013). 
Last but not least, OMICs can provide ways to investigate patterns of gene transcripts, proteins, and 
metabolites using in vitro methods and how these are associated in an AOP. In the long run, this type 
of experiments may provide helpful means to validate ITS using mechanistic in vitro assays to reduce 
animal studies and move towards predictive modelling (Basketter, 2012).  
OMICs technologies have also a number of weaknesses. Major weaknesses of OMICs are: a) the need 
for a complex arsenal of new molecular techniques, analytical tools and highly specialised training, 
b) the  need  for  sophisticated  bioinformatic  tools  to  analyse  the  innumerable  datapoints  that  are 
generated, c) the difficulty to interpret and validate the thousands of signals generated during OMICs 
experiments especially. Another key weakness relates to the sensitivity of the methodologies which 
may lead to the detection of changes that may not be biologically or toxicologically relevant. Finally, 
OMICs studies have a complex design and have been most often conducted with well known reference 
substances. This has allowed researchers to correlate the OMICs datasets with results from standard 
methodologies such as clinical chemistry or histopathological endpoints. It is foreseen that in the 
future, publicly available databases combining in vitro and in vivo OMIC datasets for large amount of 
compounds  with  MoA/AOP  knowledge  will  help  considerably  to  move  towards  identifying 
biomarkers associated with specific AOPs and to bring new tools for predictive toxicology.  
5.  Prioritisation  of  chemicals,  systems  toxicology  and  future  outlook  on  chemical  risk 
assessment  
5.1.  Prioritisation of chemicals  
There is wide international recognition that new approaches and frameworks are needed to evaluate 
the safety of large numbers of chemicals in food, consumer products and the environment.  Many 
international efforts aim to develop methods for the prioritisation of chemicals using ITS so that, when 
a concern has been identified, the chemicals can be considered either to prioritise chemicals based on 
their  hazard  and  exposure  profile for  decision  making  or  further  testing.  This  is  a  key  aspect  of 
EFSA‟s work in food and feed safety and ECHA‟s work under the REACH regulation. Recent reviews 
have proposed a number of methodologies for this purpose including the Nextgen project of the US-
EPA, the IPCS/WHO applications of the MoA and the technical report of EFSA on „the identification Modern methodologies for human hazard assessment of chemicals 
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of emerging chemical risks in the food and feed chain‟ (Thomas et al., 2013b; US-EPA, 2013; EFSA, 
2014; Meek et al., 2014).
  
5.1.1.  Prioritisation of chemicals at the US-EPA  
The Toxcast research program and the Nextgen report of the US-EPA has proposed a number of 
approaches for the prioritisation and ranking of chemicals according to their toxicological properties. 
These approaches include the Toxicological Prioritisation index (TOXPi) decision support framework 
and a tiered approach to prioritise chemicals for further testing (Reif et al., 2010; Gangwal et al., 2012; 
Thomas et al., 2013b; US-EPA, 2013). 
The ToxPi decision support framework has been originally developed from the results of ToxCast 
research programme (see Section 2.3.1) under the U.S. EPA‟s Endocrine Disruptor Screening Program 
which has screened over 300 pesticides and environmental contaminants for their potential to affect 
the endocrine systems of humans and wildlife. In order to facilitate the rationale prioritisation of 
chemicals for further evaluation, Reif et al. (2010) proposed aToxPi score which incorporates data 
from  in vitro  assays,  chemical  descriptors,  biological  pathways.  These  ToxPis  provide  a  flexible, 
ranking  of  each  chemical‟s  potential  endocrine  activity  and  focusing  on  estrogen,  androgen,  and 
thyroid pathways, putative endocrine profiles were first defined to then derive a relative rank or score 
for the entire ToxCast library. Recently, a ToxPi visualisation tool (the ToxPi graphical user interface 
ToxPi  GUI)  has  been  developed  to  integrate  the  relative  contribution  of  all  information  sources, 
including hazard and exposure information for a particular chemical, to an overall priority ranking. A 
software tool based on this method and the ToxCast Data is available and described in Reif et al. 
(2013). More recently, Gangwal et al. (2012) proposed the use of ToxPi decision support tool to 
enable the integration of multiple sources of evidence or toxicity and incorporate exposure surrogates. 
The results are then transformed into transparent visual rankings to facilitate decision making and 
prioritise chemicals for further testing. The approach taken by Gangwal et al. (2012) highlights the 
utility of the ToxPi framework for incorporating exposure information to rank chemicals and improve 
understanding of key exposure surrogates. However, this analysis has been performed for relatively 
data  rich  compounds  and  demonstrate  the  need  for  further  studies  to  understand  the  relationship 
between  simple  exposure surrogates, tiered  screening-level  exposure  assessments,  and  population-
level biomonitoring data (Gangwal et al., 2012).  
Thomas et al. (2013b) proposed a tiered approach for the prioritisation of chemicals which allows the 
integration of results from new methodologies and standard toxicity testing in a flexible manner. This 
framework has evolved from tiered approaches developed previously to address regulatory mandates, 
to prioritising and assessing large numbers of chemicals (Meek et al., 2011; Thomas et al., 2013b). 
The framework is data-driven, can be iteratively refined as knowledge MoA/AOP and models become 
available, and involves successive tiers of testing using the MOE as the primary metric (Thomas et al., 
2013b). Tier 1 aims to use data to prioritise and screen chemicals for immediate regulatory decision, 
for further testing in Tiers 2 and 3, or in some cases, to add to the weight of evidence in Tier 2 and 3 
assessments. This would be particularly relevant with respect to identifying pathways or molecular 
signatures associated with chemical-induced diseases (US-EPA, 2013). Five components are proposed 
for tier 1: (1) use of HTS assays to separate chemicals into selective and nonselective modes of action; 
(2)  in  vitro  genotoxicity  assays  to  separate  potential  genotoxic  and  non-genotoxic  chemicals;  (3) 
IVIVE  TK  models to  convert  in  vitro  assay  concentrations to  applied  doses; (4)  high-throughput 
exposure modelling to estimate human exposures to chemicals; and (5) calculation of MOE for the 
chemical  (Thomas  et  al.,  2013b).  The  second  tier  of  the  proposed  framework  also  consists  of 
5 components:  (1)  short-term  in  vivo  transcriptomic  studies  to  identify  a  transcriptional  point  of 
departure (POD) or RP values for chemicals with a non –selective MoA; (2) in vivo studies to identify 
POD values for chemicals with a selective MoA; (3) IVIVE TK studies to link internal and applied 
dose; (4) refinement of human exposure estimates; and (5) calculation of a MOE for the chemical. The 
rationale for identifying chemicals with selective and non-selective MoA has been developed through 
the  analysis  of  the  relationship  between  transcriptomic  profiles  and  apical  responses  from 
histopathological studies. For a number of non-cancer and cancer responses, POD have been identified Modern methodologies for human hazard assessment of chemicals 
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and transcriptomic BMDL have been successfully modelled (see Section 4.2, Thomas et al., 2007, 
2011, 2012, 2013a). The third tier 3 would be conceptually equivalent to the traditional toxicological 
in vivo testing in experimental animals. In practice, Tier 3 can be applied to chemicals with a high 
volume  of  production  and  for  which  significant  potential  for  human  exposure  would  occur. 
Alternatives  include  specification  based  on  understanding  of  the  toxicological  profile  acquired  in 
lower tier testing (tier 1 and 2) studies. This could include rodent cancer bioassays, developmental or 
reproductive  toxicity  studies.  The  authors  anticipated  that,  depending  on  the  MOE  cut-off  values 
chosen, the majority of chemicals would be screened out in tier 1 or 2 leaving an estimated 3 % to 
15 % of chemicals requiring such in vivo tier 3 assessment. Still, testing itself for these chemicals can 
be prioritised by endpoints (MoA/AOP driven) based on the results from both tier 1 and 2 studies 
(Thomas et al., 2013b).  
It is worth noting that the proposed tiered approach described above can be potentially applied to the 
risk assessment of combined exposure to multiple chemicals using a hazard index approach and dose 
addition as the default assumption. In the case of interactions of TK and/or TD nature, these hazard 
indexes can be modified to take into account the magnitude of the interactions, which can be based on 
either TK data (decrease or increase elimination such as clearance ratios) and/or TD data (e.g. BMDL 
ratios) (EFSA, 2013).  
5.1.2.  Application of the WHO/IPCS mode of action framework 
The IPCS/WHO has proposed applications of the MoA framework to the prioritisation of chemicals 
using endocrine disruption potential as an example. This application refers to „how best to focus on 
chemicals that are most likely to cause adverse effects without empirically testing all chemicals of 
regulatory  concern‟.  An  expert  (QSAR)  system,  which  had  already  been  developed  to  predict 
oestrogen  receptor  binding  affinity  using  MoA/AOP  knowledge  is  described  (OECD,  2009b; 
Schmieder et al., 2003, 2004; US EPA, 2009. In this case, the AOP starts with a MIE, which is direct 
binding of the chemical to the oestrogen receptor. The authors discussed that such an event can be 
tested through the development of two in vitro assays based on the trout as a model. The first assay 
can measure the interaction of the chemical with the oestrogen receptor using a competitive binding 
assay. The second assay can measure the consequences of oestrogen receptor activation or inhibition 
as a result of tissue uptake and partitioning of the chemical after xenobiotic metabolism using a trout 
liver slice assay. Another example discussed include the development and use of alternative (in vitro) 
assays to target particular cellular or physiological key events along a specific toxicity pathway. Once 
the MoA has been established, the key event data can be used for read-across from other chemicals. If 
a new chemical fits the established MoA, this existing knowledge can be used to justify a  more 
efficient testing strategy, so that not every chemical needs to be evaluated in an in vivo test (Meek et 
al., 2014). 
5.1.3.  EFSA technical report on the identification of emerging chemical risks in the food and 
feed chain 
EFSA  has  recently  published  a  technical  report  presenting  a  systematic  framework  for  the 
identification of emerging chemical risks that may occur in the food and feed chain and which may 
have a direct or indirect impact on human, animal and/or plant health. Such exposure may arise from 
industrial chemicals that are either intentionally or non-intentionally, produced (contaminants)as well 
as  from  certain  natural  contaminants  that  may  be  transferred  to  the  food/feed  chain  through  the 
environment. The framework uses a number of data sources as input, relating to the source of the 
chemical (industrial chemical, contaminant) and software models as tools to predict the environmental 
behaviour and potential toxicity of chemicals from structural features and physico-chemical properties 
(e.g. QSAR models and PB-TK models). The application of the framework consists of a multi-step 
selection process initiating with a list of chemicals to which a sequence of selection criteria is applied 
to identify the substances of potential concern. The selection criteria take into account a number of 
parameters including volumes of production or import data related to the chemical, its environmental 
persistence,  bioaccumulation  potential,  dispersive  uses,  toxicity,  and  any  available  outcomes  of 
previous risk assessments. The procedure has two main entry points either for industrial chemicals Modern methodologies for human hazard assessment of chemicals 
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registered under REACH Regulation or for substances consistently detected in the environment with a 
subset of more specific entry points depending on specific objectives and relevant data availability. 
Further work has been recommended to further test this methodology through: 1) Consideration of 
additional data sources and selection criteria, 2) Development of databases and software to  apply 
efficiently  and  systematically  the  inclusion/exclusion  criteria,  which  characterise  the  different 
selection steps of the proposed methodology, 3) Application of this methodology to the systematic 
identification of emerging chemical risks through the food/feed chain (EFSA, 2014a). 
5.2.  Systems toxicology and future perspectives for chemical risk assessment  
5.2.1.  Systems toxicology and integrated testing strategies 
There  are  many  definitions  of  systems  biology  that  differ  between  different  international  bodies. 
Systems biology has been defined by the OECD as the „Study of the mechanisms underlying complex 
biological processes as integrated systems of many diverse, interacting components‟ (OECD, 2013). 
The NIH has defined systems biology as „an approach in biomedical research to understanding the 
larger picture - be it at the level of the organism, tissue, or cell - by putting its pieces together‟. 
Systems biology is in stark contrast to decades of reductionist biology, which involves taking the 
pieces apart. From the definition of systems biology, systems toxicology aims to identify toxicity 
pathways and potentially predict toxicity. In other words, systems toxicology is the means to depict 
AOPs through the integration of the knowledge at different levels of biological organisation using ITS 
(see Section 2.1). Recently, Sturla et al. (2014) discussed that systems toxicology aims at „decoding 
the toxicological blueprint of active substances that interact with living systems‟ and „should allow 
exploring how biological components function as a network in cells, tissues and  organisms‟. The 
authors discussed the development of dynamic AOP models suggesting that such dynamic AOPs will 
enable the simulation of the population-level effects of an exposure as „the ultimate goal of Systems 
Toxicology‟. Three steps are proposed to develop the dynamic AOPs following a top down approach: 
1. Development of causal computable biological network models, that link the systems interaction of a 
toxicant with the organ-level responses.  Such models can then be used to quantify the biological 
impact  of  an  exposure  in  the  context  of  quantifiable  endpoints  (e.g.  histology  or  physiological 
measurements). 2. Development of mechanistic knowledge derived from quantitative measurements 
and dynamic models linking the exposure with the organ-level responses. 3. Representation of the link 
between exposure and population outcome using  mathematical models enabling the simulation of 
population-level effects of the exposure (Sturla et al., 2014).  
Overall,  such  systems  approaches  in toxicology  take  advantage  of  the  historical  developments  of 
modern biology such as the human genome project and advances in ITS such as the one developed and 
explored in the TOX 21 and SEURAT programme and discussed previously, such as HTS assays, 
OMIC  technologies,  physiologically-based  models  and  in  silico  tools.  In  addition  to  these  tools, 
alternative  species  (i.e.  non-mammalian  species)  provide  in  vivo  models  for  identifying  hazards, 
integrating dose-response effects, and understanding pathways and apical effects useful for assessing 
chemical risks to humans and to other species. The shorter life spans of alternative species enable the 
evaluation of toxicity over the full life span of the intact organism, facilitating the study of the entire 
aetiology of disease from the MIE to apical outcomes, including more complex phenomena such as 
birth defects or neurobehavioral impairment. Alternative species studies are progressively playing a 
more integral role in hazard assessment of chemicals for humans and the environment (ECHA, 2013; 
Perkins et al., 2013; Villeneuve et al., 2014). Both the European Chemicals Agency (ECHA) and the 
US-EPA use alternative species tests as part of required tests for endocrine disruptors (US-EPA, 2013 
Scholz et al., 2013).  
Truong et al. (2014) examined all 1078 ToxCast phase 1 and 2 chemicals (1060 unique chemicals) for 
developmental and neurotoxicity in the embryonic zebrafish using a rapid in vivo approach. Each 
chemical was tested using broad dose ranges spanning 4 orders of magnitude (6.4 nM to 64 μM) with 
multiple replicates (n = 32) at each dose. Twenty-two endpoints were simultaneously evaluated and 
distinct  toxicity  patterns  in  response  to  chemicals  were  identified.  The  author  then  pursued  a Modern methodologies for human hazard assessment of chemicals 
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concordance analysis of the phase I chemicals tested in Toxcast to test the complementarity of the 
developmental zebrafish outcomes with the in vitro outcomes in xenobiotic metabolism and CYP 
inhibition assays, and developmental rat or rabbit maternal and pregnancy studies. Concordance of 
xenobiotic-related in vitro assays and morphologically abnormal embryonic zebrafish was concluded 
in a number of cases (Lieschke and Currie, 2007; Goldstone et al., 2010; Santoriello and Zon, 2012; 
Scholz, 2013). For the chemicals and endpoints lacking concordance with ToxCast Phase I results, the 
authors concluded that these results would indicate toxicity pathways or chemical classes that would 
require  more  attention  in  future  phases  of  testing.  Hence,  the  authors  propose  to  integrate  the 
developing zebrafish into the existing in vitro HTS assays for the hazard assessment of chemicals. 
They  proposed  to  use  the  zebrafish  as  the  „tier  1‟  of  the  hazard  identification  process  where  all 
chemicals are assessed and all those with potential to cause adverse effects will be further screened in 
the battery of in vitro tests and evaluated in the predictive models already developed in the TOX-21 
programme. Having a whole-organism system as the first tier provides the ability to detect endpoints 
that may be missed in a screen using in vitro assays, such as metabolism and pathway sensors (Truong 
et al., 2014). 
From  a  global  risk  assessment  perspective,  the  systems  toxicology  approach  needs  the  exposure 
dimension  to  complete  the  picture.  Recently,  the  three  non-food  committees  of  the  European 
Commission have emphasised that there is paradigm shift moving from a hazard-driven process to one 
that  is  exposure-driven.  Exposure  assessment  is  beyond  the  scope  of  this  document,  however, 
combining toxicity data in a systems toxicology perspective requires the integration of the relevant 
exposure data (external dose) into an internal dose (TK) to then relate it to the MoA/AOP (TD). For a 
particular compound, the translation of an external dose to an internal dose will require absorption and 
biovailability data as well another ADME data such as half-life and clearance. Finally, exposure can 
also be investigated from a systems perspective as a complete entity: the exposome. The exposome 
refers to the totality of environmental exposures from conception onwards, and has been proposed to 
be a critical entity for disease aetiology (Wild et al., 2013). The exposome approach is increasingly 
used  by  epidemiologists  for  genome-wide  association  studies  (GWAS),  in  order  to  investigate 
diseases,  while  relying  on  questionnaires  to  characterise  „environmental‟  exposures.  In  addition, 
assessment of the exposome is now facilitated using OMICs technologies and analytical techniques, 
which are able to measure multiple chemical residues and multiple biomarkers of exposure and effects 
(e.g. adductomics to measure DNA adducts) (Rappaport and Smith, 2011; Wild et al., 2013).  
5.2.2.  Future perspectives for the human risk assessment of chemicals 
Overall, this report has highlighted a number of new and emerging methods to depict TK and TD 
processes using a MoA/AOP approach for hazard assessment of chemicals including PB-TK and PB-
TK-TD models, in silico (QSAR, read-across and TTC) and OMICs (transcriptomics, proteomics and 
metabolomics). These methodologies can provide a way to bring mechanistic thinking into toxicity 
testing and give quantitative insights on key issues in TK and TD for hazard assessment, and reduce 
animal use in toxicological testing. In vivo and in vitro examples of application of these modern tools 
to the hazard assessment of chemicals for humans have been highlighted for a number of fundamental 
issues in hazard assessment: interspecies differences, human variability in TK and TD processes, in 
vitro to in vivo extrapolation and combined exposure to multiple chemicals both using traditional in 
vivo standard toxicity combined with in vitro techniques, PB-TK, PB-TK-TD models, in silico tools.  
Key  recommendations  of  the  three  non-food  committees  of  the  European  Commission  and  the 
Nextgen project of the US-EPA are presented and some perspectives on the future chemical risk 
assessment are given.  
5.2.2.1.  Recommendations from the three non-food committees of the European Commission  
The  three  non-food  committees  of  the  European  Commission  published  a  joint  opinion  on  new 
challenges in risk assessment with specific recommendations (SCCS, SCHER, SCENIHR, 2013). The 
committees specifically included the new methods described in this report. A key conclusion and 
recommendation refers to the need to combine these methods into ITS based on Weight-of-Evidence Modern methodologies for human hazard assessment of chemicals 
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methods that integrate independent sources of information and information on MoA (Boobis et al., 
2008; SCCS, SCHER, SCENIHR, 2013). Key requirements for such a shift include: 
  The  need  for  new  in  vitro  methods.  These  should  have  similar  properties  to  in  vivo 
counterparts and allow for testing over longer periods of time (sub-chronic to chronic) to establish 
clear relationship between in vitro endpoints and adverse effects in vivo. These in vitro systems should 
also reflect in vivo TK. 
  New endpoints: Sensitive measurement methods are needed to allow studies to be made at 
exposure levels that reflect likely human exposures and OMICs are likely to play progressively a key 
role in such a development. 
  MoA should become the central point of a future risk assessment, and this knowledge should 
be considering the OMICs technologies; particular focus is needed on how they might improve MoA 
understanding  and  how  they  may  themselves  benefit  from  such  MoA  knowledge.  The  MoA 
information is also essential for the assessment and the prediction of chemical interactions in mixtures.  
  A tiered approach for risk assessment is recommended to use resources in the most efficient 
way and limit unnecessary animal testing. The tiered approach combines hazard and exposure for 
individual stressors.  
  Comprehensive, validated and up-to-date databases are needed to develop a new paradigm for 
risk assessment. The most important include databases on  effects of various stressors in humans, 
monitoring data of human exposure to various stressors, extension of the TTC database, and inclusion 
of MoA/AOP for each type of adverse effect. 
  Validation of SARs or QSARs and read-across approaches 
5.2.2.2.  Challenges ahead and recommendations from the US-EPA NextGen report  
The  Nextgen  report  of  the  US-EPA  has  reviewed  new  approaches  and  frameworks  to  identify 
biological  patterns  and  MoA/AOP  associated  with  specific  diseases.  Such  patterns  facilitate  the 
grouping and the evaluation of chemicals based on mechanistic understanding of specific diseases 
(US-EPA, 2013). 
Key  challenges  and  data  gaps  for  these  new  and  emerging  methods  and  tools  for  human  risk 
assessment of chemicals. Such data gaps need to be filled to incorporate new information into risk 
assessment frameworks: 
(1) metabolism of test compounds cannot currently be predicted;  
(2) need for an understanding of the biology from a systems perspective; 
(3) evaluate methods available to measure key aspects of the biological space across multiple 
levels of organisation (from cellular level to organ and level of the individual); 
(4) availability of the relevant data through the implementation of a knowledge infrastructure.  
Recurrent and problematic issues were identified as including problem formation, classifications of 
adversity and WoE, dose-response modelling (particularly at the low-dose end), human variability 
including differences in TK, TD, life stages, diseases, nutrition, interspecies differences in TK and TD 
and consequences for intra-species extrapolation, risk assessment of multiple chemicals (chemical 
mixtures)  and  characterisation  of  uncertainty.  These  issues  have  been  explored  in  a  number  of 
„prototype‟ case studies on specific chemicals for which different level of knowledge were available Modern methodologies for human hazard assessment of chemicals 
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including  molecular  information,  in  silico,  toxicological  studies  in  animals  and  epidemiological 
evidence in humans (US-EPA, 2013). 
Next steps have been identified to facilitate the incorporation of these new methods and the data 
generated from such methods in risk assessment and the decision-making processes: 
  More cases studies on chemicals, are needed to test the incorporation of HTS toxicity data and 
other novel data types (e.g. data from HTS assays from ToxCast and TOX-21 OMICs…). This will 
also allow to inform the risk assessment process and demonstrate the added value of such new tools 
and identify further scientific gaps. Validation of HT toxicity testing schemes and development a 
framework for such validation is also recommended since the traditional „validation‟ schemes do not 
address this gap. Plans are in place to develop criteria for systematic review of new types of data, 
disease signatures, adequate weight of evidence for use in risk assessment, and new approaches for 
risk assessment.  
  Using new data types to guide development of NexGen approaches on challenging questions 
such as population-level risks (using traditional and molecular biology data), with an emphasis on 
epigenomics  and  influences  of  broadly  defined  environmental  factors.  Application  of  these  new 
methods might also better inform our understanding of the combined effects of multiple stressors 
(multiple chemical exposures, diet, stress, and pre-existing disease). 
  Using tier 1 screening and prioritisation approaches for chemicals (Thomas et al., 2013b; see 
Section 5.1). Results should then be fedback into the testing paradigm for its refinement. 
  Develop  toxicity  values  for  each  tier.  Toxicity  values  informed  by  new  methods  will  be 
developed in each tier. This will allow to address needs from screening chemicals for future testing to 
assessment for potency/category of adverse effects.  
  Expand stakeholder discussion and peer review. Levels of confidence in these toxicity values 
will be characterised depending on the types/quality of the supporting data. New assessments will 
receive public comments and peer review.  
  Collaboration between US-EPA with other national and international agencies involved in risk 
assessment,  testing,  and  research.  This  will  allow  to  coordinate  and  harmonise  activities,  and  to 
improve data collection, analyses, curation, sharing, and warehousing. 
5.2.2.3.  Future perspectives 
This report has highlighted the shift towards a MoA/AOP approach in chemical risk assessment to 
depict TK and TD processes using ITS, including in vitro methods based on human cells (e.g. HTS 
assays), OMICs, physiologically-based models and in silico tools. This paradigm shift will allow to 
move towards new approaches for the safety evaluation of chemicals, reduce animal use in toxicity 
testing and provide support for the prioritisation of thousands of chemicals. 
Within the coming year, it is foreseen that the AOP initiative of the OECD will develop 18 AOP and 
3 case studies that are applicable to both human health and environmental risk assessment (see Section 
2.3). These AOPs will be of great values to screen chemicals according to specific or non-specific 
MoA. These AOPs may be of qualitative nature to start with but will increasingly move towards a 
quantitative understanding, which will also provide a basis to move towards a systems toxicology 
approach and, further down the line, develop dynamic AOPs. However, the OECD recognised that a 
key gap in the AOP development is the fact that, currently, TK information (ADME) and PB-TK 
models are out of the scope of the AOP development and will have to be addressed. In this context, the 
lack of TK information from human cells is a key aspect that needs to be fulfilled in order to identify 
the  ADME  of  a  chemical  and  of  the  extent  to  which  metabolism  results  in  bioactivation  or 
detoxification. This will support the integration of TK and TD processes in the MoA/AOP framework Modern methodologies for human hazard assessment of chemicals 
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as well as give a starting point for further HTS assays for toxicity testing. Indeed, HTS assays do not 
have  metabolic  capacities  so  that  if  the  metabolite(s)  of  a  compound  is/are  the  toxic  form(s), 
measurements of toxicity may be biased. In addition, such knowledge of human  metabolism will 
provide a basis to investigate interspecies differences in TK and, for known compounds, to test the 
biological relevance of the test species.  
In the future, it is foreseen that HTS assays  to investigate TK will need to be designed to allow 
incorporation  of  human  variability  (genetic  polymorphisms,  subgroups  of  population).  Key  issues 
throughout this report  raised  the need  for  validation  of  in  vitro  methods  and OMIC  technologies 
(analytical methods and statistical approaches), physiologically-based models and in silico tools. As 
discussed by the US-EPA, in parallel to such validation, more case studies should be developed to test 
these  methods  combining  new  knowledge  and  historical  data  for  proof  of  concept.  The  need  for 
publicly accessible databases integrating data from these new methods/tools is also a key issue since in 
the future it can be foreseen that, as knowledge advances, risk assessors and toxicologist will be able 
to  refine  models  and  tools  (e.g.  dynamic  AOPs,  complex  cellular  network  models).  Finally, 
methodologies  for  weight  of  evidence  and  uncertainty  analysis  to  integrate  data  from  such  new 
methodologies  in  the  MoA/AOP  framework,  including  testing  the  biological  relevance  (species 
concordance  analysis)  and  report  uncertainties  in  a  transparent  way,  are  needed.  These  future 
perspectives are further discussed below to provide detailed recommendations. 
The human microbiome, which refers to the community of microorganisms that live in or on the 
human body, is another key aspect that needs to be taken into account to move towards a systems 
toxicology  approach.  The  Human  Microbiome  Project  (HMP)  of  the  National  Institute  of  Health 
(NIH) is currently investigating the role of human microbiota and analysing its role in human health 
and disease. The HMP is currently sequencing the genomes of a number of microorganisms isolated 
from the human body as well as samples of digestive tract, mouth, skin, nose, and female urogenital 
tract of human volunteers. These genomes will then be considered for metagenomic analysis. The 
HMP has opened new horizons for studying how the composition and functional variations of the 
microbiome affect drug action, fate, and toxicity (pharmacomicrobiomics) particularly in the human 
gut. The gut microbiome is the most predominant and most diverse microbial community residing in 
the human body with hundreds of species and its contribution and influence on xenobiotic metabolism 
is substantial. The integration of OMICs methodologies has provided very useful means to elucidate 
the microbiome‟s influence on chemical metabolic profiles through DNA sequence-based phylogeny 
and metagenomics (Hood, 2012). Recently, the toxicity of a number of chemicals on microbiota has 
recently been demonstrated from metagenomics and metabolomics analysis for contaminants such as 
cadmium and arsenic (Liu et al., 2014; Potera, 2014). Ishii et al. (2012) demonstrated that enteric 
bacteria induce the expression of CYP3A in mouse liver. Recent studies have begun to identify the 
key events of the regulation between the gut microbiota and its host but the underlying molecular 
mechanisms  of  host-microorganism  interactions  remain  largely  unknown.  In  addition,  findings 
obtained from the study of animal models remain to be translated to humans and a potential caveat is 
that  microbiota  members  differ  not  only  among  host  species  but  also  between  individual  host 
organisms (Sommer and Bäckhed, 2013). However, progresses made in the development of genetic 
tools, such as whole-genome sequencing, and in the availability of novel genetic models will allow for 
dissecting the interplay between the microbiome, host genetics and host physiology. Combining these 
tools for further studies in the upcoming years will greatly deepen our understanding of the molecular 
targets in the homeostatic interaction between the gut microbiota and the host and thereby their global 
impact on chemical metabolism (Sommer and Bäckhed, 2013). To conclude, the human microbiome 
highlights another important source of high inter-individual differences in the metabolism and toxicity 
of chemicals that will need to be taken into account to move towards a systems toxicology approach. Modern methodologies for human hazard assessment of chemicals 
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6.  Recommendations for future activities at EFSA on new and emerging tools for human 
hazard assessment of chemicals in the food and feed safety area  
The section below provides recommendations resulting from a consultation of EFSA panels and staff 
dealing with chemical risk assessment and other experts from international bodies (ECHA, OECD, 
WHO…). 
6.1.  Terminology and general considerations 
6.1.1.  Terminology  
Harmonisation of terminology 
A major aspect of EFSA‟s science strategy 2012-2016 is the further development of internationally 
harmonised risk assessment methodologies including terminology (EFSA SC, 2012). With regards to 
new and emerging methods and tools for hazard assessment, harmonisation of the terminology and 
definitions are needed at the concept level (MoA, mechanism of action, AOP, key events, molecular 
initiating key events, systems toxicology, …) and for each of the tools available (physiologically-
based models, in silico tools and OMICs).  
Harmonisation of terminology also applies  beyond the human context, which is the focus of  this 
report, to animal health and environmental risk assessment. As discussed previously in the context of 
the  scientific  report  dealing  with  combined  exposure  to  multiple  chemicals,  harmonisation  of  the 
terminology  is  not  straightforward  because  different  communities  may  use  different 
terminology/interpretation  for  the  same  concept,  or  the  same  tool  or  the  same  terminology  for  a 
different concept/tool. This can be exemplified by the concepts of biovailability in toxicokinetics and 
mode of action, which have different meanings for the human and the ecological risk assessment 
communities (EFSA, 2013). 
6.1.2.  General considerations 
Animal health and ecological risk assessment  
Further work on viewing the potential use of these modern tools and methodologies for chemical risk 
assessment in the context of animal health and ecological risk assessment is recommended. In the 
short-term, these reviews (including the current document) could be the starting point of developing 
(a) guidance(s) to apply these new and emerging methods, in a context-dependent manner and using 
tiered approaches, and the WoE approach which would be valuable for EFSA. The development of a 
guidance for the use of the WoE approach in risk assessment including distinct lines of evidence (in 
vivo, in vitro, in silico, population studies etc.) has been identified by the Scientific Committee as a 
priority topic for EFSA (EFSA, 2013).  
Guidance on the use of mode of action in risk assessment 
 A specific recommendation relates to the development of a guidance on the use of mode of action in 
chemical risk assessment, particularly in relation to the recent new developments highlighted by the 
WHO (criteria for species concordance analysis and human relevance, modified Bradford Hill criteria, 
use of epidemiological data, data from recent new and emerging methods (in vitro and high throughput 
screening  tests,  physiologically-based  models,  AOP  developments,  OMICs)).  Weight  of  evidence 
approaches should be explored further to consider the integration of such multi-level and complex 
information for hazard assessment and risk assessment as a whole (e.g. integration of hazard and 
exposure data for risk characterisation). In this context, data needs (and the likelihood of getting such 
data), biological relevance and statistical aspects would need particular attention for WoE approaches.  
Risk assessment of chemical mixtures and multiple stressors Modern methodologies for human hazard assessment of chemicals 
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Finally, a possible activity in the longer term would be the development of methodologies to apply 
these new tools to the risk assessment of exposure to multiple chemicals as well as multiple chemicals 
combined with other stressors (e.g. biological hazards, physical agents…). WoE approaches would 
have to be considered including biological relevance and statistical aspects. This recommendation has 
already been formulated in the context of the EFSA scientific report on combined exposure to multiple 
chemicals, the EFSA colloquium on bee health and the recent scientific report on integrated risk 
assessment of multiple stressors in bees (EFSA, 2013, 2014b). 
6.2.  Physiologically-based models and in silico models 
6.2.1.  Investigating toxicokinetics 
The  first  key  recommendation  is  the  need  for  human  TK  data  in  hazard  assessment  to  better 
understand interspecies differences, human variability. Such TK data will ultimately link exposure, 
internal dose and toxicity using physiologically-based models for risk assessment purposes.  
Such TK is needed to: 
-  understand  the  relevance  of  test  species  to  the  human  situation  from  a  TK  point  of  view  (e.g. 
evolutionary conservation of enzymes and their respective isoforms) parallel to the investigation of 
species differences in TD (e.g. receptors, signalling pathways…); 
- design sound physiologically-based models integrating species differences in TK and TD and/or 
human variability in TK for the hazard assessment in metabolic, excretion and transport pathways;  
- provide a scientific basis to set Assessment Groups based on TK for multiple chemicals particularly 
when the metabolic route is a key event (bioactivation to a toxic metabolite or TK interactions such as 
inhibition of cytochrome P-450). Criteria to set these assessment groups using TK data would also 
need to be considered using a WoE approach including consideration of interspecies differences and 
human variability (relevance of the metabolic route in test species to the human situation, availability 
of human data on metabolism (in vitro/in vivo). This recommendation has already been formulated in 
the context of the scientific report on combined exposure to multiple chemicals (EFSA, 2013). 
Improvement of in vitro methods for generating TK data 
A key to generating TK data in humans is the improvement of current in vitro methods to measure 
human absorption (bioavailability, …), distribution (volume of distribution, protein binding, hepatic 
extraction),  metabolism  (e.g.  Vmax,  Km,  inhibition  constants…)  for  phase  I  (cytochrome  P-450, 
esterases…) and phase II (UDP-glucuronyl transferases, glutathione-s-transferases), isoforms involved 
in gut metabolism versus hepatic metabolism, transporters (e.g. transport via P-glycoprotein, Organic 
Anion Transporter Proteins (OATP),….), and excretion of chemicals. 
6.2.2.  Physiologically-based models 
Further  exploration  of  the  use  of  physiologically-based  models  in  chemical  risk  assessment  is 
recommended, namely: 
- to develop a guidance on the use of physiologically-based models in chemical risk assessment. This 
includes toxicokinetic and toxicodynamic models incorporating data from standard in vivo assays and 
alternative  methodologies  (in  vitro  methods  and  in  silico  data  (QSAR,  read-across,  TTC)).  The 
guidance could explore, through tiered approaches, the relevance and needs for such models in a 
context-dependent  manner  (data-poor  chemical  specific  situation,  prioritisation,  data-rich  chemical 
specific situation, combined exposure)  
- to develop prototype physiologically-based models using specific case studies to integrate exposure 
(external dose), internal dose and TK information and toxicity data for hazard assessment purposes. 
These models can also be used to refine uncertainty factors used in hazard assessment (categorical or Modern methodologies for human hazard assessment of chemicals 
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chemical-specific)  as  recommended  in  the  scientific  report  on  combined  exposure  to  multiple 
chemicals. 
- It is recommended to develop relatively simple models that may refine the link between exposure 
(external dose), basic TK data (internal dose), and toxic effects in the short term. For example, case 
studies could be explored to develop models for single compounds and binary mixtures based on in 
vitro  and  in  vivo  data.  In  the  mid-term,  as  knowledge  advances,  a  full  exploration  of  full 
physiologically-based  toxicokinetic  models  and  physiologically-based  toxicokinetic-toxicodynamic 
models  that  would  integrate  more  complex  quantitative  knowledge  can  then  be  explored  and 
implemented (e.g. inter-species differences, human variability in TK and TD, epidemiological data, in 
vitro models, in silico models). Finally, it is worth highlighting that the data used to build the models 
and their associated uncertainty should be described and analysed in a transparent manner to optimise 
their use and ensure reproducibility. 
- A practical need to further develop such physiologically-based models is the need for databases 
providing  critical  parameters  such  as  physicochemical  properties,  biological  and  physiological, 
toxicokinetic  and  toxicity  variables  (body  weight,  age,  ventilation  rate,  Vmax,  Km,  clearance, 
bioavailability, half life, AOPs), and bioinformatic tools/algorithms, to analyse and integrate the data.  
6.2.3.  In silico tools 
Further work is needed to explore application of in silico tools in chemical risk assessment. This will 
allow  to  use  currently  available  databases  comprising  vast  amount  of  physicochemical  and 
toxicological data and validate the available predictive models to reduce animal use. In addition, it will 
provide the opportunity to explore the applicability domain of the predictive methods and their degree 
of specificity. It can be foreseen that the domain of applicability of such tools will be encompassing 
human health, animal health, and ecological risk assessment.  
Development of a framework for systematic and harmonised approach for the use of in silico tools 
(SAR, QSAR, read-across) is recommended. It is proposed to further explore their use as potential 
tools to 1. support the hazard identification of genotoxic compounds by building batteries of models 
based on structural alerts, toxicity data and existing databases, 2. design physiologically-based models, 
3. elucidate the mode of action (including toxicity pathways) for the prioritisation of chemicals. A key 
aspect  of  these  applications  is  the  need  to  compare  the  currently  available  (Q)SAR  tools  in  a 
transparent way to allow optimisation and calibration of the models.   
Further development is proposed for the read-across methodologies in terms of further investigations 
into  their  use  in  the  hazard  assessment  of  chemicals,  particularly  to  integrate  (Q)SAR  and 
physicochemical properties with TK and TD data (potency estimates, AOP) using specific chemicals 
as case studies for „proof of concept‟. This can also be useful to explore category-approaches for 
prioritisation  of  chemicals,  especially  for  data-poor  substances  (e.g.  flavourings,  emerging 
contaminants…) using for example the OECD QSAR toolbox or the ADMET-SAR tool. 
Potential refinements of the TTC approach for hazard assessment have been previously discussed by 
the  Scientific  Committee  of  EFSA  in  their  recent  TTC  opinion  (EFSA  SC,  2012).  The  key 
recommendations  can  be  highlighted  as:  1.  Re-evaluation  and  update  of  the  Kramer  classes  and 
toxicological  databases  to  improve  accuracy,  applicability,  and  availability  of  in  silico  models. 
2. Development and refinement of models for the prediction of TK (bioaccumulation in humans, and 
quantitative  simulation  of  metabolite  degradation/formation)  and  TD  (genotoxic  potential, 
carcinogenic potency) with, as far as possible, an understanding of MoA.  Modern methodologies for human hazard assessment of chemicals 
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6.3.  OMICs 
Validation of OMIC technologies for their use in human hazard assessment  
Further work is needed on the validation and standardisation of OMIC technologies for their use in 
human hazard assessment. Detailed guidance on the criteria that are needed for their acceptability will 
support  this  activity:  data  needs,  statistical  and  bioinformatic  methodologies  for  data  analysis, 
mechanistic and statistical aspects, biological and toxicological relevance, relevance of in vitro OMICs 
data to the in vivo situation.  
Case studies relevant to the food safety area  
It is recommended to further explore the use of OMICs in human hazard assessment using case studies 
relevant to the food and feed area to investigate: mode of action, epigenetic mechanisms, in vitro to in 
vivo extrapolation, interspecies differences, human variability for both single compounds and exposure 
to multiple chemicals. Key aspects include: 1) Exploration of the derivation of reference points such as 
benchmark doses and their limits based on transcriptomic and/or proteomic and/or metabolomic data, 
with  case  studies.  These  should  include  comparison  of  the  benchmark  doses  and  their  limits  at 
different time points/study lengths. 2) Exploration of the use of in vitro OMICs data for the ranking 
and prioritisation of chemicals. 3) Use of biomarkers of effects and exposure generated from OMIC 
technologies  in  subgroups  of  the  human  population  to  incorporate  human  variability  in  hazard 
assessment of chemicals. 4) Applications of OMICs in other areas of chemical hazard assessment are 
recommended including animal health risk assessment, ecological risk assessment.  
In the nutrition area, a number of general recommendations can be formulated: 1) Exploration of the 
use of OMICs in both Hazard and Benefit Assessment. 2) Use of OMICs in Health claims: evaluation 
of microbiome/metagenomics in gut and systems resilience. 3) A mechanistic OMICs approach to 
depict mode of action can be applied to novel food safety. 
6.4.  Prioritisation  of  chemicals,  systems  toxicology  and  the  future  of  chemical  risk 
assessment  
Integrated testing strategies and MoA, prioritisation of chemicals 
Future work on integrated testing strategies is recommended using case studies of specific chemicals 
to investigate both MoA from the toxicokinetic and toxicodynamic processes (in vitro methods to 
depict AOPs, QSAR, physiologically-based models..). This will also allow identifying data gaps and 
research  needs.  Further  investigations  are  needed  on  the  use  of  ITS  to  differentiate,  as  much  as 
possible, chemicals with receptor or pathway driven specific MoAs, chemicals with multiple or non-
specific MoA. This may provide a basis to rank chemical potencies for prioritisation. 
The use of alternative test species (including fish species) as a bridge between in vitro methods and 
mammalian tests should be further explored and historical data from the literature could be used in a 
systematic review/meta-analysis.  
In  practice,  further  exploration  of  new  methodologies  for  hazard  assessment  are  needed  for  both 
regulators and industry and these include: 1) Screening of large sets of chemicals to group them based 
on hazard data (toxicokinetics, toxicity (potency)..). In order to prioritise chemicals, further data for 
compounds  of  concern/industry  can  focus  on  candidates/use  information  for  risk  assessment. 
2) Assessment of chemicals for a specific purpose to fill in data gaps for risk assessment or for dossier 
submission. 
For exposure to multiple chemicals, a better understanding of MoA/AOP of multiple substances using 
predictive and alternative methodologies (including  in vitro models, QSAR, physiologically-based 
models  and  OMICs)  is  needed  for  regulated  and  active  substances  such  as  pesticides  and 
contaminants. This will allow improving the basis for setting Assessment Groups.  Modern methodologies for human hazard assessment of chemicals 
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Future of chemical risk assessment 
Three recommendations for the future of chemical risk assessment can be formulated.   
1. New flexible risk assessment frameworks for chemicals and applications 
Explore the use of new risk assessment frameworks to bring the perspective of systems toxicology in 
chemical risk assessment using case studies. In this context, applications include the integration of 
AOP data for the prioritisation of chemicals, the development of dynamic AOP and the integration of 
the impact of the human microbiome on TK and TD events. A key aspect of AOP development is to 
explore the use of TK data, since TK information (ADME) and PB-TK models are currently out of its 
scope. For risk assessment another key aspect is to integrate the exposure dimension with the TK data.  
2. Weight of evidence and uncertainty analysis  
Weight  of  evidence  and  uncertainty  analysis  methodologies  for  the  integration  of  data  from  new 
methodologies in the MoA/AOP framework and chemical risk assessment as a whole are needed. This 
includes testing the biological relevance of the MoA/AOP (species concordance analysis, severity of 
the effect) and reporting uncertainties in a transparent way.  
3. International Collaborations 
In order to integrate these new methods in new frameworks for risk assessment and explore them 
through  case  studies  and  facilitate  international  harmonisation,  reinforcing  collaboration  with 
international institutions such as ECHA, the JRC, the OECD, the WHO, the NTP and the US-EPA is 
critical for EFSA and highly recommended. 
 
CONCLUSIONS AND RECOMMENDATIONS 
CONCLUSIONS 
  Over the last decade, a number of in vivo, in vitro and in silico methodologies and tools have 
been developed to investigate the mode of action (MoA) or Adverse outcome pathway (AOP) 
leading  to  human  adverse  health  effects  resulting  from  chemical  exposure. These  modern 
methodologies and tools provide two key opportunities to risk assessors dealing with human 
hazard assessment of chemicals: 1. to move towards a mechanistic understanding of toxicity 
taking into account both toxicokinetic (TK) and toxicodynamic (TD) processes  for hazard 
assessment, 2. to reduce animal use in toxicological research (3Rs: reduce, replace, refine). 
These modern methodologies are reviewed in this scientific report to present their potential 
use in the future of human hazard assessment of chemicals with a view to anticipating their 
future use within EFSA‟s work.  
  Currently, MoA information are not often available for specific chemicals, and risk assessors 
rely often on dose response assessment to translate external dose to a quantitative reference 
point for hazard characterisation in test species. However, recent international developments 
support  the  move  towards  elucidating  such  MoA/AOPs  for  human  hazard  assessment  of 
chemicals. These include the new applications of the WHO framework on MoA, the OECD 
international programme on AOPs and the TOX-21 and the SEURAT-1 research programmes 
in the US and Europe, respectively, both dealing with alternatives to animal testing such as in 
vitro methods and other integrated testing strategies (ITS). Strengths of  ITS such as high 
throughput screening (HTS) assays include the possibility to screen and prioritise chemicals in 
a single experiment and in a cost effective fashion while minimising animal testing. However, 
they have a number of limitations which include their lack of prediction for a) chemical-Modern methodologies for human hazard assessment of chemicals 
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induced disease associated pathways, b) metabolism, c) interactions between different cell 
types, d) tissue-level cellular interactions, e) chronic exposure.  
  Methodologies and tools to investigate TK processes (absorption, distribution, metabolism, 
excretion of chemicals (ADME)) in humans include a number of in vitro systems. The current 
updated OECD Test Guideline 417, dealing mainly with absorption and metabolism, indicates 
that in vitro testing using human cells can provide supplemental TK information which may 
substantially  reduce  in  vivo  animal  testing.  Even  though  these  in  vitro  models  have  still 
received little attention in hazard assessment of chemicals for the food safety area, they can 
provide key information on absorption, biovailability, protein binding and the identification of 
human transporters and metabolic pathways such as efflux transporters (phase 0 and phase III) 
and phase I and phase II enzymes. These parameters can be used to determine the in vivo 
hepatic clearance of a chemical and then be scaled up to the whole liver and take into account 
human variability to build physiologically-based (PB) models for both TK (PB-TK) and TD 
(PB-TK-TD) processes. A critical challenge that remains to be solved in order to apply these 
in vitro methods routinely is the in vitro to in vivo extrapolation (IVIVE) to reflect human 
physiology and metabolism (hepatic an extrahepatic such as intestinal metabolism). Ideally in 
the future, IVIVE would also incorporate human variability in quantitative IVIVE (QIVIVE).  
  PB-TK models provide a quantitative means to address TK processes and are therefore very 
useful tools in hazard assessment. PB-TK-TD are more complex than PB-TK since they link 
both the TK and the TD dimensions. The use of such models has been recommended by 
regulatory authorities around the world such as the US-EPA and the WHO which have both 
highlighted the need to develop guidance to pursue common principles for their application in 
chemical hazard assessment and risk assessment as a whole. However, reservations have been 
formulated regarding their routine use since they require a) detailed knowledge of TK for a 
particular chemical which is not often available for both models and detailed knowledge of 
TD for PB-TK-TD models, b) high levels of expertise and resources, c) the need to validate 
the models. Consequently, they are mostly used in high-tier assessment. The development of 
such  models  using  ITS,  IVIVE  and  QIVIVE  also  remains  a  big  challenge  for  both  TK 
parameters and toxicity parameters. These models have been applied to the food safety area 
particularly to pesticides, contaminants and food contact materials and have provided very 
useful tools to investigate key issues in hazard assessment such as interspecies differences, 
human variability, biomonitoring programmes, combined exposure to multiple chemicals and 
in vitro to in vivo extrapolations. 
  In silico tools include (quantitative) structure activity relationships (Q)SARs) and read-across 
methods for which a large number of models and databases have been developed around the 
word to predict a number of toxicological properties of chemicals such as the OECD QSAR 
toolbox. Another tool that is increasingly used in hazard assessment and risk assessment as a 
whole  is  the  threshold  of  toxicological  concern  (TTC).  QSARs  are  typically  used  in 
combination with other non-testing methods (e.g. read-across) and testing methods (e.g. in 
vitro) in the context of ITS and Weight-of-Evidence (WoE) assessments. Overall, (Q)SARs 
and read-across methods are increasingly predictive for hazard assessment particularly for 
acute toxicity, mutagenicity, genotoxicity and bioacummulation. However, their predictability 
for  TK  properties  (ADME)  and  sub-chronic  and  chronic  toxicity  is  still  limited  and 
considerable research is undergoing in this area. In addition, an increasing number of Q(SAR) 
models and databases are available and their precision, specificity and sensitivity may vary 
and would need to be evaluated and validated. Finally, it is foreseen that the combination of 
the results from different Q(SAR) models, structural alerts, read-across estimates as well as in 
vitro and in vivo toxicological studies using a WoE approach will improve the utility and the 
validation of these tools and increase the overall reliability of in silico methods.  
  Key  OMICs  technologies  to  investigate  TK  and  TD  processes  include  transcriptomics, 
proteomics and metabolomics. OMICs technologies are valuable tools to measure biochemical Modern methodologies for human hazard assessment of chemicals 
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changes associated with a MoA/AOP, identify biomarkers in humans and animals for dose 
response  modelling,  investigate  interspecies  differences  and  their  human  relevance  and 
incorporate  human  variability  (age  differences,  inter-ethnic  differences,  polymorphisms). 
Finally, OMICs technologies can also investigate patterns of gene transcripts, proteins, and 
metabolites within an AOP using in vitro models and provide helpful means to validate ITS 
using  mechanistic  in  vitro  assays  to  reduce  animal  studies  and  move  towards  predictive 
modelling.  Weaknesses  of  OMICs  methods  include  the  need  for  complex  molecular  and 
analytical  techniques,  highly  specialised  training  and  sophisticated  bioinformatic  tools  to 
analyse huge datasets. Another key issue relates to the sensitivity of the methodologies which 
may lead to the detection of changes that may not be biologically or toxicologically relevant. 
Finally, OMICs studies have a complex design and have been most restricted to well known 
reference  substances  to  allow  researchers  to  correlate  OMICs  datasets  with  classical 
toxicological endpoints (clinical chemistry, histopathological endpoints). It is foreseen that in 
the future, publicly available databases combining in vitro and in vivo OMIC datasets for large 
amount  of  compounds  with  MoA/AOP  knowledge  will  help  considerably  to  identify 
biomarkers associated with specific AOPs and to bring new tools for predictive toxicology. 
Applications to human hazard assessment of chemicals in the food safety area have already 
been  explored  and  include  benchmark  dose  modelling  from  transcriptomic  profiling, 
investigation  of  epigenomic  mechanisms,  identification  of  biomarkers  of  toxicity 
(proteomics), and investigation of MoA for single and multiple compounds (metabolomics).  
  A number of approaches have been developed for the prioritisation and ranking of chemicals 
according to their toxicological properties. At the US-EPA, the toxicological prioritisation 
index (ToxPi) decision support framework has been developed from the results of the Tox cast 
research programme and enable to rank chemicals through the integration of multiple sources 
of evidence on toxicity and exposure surrogates. ToxPi also includes a graphical user interface 
which  allows  visualising  the  relative  contribution  of  each  information  sources  (toxicity, 
exposure, uses…) in the overall priority ranking. Future needs of ToxPi include further studies 
to  understand  the  relationship  between  simple  exposure  surrogates,  tiered  screening-level 
exposure assessments,  and  population-level  biomonitoring  data.  Another  prioritisation tool 
from the US-EPA is the tiered approach developed during the NextGen project. In practice, 
tier  1  aims  to  prioritise  and  screen  chemicals  using  ITS  (Toxcast  HTS  assays,  in  vitro 
genotoxicity tests, IVIVE TK models…) for further testing in Tiers 2 and 3. Tier 2 includes 
limited in vivo toxicity testing (e.g. short-term in vivo transcriptomic studies, in vivo studies to 
identify a point of departure for chemicals with a selective MoA; and IVIVE TK studies to 
link exposure and internal dose). Tier 3 is equivalent to the traditional toxicological in vivo 
testing in experimental animals.  
  For the identification of emerging chemical risks, EFSA has recently developed a systematic 
framework  which  uses  a  number  of  data  sources  as  input,  relating  to  the  source  of  the 
chemical  (industrial  chemical,  contaminant)  and  software  models  as  tools  to  predict  the 
environmental  behaviour  and  potential  toxicity  of  chemicals  from  structural  features  and 
physico-chemical properties (e.g. QSAR models and PB-TK models). The application of the 
framework consists of a multi-step selection process starting with a list of chemicals to which 
a sequence of selection criteria is applied to identify the substances of potential concern. The 
selection criteria take into account a number of parameters including volumes of production or 
import data related to the chemical, its environmental persistence, bioaccumulation potential, 
dispersive uses, toxicity, and any available outcomes of previous risk assessments. Further 
work is ongoing to test the methodology using additional data sources, selection criteria and 
through  the  development  of  databases  and  software,  for  the  systematic  identification  of 
emerging chemical risks in the food chain. 
  This  report  has  highlighted  the  shift  towards  a  MoA/AOP  approach  in  chemical  risk 
assessment to depict TK and TD processes using ITS including in vitro methods based on 
human cells (e.g. HTS assays), OMICs, physiologically-based models and in silico tools. This Modern methodologies for human hazard assessment of chemicals 
 
EFSA Journal 2014;12(4):3638  63 
paradigm  shift  will  allow  moving  towards  a  systems  toxicology  view  for  human  hazard 
assessment of chemicals and will allow reducing animal use in toxicity testing and providing 
support for the prioritisation of thousands of chemicals.  
  Key  issues  discussed  throughout  this  report  include  the  need  for  validation  of  in  vitro 
methods,  OMICs  technologies  (analytical  methods  and  statistical  approaches), 
physiologically-based models and in silico tools. In parallel to such validation, more case 
studies should be developed to test these methods combining new knowledge and historical 
data for proof of concept. The need for publicly accessible databases integrating data from 
these new methods/tools is also a key issue since in the future it can be foreseen that, as 
knowledge  of  MoA/AOP  advances,  risk  assessors  and  toxicologist  will  be  able  to  refine 
models  and  tools  (e.g.  dynamic  AOPs,  complex  cellular  network  models,  integration  of 
knowledge  of  the  human  microbiome).  Finally,  methodologies  for  WoE  and  uncertainty 
analysis  are  needed  to  integrate  data  from  such  new  methodologies  in  the  MoA/AOP 
framework,  including  testing  the  biological  relevance  (species  concordance  analysis)  and 
report  uncertainties  in  a  transparent  way.  These  future  perspectives  are  further  discussed 
below to provide detailed recommendations. 
RECOMMENDATIONS  
  The recommendations below result from a general consultation of EFSA expert Panels and staff 
dealing  with  chemical  risk  assessment  and  other  experts  from  international  agencies  (ECHA, 
OECD,  WHO…).  Harmonisation  of risk  assessment  terminology  is  a  major  aspect  of  EFSA‟ 
science strategy. In the context of these methods, harmonisation of the terminology is required 
This recommendation also applies to animal health and environmental risk assessments.  
  General recommendations include the need for 1) reviews highlighting the use of these tools and 
methodologies for animal health and ecological risk assessment of chemicals. These reviews could 
be the starting point for developing guidance document (s) and have been identified as a priority 
topic by the EFSA Scientific Committee. 2) A guidance on the use of Mode of Action in risk 
Assessment that would include new international developments in the field. 3) Development of 
methodologies to apply these new tools to the risk assessment of exposure to multiple chemicals 
as well as to multiple chemicals combined with other stressors (e.g. biological hazards, physical 
agents…). 
  With regards to toxicokinetic processes in hazard assessment, human toxicokinetic data are needed 
to characterise interspecies differences and human variability. Such data will ultimately a) link 
exposure,  internal  dose  and  toxicity  using  physiologically-based  models  for  risk  assessment 
purposes, b) provide a scientific ground to set Assessment Groups based on toxicokinetics for 
multiple  chemicals.  In  addition,  in  vitro  methods  for  generating  TK  data  to  measure  human 
absorption  distribution,  metabolism  (gut  and  hepatic  metabolism)  and  excretion  patterns  of 
chemicals, should be improved. 
  The  development  of  a  guidance  on  the  use  of  physiologically-based  models  in  chemical  risk 
assessment is recommended together with the development of prototype physiologically-based 
models using specific case studies to integrate exposure, toxicokinetic information and toxicity 
data for hazard assessment purposes. It is recommended to first develop relatively simple models 
for single compounds and binary mixtures based on in vitro and in vivo data and, as knowledge 
advances more complex models can be developed. To further develop such models there is a 
practical need for databases providing critical parameters to build the models (physico chemical, 
physiological, toxicological) and bioinformatic tools/algorithms to analyse and integrate such data  
  Further work is needed to explore application of in silico tools in chemical risk assessment making 
use of the current data and databases available on toxicity, and to develop and validate predictive 
models and reduce animal use. Further development of in silico tools include the systematic and Modern methodologies for human hazard assessment of chemicals 
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harmonised approach for the use of QSAR, further development of the read-across methodologies 
particularly  using  QSAR,  physico-chemical  properties  and  toxicological  data  and  potential 
refinements of the TTC approach (re-evaluation/update of the Cramer classes and toxicological 
databases to improve in silico models with, as far as possible, an understanding of MoA.  
  Regarding  OMICs  technologies,  validation  and  standardisation  for  their  use  in  human  hazard 
assessment are needed. This includes detailed guidance on criteria underpinning their acceptability 
(data  needs,  statistical  and  bioinformatic  methodologies  for  data  analysis,  mechanistic  and 
statistical  aspects,  biological  and  toxicological  relevance,  in  vitro  relevance  to  the  in  vivo 
situation). Also, further exploration of the use of OMICs in human hazard assessment using case 
studies relevant to the food and feed area is recommended and include benchmark dose modelling, 
in vitro data, use of biomarkers of exposure and effects. Application in other areas such as animal 
health, ecological risk assessment and nutrition are also foreseen. 
  Future  work  on  integrated  testing  strategies  is  recommended  using  case  studies  of  specific 
chemicals to investigate mode of action from a toxicokinetic and toxicodynamic perspective and 
identify data gaps and research needs. Testing should be focused on differentiating chemicals with 
or without specific MoA, which will give an opportunity to rank potencies for prioritisation of 
chemicals. 
  The use of alternative test species as a bridge between in vitro methods and mammalian tests 
should  be  further  explored.  In  practice,  further  exploration  of  new  methodologies  for  hazard 
assessment  are  needed  for  both  regulators  and  industry  to  screen  and  prioritise  large  sets  of 
chemicals,  and  to  assess  specific  chemicals  for  a  specific  purpose.  For  exposure  to  multiple 
chemicals,  a  better  understanding  of  MoA/AOP  of  multiple  substances  using  predictive  and 
alternative  methodologies  is  needed  and  will  allow  improvement  of  the  basis  for  setting 
Assessment Groups.  
  For the future of chemical risk assessment, exploration of new risk assessment frameworks to 
bring a systems toxicology perspective to risk assessment using case studies is needed. Weight of 
evidence and uncertainty analysis methodologies are needed for the integration of data from new 
methodologies in the MoA/AOP framework and chemical risk assessment as a whole. Finally, 
reinforcing collaborations with international institutions such as: ECHA, JRC, OECD, WHO, NTP 
and the US-EPA is critical for EFSA in order to facilitate integration of these new methods and 
international harmonisation. 
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ABBREVIATIONS 
2-DE  Two-dimensional gel electrophoresis 
3-MCPD dipalmitate  3-chloropropane-1,2-dipalmitate 
AA  Acrylamide 
AA-GS  Glutathione conjugate of acrylamide 
ABC  ATP binding cassette 
ACAT  Advance Compartmental Absorption Transit 
AchE  Acetylcholinesterase 
ADAM  Advanced Dissolution model 
ADI  Acceptable daily intake 
ADME  Absorption, Distribution in the body, Metabolism and Excretion 
ADMET  Absorption, Distribution, Metabolism, Excretion and Toxicity 
AhR  Aryl hydrocarbon receptor 
AOP  Adverse outcome Pathways 
AOP-KB  AOP Wiki/Effectopedia Knowledge Base 
ArfD  Acute Reference Dose 
ATP  Adenosine triphosphate 
ATSDR  Agency for Toxic Substances and Disease Registry 
B2M  Beta-2 microglobulin 
BBDR  Biologically-based dose-response 
BMDL  Benchmark Dose Limit 
BPA  Bisphenol A 
b.w.  Body weight 
CIMR  Core Information for Metabolomics Reporting 
CLi  Intrinsic clearance 
COSMOS  Coordination of Standards in MetabOlomicS 
CPF  Chlorpyrifos 
CSAF  Chemical-Specific Adjustment Factor 
CYP  Cytochrome P-450 
DDT  1,1,1-trichloro-2,2-bis(p-chlorophenyl)ethane 
DG RTD  Directorate General for Research and Innovation 
DNEL  Derived No-Effect Level 
DZ  Diazinon 
ECHA  European Chemicals Agency 
EFSA  European Food Safety Authority 
ESI-MS  Electrospray ionisation mass spectrometry 
ESTs  Expressed Sequences Tags 
FAO  Food and Agriculture Organization of the United Nations 
FDA  U.S. Food and Drug Administration 
GA  Glycidamide 
GA-GS  Glutathione conjugate of glycidamide 
GI  Gastrointestinal 
GO  Gene Ontology 
GWAS  Genome-wide association studies 
Hb  Haemoglobin 
HBGV  Health-based guidance value 
HED  Human equivalent dose 
HI  Hazard Index 
HMDB  Human Metabolome Database 
HMP  Human Microbiome Project 
HTS  Highthroughput Screening 
HTVMD  High-throughput Virtual Molecular Docking 
IATA  Integrated Approach on Testing and Assessment 
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IKE  Intermediate Key Events 
IPCS  International Programme on Chemical Safety 
ITS  Integrated Testing Strategies 
IVIVE  In vitro to In vivo extrapolation 
JECFA  Joint Expert Committee on Food Additives 
JRC  Joint Research Centre 
KE  Key events  
Km  Michealis Menten constant 
LC–MS/MS  Liquid chromatography tandem mass spectrometry 
LOAEL  Lowest-Observed-Adverse-Effect Level 
MALDI  Matrix assisted laser desorption ionisation 
MALDI-MS  Matrix-assisted laser desorption/ionization mass spectrometry 
MeHg  Methylmercury 
MIE  Molecular Initiating Event 
MoA  Mode of Action 
MOE  Margin of Exposure 
MRM  Multiple Reaction Monitoring 
MRPs  Multidrug resistance proteins 
MSI  Metabolomics Standards Initiative 
NCBI  National Center for Biotechnology Information   
NCGC  National Chemical Genomics Center 
NCM  Northern Contaminant Mixture 
NGS  Next Generation Sequencing 
NIH  National Institutes of Health 
NMR  Nuclear Magnetic Resonance 
NOAEL  No-Observed-Adverse-Effect Level 
NRC  National Research Council 
NTP  National Toxicology Program 
OATPs  Organic anion transporting polypeptides 
OCs  Organochlorine pesticides 
OCTs  Organic Cation Transporters 
OECD  Organisation for Economic Co-Operation and Development 
OM  Oligonucleotide Microarrays 
OPLS-DA  Orthogonal PLS-Discriminant Analysis 
PB-PK  Physiologically-based pharmacokinetic models 
PB-PK-PD  Physiologically-based pharmacokinetic pharmacodynamic models 
PB-TK  Physiologically-based toxicokinetic models 
PB-TK-TD  Physiologically-based toxicokinetic toxicodynamic models 
PCA  Principal Component Analysis 
PCBs  Polychlorinated Biphenyls 
PCR  Polymerase Chain Reaction 
PCIS  Precision Cut Slice Model 
PFOA  Perfluorooctanoic acid 
PFOS  Perfluorosulphonate 
PLS  Partial Least Squares 
PLS-DA  Partial least square discriminant analysis 
PND  Post-natal day 
POD  Point of departure 
PON-1  Paraoxonase-1 
POP  Persistent Organic Pollutant 
Q  Quadrupole 
QBAR  Quantitative Biological Activity Relationship 
qPCR  Quantitative PCR 
QSAR  Quantitative Structure Activity Relationships 
RfC  Reference concentration Modern methodologies for human hazard assessment of chemicals 
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RfD  Reference dose 
RP  Reference Point 
RPF  Relative Potency Factor 
RTK  Receptor Tyrosine Kinase 
RVs  Reference Values 
SAR  Structure Activity Relationships 
SCCS  Scientific Committee on Consumer Safety 
SCENIHR  Scientific Committee on Emerging and Newly Identified Health Risks 
SCF  Scientific Committee on Food 
SCHER  Scientific Committee on Health and Environmental Risks 
SEURAT  Safety Evaluation Ultimately Replacing Animal Testing 
SHH  Sonic Hedgehog 
SLC  Solute carrier 
SRM  Selective Reaction Monitoring 
TCDD  Tetrachlorodibenzo-p-dioxin 
TD  Toxicodynamic 
TDI  Tolerable Daily Intake 
TEF  Toxic equivalency Factors 
TEQ  Toxic equivalent 
TGF  Tumour Growth Factor 
TK  Toxicokinetic 
TOXPi  Toxicological Prioritisation index 
TTC  Threshold of Toxicological Concern 
TTD  Target-organ Toxicity Dose 
TWI  Tolerable Weekly Intake 
US-EPA  US-Environmental Protection Agency 
Vmax  Maximum rate of catalysis 
VSD  Virtual Safe Dose 
WHO  World Health Organization 
Wnt  Wingless-related integration site 
WoE  Weight of evidence 
  